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1. GENERAL INTRODUCTION 
The group of human germ cell tumours (GCTs) is heterogeneous, and comprises neoplasms found at 
different anatomical localizations (1 for review). They are of interest not only for aspects of their 
tumour biology, but also from the point of view of developmental biology. The clinical course of 
GCTs depends on factors such as sex of the patient, age at clinical diagnosis, histology, and 
anatomical site of the tumor. A classification of GCTs including 5 groups, based on these parameters, 
as well as their chromosomal constitution, has been proposed (2). Within the testis, only three of these 
different entities can be distinguished: I) the teratomas and yolk sac tumours of newborn and infants 
(referred to as type I tumours), II) the seminomas and nonseminomas of adolescents and young adults 
(referred to as type II tumours), and III) the spermatocytic seminoma of the elderly (referred to as type 
III tumours). Type IV and V are the dermoid cysts and the hydatidform moles, respectively (3, 4 for 
reviews).  This distinction has recently been adopted by the 2003 World Heath Organisation (WHO) 
classification system for testicular GCTs (5). This thesis focuses on the type II tumours, the largest 
group of malignant GCTs.  
Most likely related to their cell of origin, which resembles a primordial germ cell (PGC)/gonocyte to 
prespermatogonia, GCTs show significant similarities with germ cells at various developmental stages 
(this thesis, 6). Comparison of tumours and normal counterparts can help to define normal and 
disturbed development of germ cells. This thesis focuses on the developmental potential of germ cells, 
both normal and malignant. 
 
1.1. Aspects of pathology and molecular biology of human germ cell tumours  
Besides in the gonads, both ovary and testis, GCTs can be found at different sites along the midline of 
the body, i.e. the retroperitoneal, mediastinal, and hypothalamus/pineal gland regions. Possibly this is 
due to the migration route of PGCs during embryogenesis (7). In some of these tumours the germ cell 
origin is supported by the presence of VASA (8), a germ line specific protein (9), or their specific 
pattern of genomic imprinting (10, 11, 12). As they can mimic early embryonic development, GCTs 
are at the crossroads of developmental and tumour biology, and of interest from both these points of 
view. It is of relevance to keep this in mind when interpreting data in the context of the pathogenesis 
of GCTs. This will become most eminent in the context of treatment sensitivity and resistance, as 
discussed below. 
 
1.2. Normal and disturbed male and female germ cell development  
In humans and rodents, amongst other species, the embryonic precursors of the gametes are known as 
PGCs (13 for review). These cells are set aside to an extra-embryonic localization early during 
embryonic development, and migrate to the area where the genital ridge will be formed around the 5th 
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and 6th week of human development (14). Subsequently, the gonads and sexual differentiation occur in 
the 6th and 7th week (15).  
Various risk factors for the maldevelopment of the fetal reproductive system like cryptorchidism (16) 
and gonadal dysgenesis are associated with an increased risk of testicular cancer, possibly due to 
disturbed migration and maturation of germ cells (17, 18, 19). The precursor of testicular seminomas 
and nonseminomas is well established, known as carcinoma in situ (CIS) (20), also referred to as 
intratubular germ cell neoplasia unclassified (IGCNU). 
1.2.1. Female germ cell development 
Between the 7th and 9th week during ovarian development (referred to as prefollicular stage) the germ 
cells (oogonia) and pre-granulosa cells characteristically arrange in cords and sheets without specific 
organization (21).  The population of oogonia increases by undergoing multiple divisions, after which 
they become oocytes, stop proliferating, and enter meiosis. The first distinctive change in prenatal 
germ cell development in the ovary therefore is the onset of meiosis, which starts at 11 to 12 weeks of 
gestation and extends into the second trimester (22). Contradictory data exist with regard to the onset 
of folliculogenesis, i.e. the occurrence of primordial follicles, which has been described to take place 
between 16 and 21 weeks of gestation (23, 24). Considerable changes in the total number of germ cells 
are seen, first due to the proliferation of premeiotic oogonia and later the apoptotic elimination of both 
oogonia and germ cells at different stages of folliculogenesis during intrauterine maturation (25). 
Maturation is a gradual process, characterized by the initiation of certain stages of oocyte development 
at different time points. In humans, this process is not synchronized, as germ cells at different 
developmental stages can be detected at the same time in the same prenatal ovary. This suggests that 
unknown intracellular mechanisms may govern the individual pace of maturation.   
1.2.2. Male germ cell development 
In case of testicular development, early germ cells are referred to as gonocytes, which are 
predominantly found in the central areas of the newly formed tubules. Starting around the 14th week of 
foetal development, these gonocytes gradually migrate towards the tubular periphery. Once the cells 
have reached close contact with the basal lamina of the tubule, they are referred to as 
prespermatogonia. As in the female gonad, germ cell maturation in the foetal testis is a gradual 
process. At the 20th gestational week the foetal testis predominantly contains prespermatogonial germ 
cells (26). During the first years after birth and until puberty, morphological and functional changes 
occur, including a change from large, immature germ cells (prespermatogonia) to adult type A 
spermatogonia (27, 28, 29). In contrast to the situation in the female gonad, germ cells in the male 
gonad do not enter meiosis before the onset of puberty. With the onset of puberty, spermatogonia 
undergo further spermatogenic maturation, and after meiotic divisions finally produce spermatozoa.  
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1.2.3. Disturbed germ cell development in dysgenetic gonads  
The term ‘dysgenetic gonads’ is used to describe the phenomenon of a disturbed gonadal sex 
determination or differentiation. Prolonged expression of immunohistochemical markers in various 
intersex conditions has been interpreted as a result of a maturation delay of germ cells, and has been 
linked to the high incidence of germ cell neoplasia seen in these individuals (30, 31, 32). The 
precursor lesion of the tumours of the dysgenetic gonad is called gonadoblastoma (16). 
Gonadoblastoma, like CIS/IGCNU, shows the potential to progress to an invasive GCT, mainly 
dysgerminoma, and less frequently to other tumour components, i.e. embryonal carcinoma, teratoma, 
yolk sac tumour, and choriocarcinoma. 
 
1.3. Embryonic origin and developmental potential of germ cell tumours 
CIS/IGCNU is located at the inner side of the basal layer of the seminiferous tubules, where normally 
the spermatogonia reside. Various phenotypical characteristics support the model that the 
PGC/gonocyte is the benign counterpart of the CIS cell (33, 34, 6). Accordingly, if the PGC/gonocyte 
is the cell of origin for testicular GCT, the initiation of tumourigenesis has to occur during intra-
uterine development. It has been suggested that the CIS cells are formed before the 9th gestational 
week. Various epidemiological and biological arguments support the concept of early initiation. 
Despite an early initiation, testicular GCTs become clinically manifest only after puberty. This lag 
period is most likely explained by hormonal influences on the growth and development of transformed 
(initiated) PGCs/gonocytes. The exact nature of these factors remains unknown.  
So far, it is not resolved whether CIS/IGCNU are programmed to form only seminoma, nonseminoma, 
or a combination of the two, or whether these cells are multipotent or even totipotent.  Differences 
between CIS/IGCNU surrounding nonseminomas and seminomas have been described regarding 
immunohistochemical markers and chromosomal constitution (35, 36). Therefore, a pre-determination 
of the later tumour histology already at the preinvasive stage has been suggested. However, the 
differences could also be an effect of the adjacent tumour on these cells, referred to as parallel 
evolution. 
Seminomas are uniform tumours, composed of cells resembling PGCs/gonocytes (37, 38). In contrast, 
nonseminomas are heterogenous and can contain one or more histologic subtypes representing various 
differentiation lineages and stages of normal intra-uterine development. The embryonal carcinoma cell 
is the pluripotent stem cell component, which may differentiate towards extra-embryonal tissues (yolk 
sac tumour and choriocarinoma) and embryonic tissues with mesenchymal, epithelial and neuronal 
appearance (immature and mature teratoma) (39). As they have never been shown to give rise to the 
germ line in humans, they seem to fall one step short of totipotency. 
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1.3.1. Role of the transcriptional regulator POU5F1 (OCT3/4) on germ cell development 
POU5F1 (also known as OCT3/4, which will be used in the following) is expressed in 
undifferentiated, pluripotent cells including embryonic stem cells (ES) and germ cells, both in mouse 
(40, 41, 42) and human (43, 44). It is involved in regulation of pluripotency, as levels of expression 
determine whether ES cells remain undifferentiated, or differentiate into either trophectoderm or 
extraembryonic endoderm and mesoderm (45).  In fact, OCT3/4 is the determining factor for the first 
embryonic lineage specification. Inhibition of expression of this gene in mouse or human ES cells 
results in differentiation to trophoectoderm (46, 47). In contrast, PGCs without OCT3/4 do not 
differentiate, but undergo apoptosis (48). This indicates that the role of OCT3/4 in embryonic stem 
cells and PGCs is different.  
It has been shown that expression of OCT3/4 in GCTs is highly similar to the pattern found during 
normal development (49). OCT3/4 is found specifically in CIS/IGCNU, seminoma and embryonal 
carcinoma cells, while yolk sac tumour, teratoma and choriocarcinoma are consistently negative. 
Immunohistochemical detection of OCT3/4 is of high diagnostic value for GCTs (50). In addition, its 
expression was also found in gonadoblastoma, dysgerminoma, and germinoma (49). This has been 
confirmed in multiple studies (50 for review). 
OCT3/4 has been termed a dose-dependent oncogenic fate determinant in the mouse model (51). 
However, this conclusion was drawn from results obtained in mouse ES cells, which are not a proper 
animal model for type II GCTs. Furthermore, no correlation between treatment response and OCT3/4 
staining in human germ cell tumours was observed (49). The fact that OCT3/4 expression is regulated 
during differentiation of pluripotent cells suggests that the gene is under control of a physiological 
expression machinery, rather than being an oncogene in the classical sense. However, it remains to be 
shown whether the presence of OCT3/4 is indeed a driving force in the pathogenesis of this disease in 
humans, or merely reflects the origin of these tumours and their developmental potential. 
1.3.2. Role of TSPY (testis-specific protein,Y-encoded) in germ cell development 
The human TSPY (testis-specific protein, Y-encoded) gene is organized as a repetitive gene family. It 
maps to the critical region of GBY (GonadoBlastoma on the Y chromosome) (52, 53, 54) locus on the 
short arm of the Y chromosome (55, 56). Expression of TSPY sequences has been found by RNA 
analysis in prenatal and adult human testis (57, 58, 56). It is mainly present in humans during early 
spermatogenesis. It has been suggested to play a normal role in spermatogonial proliferation and an 
oncogenic role in early germ cell tumorigenesis (59, 60). In addition to CIS/IGCNU, gonadoblastoma 
cells were also found to express TSPY in a limited number of cases (61, 60). Even though a role in the 
proliferation of human germ cells has been suggested, the function of TSPY remains speculative. 
1.3.3. Role of the microenvironment in germ cell development 
Mammalian germ cells originate from the proximal region of the epiblast. In mouse experiments, 
embryonic stem cells can be stimulated to differentiate into germ cells and extra-embryonic mesoderm 
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when grafted to the proximal epiblast (62). This indicates that the potential to become a germ cell may 
not be restricted to predetermined progenitor cells, but are under control of extracellular factors and/or 
cell-cell interactions (63). Even though a number of factors involved in germ cell survival have been 
suggested (64 for review), their exact nature is largely unknown. Recent findings indicate that in 
mouse embryonic stem cells, BMP4 might be crucial for germ cell development (65). It is noteworthy 
that differentiation occurred only when the embryonic stem cells were coaggregated with BMP4-
producing cells; no effect was seen when BMP4 was added to a suspension culture of embryonic stem 
cells, underlining the importance of a unique three-dimensional configuration of these cells (65). 
Besides BNP4/BNP8b, also stem cell factor (SCF)/KIT, and ß-catenin/E-cadherin, have been found to 
have an effect on germ cell development. The SCF/KIT system is involved in survival and 
proliferation of migrating germ cells in mice (66). In humans, recent studies suggest an important role 
of this system in female germ cells (67). Whereas some data is available on the cadherin-catenin 
complex in mouse PGC development and oocyte maturation (68, 69), little is known about the role of 
these factors in human germ cell development. 
 
1.4. Treatment sensitivity and resistance in germ cell tumours 
Modern treatment of GCTs is based on all available treatment options in the field of oncology: 
surgery, radiotherapy and chemotherapy. Even in metastatic stages, cure rates of 80% can be achieved 
by multiagent, cisplatin-based chemotherapy. These treatment results are unique among solid tumours 
of adults. GCTs are therefore considered a model for a curative malignant disease (70). The exquisite 
chemosensitivity of GCTs has been regarded as a reflection of the characteristics of their cells of 
origin, PGC/gonocyte and early embryonal cells derived from them. From a teleologic point of view, it 
is assumed that it is of paramount importance to maintain the genetic information of stem cells intact. 
In order to achieve this goal, cells with damaged DNA are thought to go into apoptosis rather than try 
to repair the damage. Thereby, they avoid errors occurring during DNA-repair, which could be 
transmitted to their progeny with detrimental effects (71). 
1.4.1. Biologic basis of treatment sensitivity 
Seminomas are highly sensitive to both radiation and chemotherapy. Nonseminomas are less 
susceptible to radiation but show an overall high sensitivity to combination chemotherapy. Treatment 
resistance, which occurs in about 10-30% of patients diagnosed with a metastatic nonseminomatous 
germ cell tumour, might in fact be related to the loss of efficient defense mechanisms for DNA 
damage recognition or acquisition of effective DNA repair mechanisms. A number of reviews on this 
issue have been published recently (72, 73, 74). The majority of findings so far indicate that the crucial 
determinators of drug sensitivity in type II GCTs are downstream of DNA binding, e.g. in the intrinsic 
or extrinsic pathways of apoptosis or DNA repair. Most tumors lack export pumps with cisplatin 
affinity and show low levels of detoxification. It has been postulated that low levels of the DNA repair 
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proteins XPA and HRAD9/HRAD9B is related to the overall sensitivity of these tumours (75, 76). The 
presence of testis-specific high mobility group (HMG)-box proteins might also be relevant (77), as 
well as the FAS-ligand system (74 for review). Although suggested multiple times, it is now accepted 
that the TP53 status is not the sole determining factor whether type II GCTs will be responsive or 
resistant to treatment (78, 72 for review). More likely, the presence of TP53 in type II GCTs could 
again be related to their origin from PGCs (79).  
1.4.2. Role of differentiation and a functional cell cycle control in treatment resistance 
While most type II GCTs show an intact DNA mismatch repair pathway (MMR), a defect leading to 
microsatellite instability has been observed in tumours refractory to cisplatin (80). In addition, a 
defective caspase 9 function has been reported in treatment resistance (81). Although all these factors 
might be important, the overall notion is that most likely not one single factor alone will determine 
treatment resistance. This is nicely illustrated by the findings in mature teratoma of nonseminomas, 
which are characteristically resistant to chemotherapy (80), possibly due to epigenetic changes 
occurring during somatic differentiation.   
Cell cycle control is crucial in determining whether a cell will remain proliferative, or will 
differentiate. Various studies on regulatory elements of the cell cycle have been performed in GCTs, 
with a number of interesting findings. For example, overexpression of cyclin D has been suggested to 
be involved in the development of GCTs. Interestingly, progression from CIS/IGCNU to invasive 
growth is associated with loss of the cell cycle inhibitor CDKN2C (p18), resulting in disturbed cell 
cycle regulation (82).  
A number of studies have linked the development of GCTs to a deregulated G1/S checkpoint. The 
absence of such a checkpoint could be related to the lack of the cell cycle regulator RB (83), and is 
reflected in the absence of CDKN1A (p21) upregulation after induction of TP53 following DNA 
damage. Interestingly, cells without p21 show reduced cisplatin-induced DNA damage repair, and 
increased sensitivity to cisplatin (84). These findings may again be related to the origin of the tumours 
(34), as neither RB nor CDKN2D (p19) are found in human foetal gonocytes or CIS/IGCNU (82, 85). 
Within the histological heterogeneity of type II GCTs, the mature teratomas are consistently resistant 
to DNA damaging agent (see above). In contrast to other invasive components, the mature teratomas 
are positive for MDR, MRP2, BCRP, LRP, and GSTπ. Moreover, mature teratomas show presence of 
RB, p21, and p27, suggesting the ability of these cells to activate G1/S cycle arrest (82, 86), in contrast 
to less differentiated elements. Taken together, there is sufficient evidence to hypothesize that 
treatment sensitivity of GCTs most likely reflects the intrinsic characteristics of the cell of origin, and 
their derivatives. Furthermore, the potential loss of characteristics of embryonic cells, and in particular 
the acquisition of somatic differentiation could be a crucial phenomenon in the development of 
resistance. 
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1.5. Aims of the thesis 
The objective of this thesis is to identify factors involved in the development of normal and malignant 
human germ cells. The particular marker profile of male and female germ cells during normal foetal 
development is established, and compared to germ cells in dysgenetic gonads. Special attention is 
given to the expression profile of OCT3/4 in germ cells during normal and disturbed gonadal 
maturation, and the role of pluripotency in germ cell tumour development is discussed. The intrinsic 
developmental potential of nonseminomatous germ cell tumours (with regard to pluri-/totipotency) 
and the role of extracellular factors like the microenvironment are investigated. Finally, links between 
pluripotency, cellular differentiation, and treatment response, are described. 
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BACKGROUND: In the development of the human ovary, the second trimester includes the transition from oogo-
nial replication to primordial follicle formation. The present study was carried out to assess differentiation and
proliferation of germ cells in a series of female gonads from 19 fetuses from the second and third trimester, and
two neonates. METHODS: Using immunohistochemistry, the following markers were studied: placental/germ-like
cell alkaline phosphatases (PLAP), the marker of pluripotency OCT3/4, the proliferation marker Ki-67, b-catenin
and E-cadherin, the stem cell factor receptor c-KIT, and VASA, a protein specific for the germ cell lineage.
RESULTS: PLAP and OCT3/4 were seen during oogenesis, but not in germ cells engaged in folliculogenesis. A
similar pattern was observed for Ki-67. Loss of pluripotency occurs once oocytes engage in follicle formation,
suggesting a role of cell–cell interactions in the process of germ cell maturation. VASA, c-KIT, b-catenin and E-
cadherin were found in germ cells at all developmental stages of oogenesis and folliculogenesis. CONCLUSIONS:
Immunohistochemically, two groups of germ cells can be distinguished. Germ cells that are predominantly found
in the cortical region of the ovary before weeks 22–24 of gestation, showing an immature phenotype, are mitoti-
cally active, and express OCT3/4, a marker of pluripotency. On the other hand, germ cells undergoing folliculogen-
esis have lost their pluripotent potential and no longer proliferate.
Key words: differentiation/fetal ovary/germ cells/immunohistochemistry/proliferation
Introduction
In humans and rodents, amongst other species, the embryo-
nic precursors of the gametes are known as primordial
germ cells (PGC) (see Donovan, 1998, for review). These
cells are set aside to an extra-embryonic location early
during embryonic development, and migrate to the area
where the genital ridge will be formed around weeks 5 and
6 of human development (Witschi, 1948). Subsequently,
the gonads and sexual differentiation occur in weeks 6 and
7 (Falin, 1969). Between weeks 7 and 9 during ovarian
development (referred to as prefollicular stage) the germ
cells (oogonia) and granulosa cells characteristically arrange
in cords and sheets without specific organization (Gondos,
1985). The population of oogonia increases by undergoing
multiple divisions, after which they become oocytes, stop
proliferating, and enter the first steps of meiosis. The first
distinctive change in prenatal germ cell development in the
ovary is therefore the onset of meiosis, which starts at
11–12 weeks of gestation and extends into the second tri-
mester (Rabinovici and Jaffe, 1990). Contradictory data
exist with regard to the onset of folliculogenesis, i.e. the
occurrence of primordial follicles, which has been reported
to take place between 16 and 21 weeks of gestation (Kur-
ilo, 1981; Konishi et al., 1986). Due to the proliferation of
premeiotic oogonia on the one hand and the apoptotic
elimination of both oogonia and germ cells at different
stages of folliculogenesis during intrauterine maturation on
the other hand, considerable changes in the total number of
germ cells are seen (De Pol et al., 1997). Whereas at 5
weeks of gestational age an estimated 700–1300 germ
cells are present, germ cell number peaks between weeks
16 and 20, reaching an estimated 6 £ 106 cells per ovary
(Baker, 1963). At birth, the total number of germ cells has
been estimated to be ,1 £ 106 cells, and the number of
follicles has been reported to be in the range of 1.3–
3.8 £ 105, with 95% being represented by primordial
follicles (Baker, 1963; Forabosco et al., 1991). Maturation
is a gradual process, as is demonstrated by the initiation of
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certain stages at certain times, i.e. the temporal regulation
of oocyte development. In humans, this process is not syn-
chronized, as germ cells of different developmental stages
can be detected at the same time in the same prenatal
ovary. This indicates that unknown intracellular mechan-
isms govern the individual pace of maturation (Rabinovici
and Jaffe, 1990).
In order to further investigate the distribution and timing
of proliferation and differentiation, we undertook an exten-
sive study on the presence of a number of markers involved
in either proliferation or maturation of normal female germ
cells spanning the intrauterine period between week 15.5
gestational age and the neonatal period. In the human ovary,
this crucial period includes the transition from oogonial repli-
cation by mitosis to primordial follicle formation. In this
study we investigated the maturation process seen in normal
development of the ovary and assess its potential as a refer-
ence for future identification of pathological processes of
maturation.
Materials and methods
Tissue samples
Use of tissues for scientific reasons has been approved by an insti-
tutional review board (MEC 02.981). The samples are used accord-
ing to the ‘Code for Proper Secondary Use of Human Tissue in the
Netherlands’, as developed by the Dutch Federation of Medical
Scientific Societies (FMWV) (version 2002). Human gonads of 19
females from the second and third trimester after spontaneous or
induced abortions (gestational ages 15.5–40 weeks), or premature
and term neonates that had died shortly after birth were obtained
from post-mortem examinations in our department. Ovaries were
dissected and fixed in 10% formalin and processed into paraffin. To
assure satisfactory quality, poor preservation of tissue samples
assessed by haematoxylin–eosin staining led to exclusion from this
analysis. Cases showing conditions that can possibly affect gonadal
development such as trisomy 18 and 21, hydrocephalus, maldeve-
loped kidneys, or gross intrauterine growth retardation, were
excluded from the study. Gestational ages were calculated in
relation to the mothers’ last menstrual cycle and were in accordance
with the foot length and the crown–heel length measurements at
autopsy.
Histochemical and immunohistochemical stainings
Stainings were performed as described before (Stoop et al., 2001).
For immunohistochemistry, sections were incubated with the pri-
mary antibody overnight at 4 8C [placental/germ-like cell alkaline
phosphatases (PLAP), c-KIT, VASA, b-catenin, E-cadherin] or 2 h
at room temperature (OCT3/4, Ki-67). The primary and secondary
antibodies used are indicated in Table I. All slides were counter-
stained with haematoxylin. For PLAP, b-catenin and E-cadherin,
positive staining of the Fallopian tube, and for c-KIT, the presence
of mast cells were used as an internal positive control. Negative
controls were performed by omitting the primary antibody, resulting
in complete absence of signal.
Double-stainings were performed by using a combination of the
same detection methods but with different substrates: Fast Blue/-
Naphtol ASMX phosphate (F3378 and N500; Sigma, Germany) for
blue staining and 3-amino-9-ethyl-carbazole (A.5754 and D4254;
Sigma)/H2O2 for red staining, without counterstaining. Endogenous
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peroxidase activity and/or endogenous biotin was blocked using 3%
H2O2 (for 5 min) and/or a blocking kit for endogenous biotin (Vec-
tor Laboratories, USA) to prevent background staining.
To semiquantitatively assess expression of the markers investi-
gated, cells showing a positive signal were counted in representative
visual fields (magnification £ 200) containing surface areas of both
the medullary and the cortical region of the ovary in comparable
proportions in all cases. In addition, cells positive for PLAP,
OCT3/4 and Ki-67 were counted in three representative high power
fields (magnification £ 400) of both the medullary and cortical
regions of seven cases (gestational ages 15.5, 20, 23, 28, 33, 35 and
36 weeks) to assess regional differences. For quantitative analysis of
OCT3/4, the percentage of positive cells among the total number of
germ cells (as identified by histology) was assessed in three cases
(gestational ages 15.5, 28 and 36 weeks) counting three representa-
tive visual fields (magnification £ 200). The counting was per-
formed independently by three different observers (H.S., F.H. and
M.C.) who were unaware of the gestational age at the time-point of
the investigation.
Results
The presence of a number of markers during normal fetal
and neonatal ovarian development (week 15.5 gestational age
until 6 weeks postnatally) was studied in 19 ovaries. Figure 1
summarizes the results of a semiquantitative assessment of
the different markers. Each black dot represents one case.
Figure 1. Absolute numbers of cells per representative visual field (magnification factor £ 200) showing a positive staining with immunohis-
tochemistry for the markers at different gestational ages (weeks). The earliest case studied in this series was 15.5 weeks, the oldest was the
ovary of a neonate of 6 weeks. The arrow indicates partus (median 40 ^ 2 weeks). The left panel (A, C, E) shows markers that remain posi-
tive throughout pre- and perinatal oogenesis and formation of primordial follicles. The right panel (B, D, F) illustrates factors associated with
germ cell differentiation and proliferation. Each black dot represents one case. Note smaller scale of the y-axis (lower overall numbers) in B
(placental/germ cell alkaline phosphatases, PLAP). As b-catenin and E-cadherin were expressed in the same cells in adjacent slides with simi-
lar localization, cell numbers for b-catenin (C) are also representative for E-cadherin.
Chapter 2   
28 
Table II shows the results of a differential analysis, compar-
ing expression of PLAP, OCT3/4 and Ki-67 in the medullary
and cortical regions of the ovaries of seven cases, aged 15.5,
20, 23, 28, 33, 35 and 36 weeks. Table III gives both the
absolute numbers and the percentage of cells positive for
OCT3/4 in three of these cases, aged 15.5, 28 and 36 weeks.
Illustrations of representative stainings are shown in Figures
2 and 3. Results of single- and double-stainings are described
below. The data in Figure 4 (grey bars) were compared to
previously published findings (black bars). Figure 5 shows a
model of the progression of markers from oogonia to primor-
dial follicles.
Immunohistochemical detection of Ki-67, PLAP and
OCT3/4
Ki-67, PLAP and OCT3/4 were all found much more fre-
quently at earlier fetal ages, and expression decreased with
advancing gestational age (Figure 1). The various regions of
the ovary showed different stages of germ cell maturation:
cells positive for Ki-67, PLAP and OCT3/4 were mainly
observed in the cortical region of the developing ovaries, i.e.
the region where most immature germ cells are located
during the process of oogenesis (Tables II and III). In the
medulla, where the majority of maturing germ cells are
found during ovarian development, positive cells were much
less frequent.
The proliferation index was assessed using Ki-67, which
showed a nuclear staining in both early germ cells and inter-
stitial cells throughout the whole period of ovarian develop-
ment investigated in this series. A marked decrease in the
number of positive cells was observed after weeks 22–24 of
gestational age, mainly due to the cessation of mitosis of
germ cells. This indicates that proliferating germ cells con-
tribute significantly to the overall number of Ki-67 positive
cells in fetal ovaries. In germ cells, Ki-67 was observed
mainly in oogonia (see Figure 2A). Yet, whereas the majority
of oocytes engaged in folliculogenesis did not show Ki-67
expression, it was occasionally observed in oocytes of pri-
mordial follicles, where it was strictly confined to the nucleo-
lus. Perinatally, only a few cells, mainly interstitial cells or
granulosa cells, were positive.
The highest number of germ cells positive for PLAP was
seen in the earliest stages of fetal development examined,
and decreased sharply after 25 weeks gestational age (Figure
1). PLAP was detected in early germ cells predominantly
located in the cortical region (Figure 2B and Table II). After
birth, PLAP positive germ cells were hardly ever seen, with
a maximum of one to three positive cells per visual field.
PLAP expression was not restricted to germ cells, but was
also seen in the Fallopian tube and occasionally in the epi-
thelial lining of the ovary.
Nuclear staining for OCT3/4 was restricted to germ cells
and the overall staining pattern was comparable to PLAP, yet
total numbers of germ cells positive for OCT3/4 were some-
what higher (Figure 1 and Table II). In addition to oogonia,
OCT3/4 was occasionally seen in early oocytes, but was
never detectable in cells involved in folliculogenesis (Figure
2C). Similar to the expression pattern of Ki-67 and PLAP, a
decline in the expression of OCT3/4 in fetal ovaries was seen
at ,24 weeks of gestation. At term and in ovaries of neo-
Table II. Differences in the expression of placental/germ-like cell alkaline phosphatases (PLAP), OCT3/4 and Ki-67 between the cortical and the medullary
region of fetal ovaries aged 15.5–36 weeks
Gestational age (weeks)
15.5 20 23 28 33 35 36
PLAP
Cortex 94 (72–115) 35 (23–44) 73 (54–85) 9 (3–12) 11 (9–13) 0 14 (12–17)
Medulla 34 (12–52) 4 (2–6) 4 (1–6) 5 (1–9) 0 2 (1–3) 3 (2–4)
OCT3/4
Cortex 131 (106–157) 57 (56–57) 122 (99–162) 32 (29–33) 2 (0–3) 0 9 (1–20)
Medulla 49 (36–58) 12 (1–21) 26 (14–43) 8 (2–14) 0 2 (0–5) 4 (1–6)
Ki-67
Cortex 234 (221–252) 136 (112–148 110 (95–118) 77 (62–98) 4 (2–7) 15 (9–18) 60 (46–75)
Medulla 163 (152–172) 86 (70–110) 61 (55–65) 53 (36–75) 0 26 (16–32) 45 (24–69)
The average and the range of cell numbers found positive for the indicated markers in three independent high power magnification fields ( £ 400) is given.
Note that expression of the early markers PLAP and OCT3/4 and the proliferation marker Ki-67 is predominantly found in the cortical region. Overall, the num-
ber of positive cells decreases between 15.5 and 28 weeks, but shows some inter-individual variation during the third trimester.
Table III. Absolute numbers compared to total present (and percentage) of cells positive for OCT3/4 in three ovaries of 15.5, 28 and 36 weeks gestational age
OCT3/4 Gestational age (weeks)
15.5 28 36
Cortex 231/681 (34%; range 32–38) 5/324 (1.5%; range 0–4) 13/242 (5.4%; range 0–7)
Medulla 35/271 (13%; range 6–18) 2/201 (1%; range 0–2) 0/188 (0)
The total number of germ cells, identified by histology, and the number of germ cells expressing OCT3/4 immunohistochemically was assessed in three inde-
pendent low power fields (magnification £ 200) in both the cortical and the medullary region of three fetal ovaries. In parentheses, the percentage of germ cells
expressing OCT3/4 is given, together with the range (as percentage) of three different counts of three different fields per case. Whereas a significant number of
germ cells express OCT3/4 at 15.5 weeks, predominantly in the cortex, the percentage of positive cells decreases markedly during the third trimester. Note the
decrease in overall numbers of germ cells.
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Figure 2. Results of immunohistochemical analysis of different markers in fetal germ cells. The cortex (C) and medulla (M) are indicated.
(A) Fetal ovary (15.5 weeks of development) (magnification £200); Ki-67 (brown nuclear signal) seen both in germ cells and cells of non-
germ cell origin (e.g. stromal cells, endothelial cells, granulosa cells). Positive cells are mainly seen in a cortical localization (indicated by an
arrow). (B) Fetal ovary (same case) (magnification £200); placental/germ cell alkaline phosphatase (PLAP); red cytoplasmic signal. Note
high number of positive cells (oogonia) at a cortical localization. (C) Fetal ovary (22 weeks of development) (magnification £400); OCT3/4
(brown nuclear signal). Oogonia and immature oocytes, mainly cortically localized, are positive, whereas primordial follicles are negative.
(D) Fetal ovary (same case) (magnification £400); double-staining for OCT3/4 (red nuclear signal) and PLAP (blue cytoplasmic signal).
OCT3/4 and PLAP are co-expressed in the majority of immature germ cells, and occasionally cells are positive for OCT3/4 but negative for
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nates, hardly any positive germ cells were detectable.
Immunohistochemical detection of c-KIT, b-catenin/
E-cadherin and VASA
A comparable staining pattern was seen for c-KIT, b-catenin
and E-cadherin (Figure 3A–F). Both in early, immature
germ cells (oogonia) and at all later stages of folliculogen-
esis, these factors were predominantly localized at the mem-
brane, but sometimes also showed a cytoplasmic localization
(see also Figure 1). In primordial follicles, all three factors
showed strong signal intensity at sites of cell–cell interaction
(Figure 3A–F). As b-catenin and E-cadherin were expressed
in the same cells in adjacent slides in similar localization,
these factors could be linked, forming an E-cadherin–catenin
complex in germ cells. In addition to their presence in germ
cells, these factors were also seen in epithelial cells of the
Fallopian tube, serving as an internal positive control.
VASA was observed in the cytoplasm of germ cells, both
oogonia and oocytes, at all gestational ages and after birth
(Figure 1G and H). In addition to oogonia and early oocytes,
all stages of follicle maturation showed presence of VASA.
Signal intensity varied with maturation of germ cells: early
germ cells showed only weak staining for VASA, and signal
intensity increased with maturation and was strongest in pri-
mordial follicles (Figure 3G). The total number of germ
cells, determined by VASA, decreased with gestational age:
whereas at 15.5 weeks ,600 germ cells, mostly oogonia and
early oocytes, were seen per visual field, the average number
of germ cells at term was ,100–200 per visual field.
Results of double-stainings
Double-stainings were performed to assess correlations or
differences of markers at different stages of maturation. A
total of nine cases of 15.5, 18, 24 (three different cases), 28,
33, 36 weeks gestational age, and a neonate of 2 weeks, born
at term, were stained for six different combinations: OCT3/4
and PLAP, PLAP and c-KIT, OCT3/4 and c-KIT, OCT3/4
and VASA, OCT3/4 and b-catenin, and PLAP and Ki-67
(Figure 2D–H respectively). The results of all double-stain-
ing experiments were in accordance with the results of the
respective single-staining experiments. Staining for OCT3/4
and PLAP revealed that a higher number of germ cells were
positive for OCT3/4 than for PLAP, with a constant ratio of
1.4:1 observed for all ages investigated (Figure 2D). PLAP
was never detected in germ cells negative for OCT3/4, and
expression of OCT3/4 was still observed at later stages of
development, when PLAP was already undetectable. Double-
staining for PLAP and c-KIT showed that at all gestational
ages more germ cells were positive for c-KIT than for PLAP.
PLAP was never detected in oogonia without expression of
c-KIT, but in contrast to PLAP, c-KIT remained positive
throughout maturation, including different stages of folliculo-
genesis (Figure 2E). In accordance with these findings,
OCT3/4 and c-KIT were found in comparable numbers only
in early germ cells, whereas during folliculogenesis, c-KIT
remained positive in germ cells that had already lost OCT3/4
expression (Figure 2F). Similar staining patterns were
observed for the combinations OCT3/4 and VASA, and
OCT3/4 and b-catenin (not shown), where co-expression was
restricted to early germ cells, whereas expression of OCT3/4
was no longer seen at later stages of maturation. Interest-
ingly, an inverse correlation was found between the presence
of OCT3/4 and the staining intensity of VASA. Oogonia
were positive for OCT3/4, but only weakly positive for
VASA, whereas primordial follicles staining strongly for
VASA no longer showed OCT3/4 (Figure 2G). Double-stain-
ing for PLAP and Ki-67 revealed that significantly more cells
were positive for Ki-67 than for PLAP at all ages. Further-
more, not all early germ cells (identified by PLAP
expression) were proliferating at the same time (Figure 2H).
A proportion of germ cells of between 50% at earlier and
37% at later gestational ages showed co-expression of both
markers. This indicates that in addition to a decrease in the
absolute number of early germ cells, these cells are also less
likely to proliferate at later stages of ovarian development.
During the third trimester, expansion of the pool of early
germ cells (indicated by co-expression of Ki-67 and PLAP)
has basically ceased.
Discussion
The aim of this study was to examine the differential
expression of a number of factors involved in proliferation
and differentiation of human fetal germ cells. The findings
give an indication of the temporal scale as well as the
regional differences during the maturation of normal female
germ cells in the human ovary. The overall picture of the
presence of the different factors in fetal and neonatal ovaries
is shown graphically in Figure 4 (grey bars) and compared to
findings in humans published so far in the literature (black
bars). Figure 5 gives a scheme of marker progression during
maturation from oogonia to primordial follicles.
PLAP (indicated by an arrowhead). (E) Fetal ovary (same case) (magnification £ 400); double-staining for PLAP (blue cytoplasmic signal)
and c-KIT (red membranous signal). Primordial follicles express only c-KIT, and only a minority of cortically located immature germ cells is
positive for both markers. (F) Fetal ovary (same case) (magnification £ 400); double-staining for OCT3/4 (blue nuclear signal) and c-KIT
(red membranous signal). Similar staining pattern as seen in E, but note that more germ cells are positive for OCT3/4 than for PLAP. (G)
Fetal ovary (same case) (magnification £ 400); double-staining for OCT3/4 (red nuclear signal) and VASA (blue cytoplasmic signal). Primor-
dial follicles, mostly located in the medullary region, show a strong intensity of VASA and are negative for OCT3/4, whereas immature germ
cells, mostly found in a cortical localization, are positive for OCT3/4 but show only weak VASA staining. (H) Fetal ovary (15.5 weeks of
development) (magnification £ 200); double-staining for Ki-67 (red nuclear signal) and PLAP (blue cytoplasmic signal). Significantly more
cells are positive for Ki-67 than for PLAP. The majority of proliferating cells are of non-germ cell origin, as demonstrated by positive stain-
ing for Ki-67 but absence of PLAP; however, a few oogonia (identified by PLAP expression) show co-expression of Ki-67, indicating that
these immature germ cells are mitotically active (indicated by an arrow).
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Figure 3. Results of immunohistochemical analysis of different markers in fetal germ cells. The cortex (C) and medulla (M) are indicated.
(A) Fetal ovary (28 weeks of development); c-KIT (red cytoplasmic and membranous signal), positive in both immature oocytes and oocytes
involved in folliculogenesis. (B) Fetal ovary (same case); c-KIT. Note staining of both immature oocytes (arrow) and primordial follicles
(arrowhead). (C) Fetal ovary (same case); E-cadherin (brown-reddish membranous signal). (D) Fetal ovary (same case); E-cadherin. (E) Fetal
ovary (same case); b-catenin (brown-reddish signal) is seen in oocytes at different stages of folliculogenesis. (F) Fetal ovary (same case);
b-catenin. Note strong submembranous signal intensity in the primordial follicles (arrow), suggesting formation of an E-cadherin–catenin
complex. (G) Fetal ovary (22 weeks of development); VASA (red cytoplasmic signal), seen both in germ cells of all stages of development.
(H) Fetal ovary (same case); VASA. Magnifications: left panels £200, right panels £400.
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Figure 4. Overview of the data currently available from the literature on the expression of different antigens in germ cells during female
intrauterine development (black bars), compared with findings of this study (grey bars). Heights of grey bars represent numbers of germ cells
expressing the individual factor at different developmental ages.
Figure 5. Progression of markers during germ cell maturation from oogonia to primordial follicles during the pre- and perinatal periods.
In the following paragraphs, the most interesting findings
of the individual markers included in this study will be dis-
cussed in more detail.
To assess proliferation, we used Ki-67, a nuclear protein
that is present in all phases of the cell cycle, but is absent in
G0-phase cells (Gerdes et al., 1984). Overall expression of
Ki-67 in both germ cells and cells of non-germ cell origin
(mostly interstitial cells and granulosa cells) was highest in
the earliest case investigated (15.5 weeks), and decreased
steadily throughout the second and third trimester. Around
term, almost all germ cells (mostly oocytes in primordial fol-
licles) and the majority of cells of non-germ cell origin have
entered a quiescent phase. Expression of Ki-67 was markedly
higher in the cortex than in the medulla at earlier ages,
whereas no differences between the two regions were found
during the third trimester (Table II). To assess the proportion
of germ cells of overall Ki-67 positive cells and examine the
percentage of proliferating germ cells, we performed double-
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stainings using a combination of PLAP and Ki-67. Of all
cells positive for Ki-67, ,50% were early germ cells. The
percentage of proliferating versus quiescent germ cells was
45 to 50% at 15.5 and 20 weeks, and between 37 and 40%
of the few early germ cells found at week 28 gestation
and 3 weeks after birth respectively. This indicates that
immature germ cells at early stages show strong proliferation
around weeks 15.5 to 20, whereas at later ages both the num-
ber and the fraction of proliferating germ cells decreases. At
term, the expansion of germ cells has almost ceased. This
finding is in line with earlier reports on germ cell numbers
during the prenatal period (for review, see Rabinovici and
Jaffe, 1990). Interestingly, a small number of oocytes in pri-
mordial follicles showed presence of Ki-67 in the nucleolus.
Similar findings have been reported previously, suggesting a
role of this factor not only during mitosis, but also during
meiosis (Wrobel et al., 1996; Traut et al., 2002). The number
of positive meiotic cells was too small to influence the over-
all conclusion, and did not allow conclusions regarding poss-
ible physiological meaning.
Alkaline phosphatases are regarded as archetypal onco-
fetal proteins. They are detectable at the mammalian blasto-
cyst stage and have been described in germ cells of human
embryos of ,4 weeks gestational age (Pinkerton et al.,
1961). PLAP expression has been described in primordial
germ cells at 8–13 weeks and at later ages in human oogonia
not yet engaged in cell–cell interactions with somatic cells,
whereas ovaries of neonates and infants were devoid of any
immunopositivity (Hustin et al., 1990; Gould et al., 2000).
Our finding that PLAP expression is restricted to early germ
cells, most likely oogonia, is in line with these previous
reports. The highest expression was seen in the cortex, where
the number of positive cells decreased steadily with advan-
cing age. In the medulla, differences at different ages were
less pronounced after week 20. In our study, PLAP was still
occasionally detected in germ cells of neonates shortly after
birth, albeit at very low numbers.
OCT3/4 is a transcriptional regulator, expressed exclu-
sively in pluripotent human embryonic stem cells and germ
cells, including PGC (Goto et al., 1999; Hansis et al., 2000).
In addition, presence of OCT3/4 has been described in germ
cell tumour cells with pluripotent potential such as embryo-
nal carcinoma and seminomas (Looijenga et al., 2003). In
fetal human testes, OCT3/4 has been found to be highly
expressed in PGC between weeks 17 and 24 and to a lesser
extent at later stages (Looijenga et al., 2003). Expression of
OCT3/4 in normal and dysgenetic human ovaries has been
reported recently (Rajpert-De Meyts et al., 2004). In our ana-
lysis, OCT3/4 was occasionally seen in early oocytes, but
never in germ cells involved in folliculogenesis, indicating
that human female germ cells irreversibly lose pluripotency
once they progress to meiosis and engage in a close cell–cell
interaction with granulosa cells. It is therefore tempting to
speculate that both the processes of cell–cell interaction and
down-regulation of OCT3/4 are important for germ cell
maturation. It should be noted that this is different from the
situation found in mouse follicles, where germ cells after
completion of meiotic prophase I express OCT3/4 (see Table
IV) (Pesce et al., 1998). However, the exact mechanisms of
interaction are not yet understood, and deserve further inves-
tigation. In this context it is interesting that ovarian teratomas
originate from germ cells at different stages of meiosis (Surti
et al., 1990). The finding that these tumours show a restricted
potential to differentiate and exclusively demonstrate somatic
differentiation is in line with previous reports that the pre-
sence of OCT3/4 in embryonic stem cells is crucial to keep
these cells in an undifferentiated state (Niwa et al., 2000).
We therefore speculate that ovarian teratomas arise from
germ cells that have already lost expression of OCT3/4. Our
findings demonstrate the value of both PLAP and OCT3/4
for the characterization of immature germ cells in the female
gonad and indicate that these markers can be useful for the
identification of developmentally arrested germ cells in
pathological conditions, e.g. in dysgenetic gonads, as has
been described recently (Rajpert-De Meyts et al., 2004).
VASA is a member of the DEAD box family of RNA heli-
cases and is specifically expressed in the germ cell lineage
(Castrillon et al., 2000). Furthermore, VASA expression has
been detected by immunohistochemistry in migratory PGC at
gestational week 7 and in germ cells both before and after
birth (Castrillon et al., 2000). It is most abundantly expressed
in postmeiotic germ cells, i.e. in males in spermatocytes and
in females in mature oocytes. VASA has also been described
in testicular germ cell tumours retaining germ cell
characteristics (Zeeman et al., 2002). Interestingly, in murine
embryonic stem cells, expression of Mvh, the mouse VASA
homologue, has been described as an early event in the com-
Table IV. Comparison of gene expression of female human and mouse
germ cells during maturation
Marker Early
postmigratory
germ cells (pre-
meiotic)
Maturing germ
cells
Late germ cells
(post-meiotic
prophase I)
Human Mouse Human Mouse Human Mouse
OCT3/4 þþ þþ*,a þ /2† 2a,b ?† þb
c-KIT þ þ*,a þþ 2*,a þþ þc
VASA þ þ*,a þþ þþ*,a þþd þþ e
*Results are based on RT–PCR (expression of mRNA); all other results are
based on immunohistochemistry.
†Note that the exact time-point of down-regulation of OCT3/4 with regards
to onset of meiosis has not yet been established in human oocytes. We could
not detect re-expression of OCT3/4 in primary and secondary follicles of 34
adult women (data not shown). However, the observation that OCT3/4
mRNA is not present in earlier stages of folliculogenesis but can be detected
both in bovine and human mature oocytes and preimplantation embryos
(Daniels et al., 2000; Huntriss et al., 2002) warrants investigation at what
stage this protein is re-expressed in mature/ovulating oocytes or during
fertilization.
aReferences: Hubner et al. (2003);
bPesce et al. (1998);
cHorie et al. (1991);
dCastrillon et al. (2000);
eToyooka et al. (2000).
The expression of a number of markers in human female germ cells (early
postmigratory cells and cells at different stages of maturation), investigated
in this analysis, is compared to data from the literature on the expression of
these markers in mouse germ cells at comparable stages of maturation. The
most striking difference between human and mouse germ cells is seen in
expression of c-KIT, which is down-regulated in the mouse during oocyte
maturation, but remains expressed in human oocytes throughout maturation.
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 mitment of stem cells to the germ cell lineage (Toyooka
et al., 2000, 2003). In our study, expression of VASA has
been found both in germ cells at all gestational ages. In
accordance with previous reports (Castrillon et al., 2000),
staining intensity was stronger in maturing oocytes than
oogonia. Our results illustrate the usefulness of this protein
as a marker of germ cells at all stages of development and
allow an estimation of germ cell numbers at different ages.
c-KIT, b-catenin, and E-cadherin are all involved in cell
signalling and cell–cell interaction. c-KIT is a type III recep-
tor tyrosine kinase found on early germ cells, whereas the
ligand stem cell factor (SCF or KIT-L) is present in granu-
losa cells (Matzuk et al., 2002, for review). The c-KIT/SCF
system has been found to be involved in survival and pro-
liferation of migrating germ cells in mice (McLaren, 1992).
In human intrauterine gonadogenesis, c-KIT expression has
been described in female PGC at the period of arrival of
PGC at the gonadal ridges at week 7 and later between 13
and 21 weeks of gestational age (Horie et al., 1993; Jørgen-
sen et al., 1995; Robinson et al., 2001). During folliculogen-
esis, c-KIT has been postulated to play a role in germ cell
survival, possibly by up-regulating Mcl-1, an anti-apoptotic
member of the Bcl-2 family (Hartley et al., 2002).
Whereas some data are available on the cadherin–catenin
complex in mouse PGC development and oocyte maturation
(Ohsugi et al., 1999; Di Carlo and De Felici, 2000), little is
known about the role of these factors in human germ cell devel-
opment. In an earlier analysis, the presence of E-cadherin on
human oocytes has been demonstrated (Campbell et al., 1995).
Here we show that c-KIT, b-catenin and E-cadherin are all
present in germ cells throughout all stages of female intra-
uterine development. The presence of these factors not only in
maturing oocytes and germ cells during folliculogenesis, but
also in oogonia could be demonstrated by double-stainings
combining markers for early germ cells such as OCT3/4 and
PLAP with c-KIT and b-catenin. As oogonia are often found in
clusters, these factors seem to be involved in signalling between
neighbouring immature germ cells. In primordial follicles,
expression of these factors was predominantly seen in oocytes
at the site of cell–cell interaction with granulosa cells. This
suggests that cell–cell contacts play an important role, both for
immature germ cells and later between oocytes and surrounding
granulosa cells. In fact, E-cadherin has been reported to be
required for germ cell determination in PGC (Okamura et al.,
2003), and in oocyte growth and acquisition of meiotic compe-
tence in mice (Carabatsos et al., 2000). The functional import-
ance of E-cadherin has further been demonstrated by
dissociation/reassociation experiments in a mouse model: disso-
ciated cells from gonads were unable to reform their initial
contacts when cultured in the presence of an antibody to
E-cadherin (Mackay et al., 1999).
The total numbers of germ cells seen in one visual field, as
assessed by either c-KIT, b-catenin or VASA at different
gestational ages (see Figure 1), are in accordance with pre-
vious reports, where a steady decrease of germ cells from
around weeks 18–20 gestational age resulted in numbers that
were only one-sixth of peak values at term (Baker, 1963).
We therefore conclude that assessment of cell numbers in
one representative visual field at magnification £ 200 and
including comparable surface areas of cortical and medullary
areas is a reliable method for semiquantitative analyses. Our
results allow some interesting comparisons with data on
mouse germ cell maturation (see Table IV).
Taken together, our data provide a number of interesting
findings regarding the development and differentiation of
human germ cells in the fetal ovary. Immature germ cells are
characterized by expression of PLAP and show pluripotent
potential, as is illustrated by the expression of OCT3/4.
During the first part of the second trimester included in our
study (gestational ages of weeks 15.5–20), the number of
immature germ cells is high, and the pool of these cells
decreases significantly after weeks 22–24. In accordance
with previous reports, regional differences in the number of
immature germ cells were found when comparing the cortex
and medulla of the ovary. This finding supports the model of
compartmentalization, in which the cortex is the area where
expansion of immature germ cells take place, the medulla
providing the environment needed for germ cell maturation.
Accompanying the gradual shift from oogonia and early
oocytes to germ cells engaged in formation of primordial fol-
licles, loss of expression of first PLAP and consecutively
OCT3/4 can be observed. Interestingly, in male fetal germ
cells loss of pluripotency as judged by loss of OCT3/4 is
observed at the time when gonocytes become attached to the
basal membrane of the seminiferous tubules and come into
close contact with nurturing Sertoli cells (Honecker et al.,
2004). As down-regulation of OCT3/4 in female germ cells
occurs at a time when oocytes become surrounded by granu-
losa cells and start to form primordial follicles, a major role
of cell–cell interactions in the maturation of germ cells in
both sexes can be postulated. Expression of c-KIT, b-catenin,
and E-cadherin in germ cells at all stages of germ cell devel-
opment points towards a role of these factors for germ cell
survival and maturation. Our findings help to define normal
germ cell development and maturation in the human fetal
ovary and will serve as a reference for further analyses inves-
tigating both normal and pathological processes in germ cell
maturation, i.e. in dysgenetic gonads or in individuals show-
ing chromosomal aberrations (Kersemaekers et al., 2005,
M.Cools et al., unpublished data).
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Abstract
Several proteins, such as the placental/germ cell alkaline phosphatases (PLAPs), the stem
cell factor receptor c-KIT, and the transcriptional regulator and marker of pluripotency
OCT3/4, have been found in both normal immature and malignant germ cells, known
as carcinoma in situ/intratubular germ cell neoplasia unclassified (CIS/ITGCNU). In the
present study, immunohistochemical methods were used to evaluate the expression of these
markers in a series of male gonads from fetuses from the second and third trimesters,
and neonates. In addition to these markers, the presence of VASA (a protein specific for
the germ cell lineage), TSPY (the testis-specific protein, Y-encoded), and the proliferation
index (Ki-67 antigen) was analysed. All these proteins are reported to be present both during
spermatogenesis and in CIS/ITGCNU. Positive staining for VASA with varying intensity was
found in all germ cells, while TSPY was predominantly located in the prespermatogonial
cells at all developmental ages. In contrast, the markers PLAP, c-KIT, OCT3/4, and Ki-
67 were more frequent at earlier developmental stages and decreased gradually with time,
although they could occasionally be detected in germ cells of neonates. These findings are
in line with a declining number of gonocytes during fetal development, concomitant with
an increase in the number of prespermatogonia. The latter have lost the immature germ
cell phenotype. These findings are compatible with the hypothesis that CIS/ITGCNU arises
from developmentally arrested germ cells, most likely primordial germ cells/gonocytes, at
an early time point during intrauterine development.
Copyright  2004 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
Keywords: germ cells; fetal gonads; carcinoma in situ/intratubular germ cell neoplasia
unclassified (CIS/ITGCNU); immunohistochemistry; developmental arrest
Introduction
In humans and rodents, amongst other species, the
embryonic precursors of the gametes are known as
primordial germ cells (PGCs) (see ref 1 for a review).
These cells are set aside to an extra-embryonic
localization early during embryonic development and
around the fifth and sixth weeks of human develop-
ment, they migrate to the area where the genital ridge
will be formed [2]. Subsequently, gonadal and sexual
differentiation occur in the sixth and seventh weeks
[3]. With regard to testicular development, the germ
cells at this particular stage are referred to as gono-
cytes, which are predominantly found in the central
areas of the newly formed tubules. Starting around the
14th week of development, these gonocytes gradually
migrate towards the tubular periphery. Once the cells
are in close contact with the basal lamina of the tubule,
they are referred to as prespermatogonia. Maturation
is a gradual process; at the 20th gestational week, the
fetal testis predominantly contains prespermatogonial
germ cells [4]. During the first few years after birth and
until puberty, morphological and functional changes
occur, including a change from large, immature germ
cells (prespermatogonia) to adult type A spermatogo-
nia [5–7]. With the onset of puberty, spermatogonia
undergo further spermatogenic maturation and after
meiotic divisions, finally produce spermatozoa.
On the basis of multiple findings, it has been hypoth-
esized that CIS/ITGCNU, the common precursor
lesion of adult testicular germ cell tumours (TGCTs),
originates early during fetal development (see ref 8 for
a review). This is illustrated by the presence of a num-
ber of markers common to CIS/ITGCNU and imma-
ture germ cells, including germ cell/placental alkaline
phosphatases (PLAPs), the proto-oncogene receptor c-
KIT, and the transcriptional regulator and marker of
pluripotency OCT3/4. CIS/ITGCNU cells phenotyp-
ically and ultrastructurally resemble PGCs/gonocytes
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Table 1. Antibodies (source) and detection method used for immunohistochemistry
Antibody Company Code Pretreatment Dilution
Secondary antibody
(1 : 200) (biotinylated) Visualization
PLAP Cell Marque CMC203 HIAR∗ 1 : 200 Rabbit anti-mouse (Dako E0413) ABCplx-ap†
c-KIT Dako A4502 HIAR 1 : 500 Swine anti-rabbit (Dako E0413) ABCplx-ap
OCT3/4 Santa Cruz sc-8629 HIAR 1 : 1000 Horse anti-goat (Vector BA9500) ABCplx-hrp‡
VASA Provided by D Castrillon [43] HIAR 1 : 2000 Swine anti-rabbit ABCplx-ap
TSPY Provided by Y Lau [39] None 1 : 3000 Swine anti-rabbit ABCplx-ap
Ki-67 Dako A047 HIAR 1 : 50 Swine anti-rabbit ABCplx-hrp
∗ Heat-induced antigen retrieval [42].
† ABC complex, alkaline phosphatase, Dako Code: K0391.
‡ ABC complex, horseradish peroxidase, Dako Code: K0377.
[9–11]. Moreover, epidemiological data support the
hypothesis that the initiating event of TGCT devel-
opment occurs during the fetal period [12]. In spite
of these data, an alternative origin of TGCTs has been
suggested, in which the pachytene spermatocyte, a cell
not found during the prepubertal period, has been sug-
gested to be the target of transformation [13].
In order to investigate the origin of CIS/ITGCNU
further, we undertook an extensive study of the pres-
ence of a number of markers during normal fetal tes-
ticular development. This will help us to define further
the emerging phenotype of CIS/ITGCNU and shed
light on the possible limitations of these markers for
early diagnosis of CIS/ITGCNU in high-risk neonates
and infants.
Material and methods
Tissue samples
Use of tissues for scientific reasons was approved
by an institutional review board (MEC 02.981). The
samples were used according to the ‘Code for Proper
Secondary Use of Human Tissue in The Netherlands’,
as developed by the Dutch Federation of Medical
Scientific Societies (FMWV) (version 2002).
Human fetal gonads from 27 males from the sec-
ond and third trimesters after spontaneous or induced
abortions (gestational age 15–40 weeks), or from pre-
mature and term neonates that had died shortly after
birth, and one infant who died from cot death at the
age of 6 weeks were obtained from post-mortem sec-
tions in our department. Testes were dissected and
fixed in 10% formalin and processed into paraffin wax.
To ensure satisfactory quality, poor preservation of
tissue samples assessed by haematoxylin and eosin
staining led to exclusion from this analysis. Cases
showing conditions that possibly affect gonadal devel-
opment, such as trisomy 13, 18 and 21, hydrocephalus,
maldeveloped kidneys, or gross intrauterine growth
retardation, were excluded from the study. Gestational
ages were calculated in relation to the mother’s last
menstrual cycle and were in accordance with the foot
length and the crown–heel length measurements at
autopsy, showing a maximum variation of 2 weeks.
Histochemical and immunohistochemical staining
For immunohistochemistry, sections were incubated
with the primary antibody overnight at 4 ◦C (PLAP,
c-KIT, TSPY, VASA) or for 2 h at room temperature
(OCT3/4, Ki-67). The antibodies used are indicated
in Table 1. Sections were counterstained with haema-
toxylin.
Double staining was performed by using a combi-
nation of the same detection method but with differ-
ent substrates: Fast blue/naphthol ASMX phosphate
(F3378 and N500; Sigma, Steinheim, Germany) for
blue staining and 3-amino-9-ethyl-carbazole (A.5754
and D4254; Sigma, Steinheim, Germany)/H2O2 for
red staining, without counterstain. Endogenous perox-
idase activity and/or endogenous biotin was blocked
using 3% H2O2 (for 5 min) and/or a blocking kit for
endogenous biotin (Vector Laboratories, Burlingame,
CA, USA) to prevent background staining [14].
For quantification, cell numbers showing a positive
signal were counted in five to ten cross-sections of
seminiferous tubules by two different observers (FH
and HS) who were blinded to the gestational age at
which the material was sampled.
Results
The presence of a number of well-known and novel
markers for CIS/ITGCNU during normal fetal testic-
ular development was studied. The available data on
these markers are summarized in Table 2. The results
are reported separately for the known CIS/ITGCNU
markers (PLAP, c-KIT, and OCT3/4) and the other
markers analysed (VASA, TSPY, and Ki-67). Subse-
quently, the results of double staining are described.
Representative illustrations are shown in Figure 1.
Figure 2 summarizes the results of each marker for
each case individually. For the majority of cases,
intra-individual comparison of the expression of
CIS/ITGCNU markers (PLAP, c-KIT, and OCT3/4)
gave consistent results, reflecting the state of matu-
ration of one particular case. The data for the whole
population are depicted graphically in Figure 3 (grey
bars) and compared with findings published so far
(black bars).
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Table 2.Overview of markers for carcinoma in situ/intratubular
germ cell neoplasia unclassified (CIS/ITGCNU), proliferation,
and germ cell-specific factors
Marker/
antigen
CIS/ITGCNU
(intensity) References
Glycogen +++ Nielsen and Lein, 1974 [20]
PLAP +++ Beckstead, 1983 [44]; Jacobsen and
Norgaard-Pedersen, 1984 [45]
c-KIT +++ Rajperts-De Meyts and Skakkebæk, 1994
[46]; Strohmeyer et al, 1995 [47]
OCT3/4 +++ Looijenga et al, 2003 [27]
VASA + Zeeman et al, 2002 [48]
TSPY ++ Schnieders et al, 1996 [38]; Lau et al,
2000 [39]
Ki-67 +++ Datta et al, 2000 [30]
Immunohistochemical detection of PLAP, c-KIT,
and OCT3/4
Positive staining for PLAP, c-KIT, and OCT3/4 was
seen specifically in the germ cells, while no staining
was present in Sertoli, Leydig, or interstitial cells (see
Figure 1).
The highest number of germ cells staining for
PLAP was seen in the earliest stages of fetal develop-
ment examined and decreased continuously through-
out the following weeks with advancing gestational
age. Within the tubules of earlier stages, PLAP
was predominantly detected in gonocytes, and to a
lesser extent in prespermatogonia (see Figure 1A).
After birth, PLAP could still be found occasionally
(see Figure 2A), with maximally one positive cell
per visual field. These cells were almost exclusively
located in the centre of the tubules. Mainly during the
second trimester, a large number of germ cells were
positive for c-KIT, which, like PLAP, declined grad-
ually throughout gestation. Again, positive germ cells
were detectable at term, albeit at low numbers. Within
the tubules, c-KIT was seen in both gonocytes and
prespermatogonia (see Figures 1B and 2B).
OCT3/4 resulted in nuclear staining of germ cells at
all gestational ages. With advancing gestational age,
a constant decrease in cells staining for OCT3/4 was
found (see Figure 2C). High numbers with an average
of four to six cells per tubule, mainly gonocytes,
were seen throughout the first half of the second
trimester (Figure 1C). Throughout the second half of
the second trimester, the average number of positive
cells decreased to less than three cells per tubule. At
term, only a few positive germ cells were detectable,
mainly located in the centre of the tubules.
An increased number of germ cells positive for
PLAP, c-KIT, and OCT3/4 were seen in testes
from three second-trimester fetuses with chromoso-
mal abnormalities, ie trisomy 21 and 18: these were
not included in the series presented (data not shown).
These findings are in line with previous reports [15,16]
and support the model that chromosomal abnormalities
can interfere with normal germ cell maturation.
Immunohistochemical detection of VASA, TSPY,
and Ki-67
VASA-positive germ cells were found at all gestational
ages and after birth. Although the staining intensity
was variable, prespermatogonia showed consistently
stronger staining than gonocytes (see Figure 1D). The
number of positive cells per tubule decreased only
slightly with gestational age, resulting in a different
overall staining pattern compared with the factors
described above: VASA was still found in germ cells
at term and in neonates (see Figure 2D). Nuclear and
cytoplasmic TSPY was predominantly observed in
putative prespermatogonia, based on their peripheral
localization within the tubules, at all gestational ages.
No decrease in staining was found at term or in the
first few weeks after birth (see Figure 2E). On average,
three to five cells per tubule showed positive staining,
most often seen in pairs or groups of germ cells
(Figure 1E). In contrast to the other markers described
so far, TSPY was not restricted to germ cells, but was
also detected in Leydig cells at all ages examined.
Ki-67 showed nuclear staining in a high number of
cells, both within and outside the tubules, throughout
the whole period of testicular development investi-
gated. In developing tubules, until 24 weeks of gesta-
tional age, Ki-67 was predominantly seen in gonocytes
(Figure 1F); after 24 weeks, both basally and cen-
trally located germ cells showed staining in roughly
equal numbers. The number of positive cells decreased
steadily with advancing age, and perinatally, only a
few intratubular cells in the tubules remained positive
(see Figure 2F). These were mostly centrally located
in the tubules, whereas the majority of prespermato-
gonia seemed to have entered a quiescent phase at that
time.
Results of double staining
Double staining was performed to assess correla-
tions or differences in the presence of various mark-
ers in germ cells at different gestational ages. A
total of seven cases at 15, 18, 21, 24, 27, 30, and
35 weeks’ gestational age were stained for four dif-
ferent combinations: OCT3/4 and PLAP; OCT3/4
and c-KIT; PLAP and c-KIT; and OCT3/4 and
VASA (Figures 1G–1J, respectively). The results of
all double-staining experiments were in accordance
with the single staining results. Staining for OCT3/4
and PLAP revealed that at all stages, a higher num-
ber of germ cells were positive for OCT3/4 than for
PLAP. PLAP was never detected in germ cells neg-
ative for OCT3/4 and the presence of OCT3/4 was
more frequently observed at later stages of gestational
development, when PLAP was almost undetectable. In
contrast, OCT3/4 and c-KIT were found in compara-
ble numbers of germ cells at earlier stages (second
trimester), but c-KIT remained positive in more germ
cells than OCT3/4 at later stages (third trimester).
In agreement with these findings, double staining for
PLAP and c-KIT showed that at all gestational ages
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more germ cells were positive for c-KIT than for
PLAP. PLAP was never detected in germ cells nega-
tive for c-KIT, but due to an earlier loss of PLAP, the
ratio of cells showing only c-KIT expression versus
the number of cells positive for both factors increased
from approximately 3 : 1 in the second trimester to
approximately 9 : 1 during the third trimester.
An inverse correlation was found between the pres-
ence of OCT3/4 and the intensity of VASA. Gonocytes
were positive for OCT3/4, but only weakly positive for
 Expression of markers of testicular CIS by fetal germ cells 
43 
VASA during the second trimester, whereas presper-
matogonia staining strongly for VASA mostly lacked
OCT3/4 (Figure 1J).
Discussion
The aim of this study was to examine the differential
presence of a number of factors known to be present
in both human fetal germ cells and CIS/ITGCNU, the
pre-invasive stage of TGCTs. In addition, we studied a
number of factors associated with the proliferation and
differentiation of germ cells, allowing us to correlate
our findings with the fate of these cells during the sec-
ond and third trimesters and the first weeks after birth.
Overall, the presence of all CIS/ITGCNU mark-
ers decreases during the second and third trimesters
(see Figure 2, left panels). Nevertheless, with increas-
ing age, expression was down-regulated differentially.
This resulted in a specific expression pattern for each
of these factors during fetal male germ cell devel-
opment. We interpret these data in the context of a
gradual process of maturation, extending into the first
year of life, which is in accordance with earlier reports
[17–20]. The results of the different double-staining
experiments indicate that PLAP is the first factor that
is down-regulated during the development of normal
germ cells, followed by OCT3/4 and finally c-KIT.
The fact that CIS/ITGCNU shows high expression of
PLAP points towards an early origin of the precursor
cell during intrauterine development. In the following
paragraphs, the most interesting findings of the indi-
vidual markers included in this study will be discussed
in detail, predominantly in the context of understand-
ing the patho-biological consequences of our findings.
c-KIT is a type III receptor tyrosine kinase, of
which stem cell factor (SCF) is the ligand (see ref
21 for a review). The c-KIT/SCF system has been
found to be involved in survival and proliferation of
migrating germ cells in mice [22]. Our recent finding
of the presence of activating mutations affecting one
specific site of the receptor in the majority of bilateral
TGCTs is in agreement with this model and supports
activation of c-KIT as an early initiation event in
the pathogenesis of TGCT [23]. Here we show a
high presence of c-KIT at the early stages of germ
cell development. Its expression generally declines
with advancing age during the intrauterine period, but
persists throughout the second and third trimesters
and to a lesser extent after birth. This is in contrast
to earlier reports, in which the authors concluded
from a rapid decrease of c-KIT at 10–13 weeks that
malignant transformation takes place early during fetal
development, possibly even before week 10 [10].
However, more in line with the observation of this
study, the detection of c-KIT in germ cells at later
stages of development has been described in a recent
report [24]. The discrepancies between the different
studies might be due to differences in the sensitivity
of the antibodies and the detection methods used.
OCT3/4 is a transcriptional regulator, exclusively
found in pluripotent human and mouse embryonic
stem cells and early germ cells (see refs 25–28
for a review). Recently, it has been described to
be present in specific subtypes of TGCTs, including
CIS/ITGCNU [27,29], in the context of which it is an
informative diagnostic marker [27]. Here we show,
in contrast to our earlier more limited study, that
OCT3/4 can still be present during the first weeks
after birth, albeit at very low frequency. In neonates,
OCT3/4 is almost exclusively expressed in gonocyte-
like cells located centrally in the tubules, and not in
prespermatogonia.
Ki-67 is a nuclear antigen, which is studied in
CIS/ITGCNU and TGCTs [30,31]. This antigen is
informative in the assessment of proliferation, includ-
ing germ cells in normal human testis, both during the
fetal period and in newborns. Conflicting data on Ki-
67 in germ cells at term have been reported [7,32]. To
define further the population of proliferating germ cells
during the intrauterine period, we assessed the expres-
sion of Ki-67 at different gestational ages. Throughout
the second trimester, there was a decrease in the num-
ber of positive cells, which remained constant at a
somewhat lower level at later ages. Interestingly, pro-
liferation was seen in two different populations of
germ cells at different time points. Ki-67 was predom-
inantly seen in gonocytes until the end of the second
trimester (ie around weeks 24–26). Thereafter, both
basally and centrally located cells expressed Ki-67
Figure 1. Results of the immunohistochemical analysis of different markers in fetal germ cells. (A) Fetal testis (15 weeks of
development); PLAP (red signal) is seen in gonocytes and prespermatogonia. (B) Same case; c-KIT staining (red signal) is seen in
a large number of gonocytes and prespermatogonia. (C) Same case; OCT3/4 (brown nuclear signal). (D) Same case; VASA (red
signal). Note the variation in staining, with weaker signal intensity in gonocytes (more centrally in tubules) than in prespermatogonia
(on the basal membrane of tubules). (E) Testis of a neonate (6 weeks); TSPY (red nuclear and cytoplasmic signal), mainly in
prespermatogonia. Note also the nuclear and cytoplasmic staining of Leydig cells (arrow). (F) Fetal testis, 24 weeks: Ki-67 (brown
nuclear signal) is seen both in tubules and in interstitial cells. (G) Fetal testis, 21 weeks: double staining for OCT3/4 (red nuclear
signal) and PLAP (blue cytoplasmic signal). OCT3/4 and PLAP are co-expressed in the majority of immature germ cells, and
occasional cells are positive for OCT3/4 but negative for PLAP (arrow-head). Note higher magnification. (H) Fetal testis, 15 weeks:
double staining for OCT3/4 (blue nuclear signal) and c-KIT (red membranous signal). Note co-expression of OCT3/4 and c-KIT in
the majority of germ cells. (I) Fetal testis, 15 weeks: double staining for PLAP (blue cytoplasmic signal) and c-KIT (red membranous
signal). Note that co-expression of both markers results in a dark, almost black signal. The majority of germ cells express only
c-KIT, whereas only a minority are positive for both markers. (J) Fetal testis, 21 weeks: double staining for OCT3/4 (red nuclear
signal) and VASA (blue cytoplasmic signal). Germ cells showing a strong intensity for VASA are negative for OCT3/4 and are more
often found on the basal lamina of the tubule. Note higher magnification
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Figure 2. Absolute numbers of cells per tubule showing positive immunohistochemical staining for the markers at different
gestational ages (weeks). The earliest case studied in this series was 15 weeks; the oldest was a neonate of 6 weeks. The arrow
indicates the time of birth (median 40 ± 2 weeks). The left panels (A–C) show markers for CIS/ITGCNU; the right panels
(D–F) illustrate factors associated with germ cell differentiation and proliferation. Each black spot represents one case
in roughly equal numbers, suggesting that, in addi-
tion to gonocytes, the pool of more differentiated
prespermatogonia also expands during the late sec-
ond and third trimesters, extending into the first weeks
after birth.
Human TSPY, the testis-specific protein, Y-encod-
ed, gene, is organized as a repetitive gene family
mapped to the critical region of the gonadoblastoma
(GBY) [33–35] locus on the short arm of the Y
chromosome [36,37]. It is mainly found during early
spermatogenesis and has been suggested to play a nor-
mal role in spermatogonial proliferation and an onco-
genic role in early germ cell tumourigenesis [38,39].
Expression of TSPY sequences has been found by
RNA analysis in prenatal and adult testes [37,40,41].
To our knowledge, we describe for the first time the
presence of TSPY protein in human germ cells during
male gonadal development. Staining was often seen
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Neonatal period
week 17 – week 37 (Looijenga et al, 2003) [27]
First trimester
(week 1 – week 12)
Second trimester
(week 12 – week 28)
earliest case included in this
series: 15 weeks
Third trimester
(week 28 – partus)
Ki-67
TSPY
VASA 
OCT3/4
PLAP
(Alkaline phosphatase)
c-KIT
week 4 – first year of life (Pinkerton et al 1961; Jørgensen et al, 1993) [51, 17]
week 8 – week 20 (Castrillon et al, 2000: Horie et al, 1993) [43, 52]
week 7 - term (Castrillon et al, 2000) [43]
week 16 – third trimester (Ketola et al, 2003) [32]
Partus
Figure 3. Overview of the data currently available from the literature on the expression of different antigens in germ cells during
intrauterine development (black bars) compared with the findings of this study (grey bars). The sizes of the grey bars schematically
represent the frequency of germ cells expressing the individual factor at different developmental ages
in groups of prespermatogonia throughout the second
and third trimesters and in neonates. Although little
is known about the function of this protein, a role
in the regulation of the proliferation of germ cells is
tempting, as has been suggested before [39].
In summary, our data indicate that during the sec-
ond trimester, gonocytes are positive for a number
of CIS/ITGCNU markers, such as OCT3/4, c-KIT,
and PLAP. During the process of maturation towards
prespermatogonia, these cells gradually lose these
early markers. During further development, there is
a relative decrease in the number of gonocytes com-
pared with more mature prespermatogonia. Interest-
ingly, the time point at which more and more germ
cells become attached to the basal lamina of the tubule
(between weeks 20 and 24) coincides with an over-
all decrease in Ki-67 expression, down-regulation of
the CIS/ITGCNU markers, and an increase in VASA
staining intensity. This suggests a preference for differ-
entiation over proliferation at the transition from gono-
cytes to prespermatogonia during the second trimester
and indicates that attachment to the basal membrane
could be important for germ cell maturation. This
model is supported by the results of the double-
staining experiments for OCT3/4 and VASA, where
gonocytes in the more central areas of developing
tubules show expression of OCT3/4, but low stain-
ing intensity for VASA. Although de-differentiation
and consecutive re-expression of early markers cannot
be ruled out as a mechanism for the development of
CIS/ITGCNU, our data are in line with the model of a
maturation arrest of immature germ cells as one of the
first pathogenetic hits in the development of TGCTs.
Two observations from the study presented are par-
ticularly noteworthy. First, the presence of markers
such as PLAP, c-KIT, and OCT3/4 is not restricted to
the early stages of germ cell maturation, but extends
well into the second and third trimesters and can, in
fact, still be found in neonates. Therefore, in contrast
to the situation in the testes of adolescents and adults,
these markers can be unreliable for the detection of
CIS/ITGCNU in very young children. This adds fur-
ther evidence to the notion that testicular biopsy is of
limited value in this age group [49,50]. Second, gono-
cytes that are positive for these markers at the later
stages of normal development are hardly ever found
on the basal membrane of the seminiferous tubules,
but are localized more centrally. This distinguishes
them from CIS/ITGCNU cells, which are always in
contact with the basal membrane and phenotypically
and ultrastructurally resemble prespermatogonia [11].
This indicates that CIS/ITGCNU cells, possibly due to
a maturation arrest, show a certain marker profile that
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normal germ cells in this localization have already lost.
However, while retaining features of immature germ
cells, CIS/ITGCNU cells also show some potential to
develop along the germ cell lineage, as is documented
by the presence of VASA and TSPY in these cells.
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Summary Carcinoma in situ (CIS) is the precursor of malignant testicular germ cell tumors (GCTs) of
adolescents and young adults, being the neoplastic counterpart of primordial germ cells/gonocytes.
Carcinoma in situ cells will develop into invasive seminoma/nonseminoma. Gonadoblastoma (GB) is
the precursor of invasive GCTs in dysgenetic gonads, predominantly dysgerminoma (DG). In this
process, part of the Y chromosome (GBY region) is involved, for which TSPY is a candidate gene.
A detailed immunohistochemical survey was performed for the known diagnostic markers, germ cell/
placental alkaline phosphatase (PLAP), c-KIT, and OCT3/4, as well as testis-specific protein on the
Y chromosome (TSPY) on a series of GBs, and adjacent invasive DGs. All 5 patients were XY
individuals (4 females and 1 male). In contrast to c-KIT, PLAP was positive in all cases. The immature
germ cells of GBs were positive for OCT3/4, whereas the mature germ cells were negative for this
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Abbreviations: GB, Gonadoblastoma; CIS, Carcinoma in situ; CH, Choriocarcinoma; DG, Dysgerminoma; EC, Embryonal carcinoma; (T)GCT, (testicular)
germ cell tumor; H&E, Hematoxylin and eosin; OCT3/4, Octamer binding transcription factor involved in regulation of pluripotency, also referred to as POU
domain class 5 transcription factor 1 (POU5F1); PLAP, Germ cell/placental alkaline phosphatase; TE, Teratoma; TSPY, Testis-specific protein on the
Y chromosome. This gene maps to the gonadoblastoma region on the Y chromosome (GBY); WHO, World Health Organization; YST, Yolk sac tumor.
T Corresponding author.
E-mail address: l.looijenga@erasmusmc.nl (L.H.J. Looijenga).
1 Both authors contributed equally to the work.
2 Current address: Department of Oncology and Hematology, University Hospital Hamburg Eppendorf, Martinstr. 52, 20246 Hamburg, Germany.
Keywords:
Gonadoblastoma;
Dysgerminoma;
CIS;
OCT3/4;
TSPY;
Progression;
Malignant
transformation;
Clonal selection
Chapter 4   
 52
marker, but positive for TSPY. In every GB, a minor population of germ cells positive for both markers
could be identified, similar to most CIS cells and early invasive DG. On progression to an invasive
tumor, TSPY can be lost, a process that is also detectable in invasive testicular GCTs compared to CIS.
These results indicate that GB is a heterogeneous mix of germ cells, in which the OCT3/4-positive cells
have the potential to undergo progression to an invasive tumor. These early invasive stages are initially
also positive for TSPY (like CIS), supporting a positive selection mechanism. Therefore, OCT3/4 in
combination with TSPY is valuable to identify malignant germ cells in dysgenetic gonads. This could
allow better prediction of the risk of progression to a GCT. In addition, the data support the model that
GB represents the earliest accessible developmental stage of malignant GCTs.
D 2005 Elsevier Inc. All rights reserved.
1. Introduction
Human germ cell tumors (GCTs) represent a unique and
complex group of neoplasms. Recently, we proposed a
classification system on the basis of various parameters,
including age at clinical presentation, anatomical site of the
tumor, sex of the patient, histology, and chromosomal
constitution (see Refs [1,2] for review). This classification
has been acknowledged by the World Health Organization
[3]. The group of tumors referred to as type II GCTs are the
seminomas and the nonseminomas of the testis and
mediastinum, known as (non)dysgerminomas of the ovary
and dysgenetic gonad, and (non)germinomas of the brain.
Various risk factors for these types of GCTs have been
identified, in particular, related to those of the gonads,
including cryptorchidism and gonadal dysgenesis [4-6]. The
precursor of testicular seminomas and nonseminomas is
well established and known as carcinoma in situ (CIS) [7],
also referred to as intratubular germ cell neoplasia unclas-
sified. The precursor lesion of the tumors of the dysgenetic
gonad is called gonadoblastoma (GB) [4]. Like CIS, it
shows the potential to progress to an invasive GCT, mainly
dysgerminoma (DG), and less frequently to other tumor
components, as embryonal carcinoma (EC), teratoma (TE),
yolk sac tumor (YST), and choriocarcinoma (CH). Being a
rare condition, GB has not been studied extensively, even
though it might increase our understanding of the different
pathogenetic steps involved in the development of malig-
Table 1 Clinical data and summary of immunohistochemical results of PLAP, c-KIT, OCT3/4, and TSPY staining experiments of germ
cells in GB, DG, and TGCTs of adolescents and adults
Organ Sex Case Age (y) Histology PLAP c-KIT OCT3/4 TSPY
Dysgenetic
gonad
F 1 18 GB +  ++ +
Early invasive DG +  ++ +
F 2a 20 GB + + ++ +
Early invasive DG + + ++ +
F 3 14 GB + + ++ +
Early invasive DG + + ++ +
M 4 21 GB +  ++ +
Early invasive DG +  ++ +
Progressed DG +/  ++ +/
F 5 16 GB +  ++ +
Testis M n = 31 N16 CIS ++ +/ ++ ++()
n = 21 N16 Seminoma ++ +/ ++ +
N16 Nonseminoma:
n = 18 EC + + + 
n = 9 TE    
n = 7 YST    
n = 4 CH    
The organ, phenotype of the patient (all patients with a dysgenetic gonad had a 46,XY karyotype), age of the patient at time of tissue sampling (years),
histology of the tumor, and staining results of immunohistochemistry at different stages of progression (GB, early invasive DG, progressed DG), EC, TE,
YST, and CH are indicated. Immunohistochemistry for c-KIT was not always positive in GB; all cases consistently showed expression of TSPY, OCT3/4,
and PLAP. Expression of the latter 2 was mainly found in immature germ cells (indicated by +/). Staining results were the same on both sides (data not
shown).  indicates negative; +/, heterogeneity of staining; +, moderate; ++, strong intensity of a homogenous staining.
a Case 2 presented with bilateral gonadoblastoma.
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nant GCTs. Both the comparatively young age at presenta-
tion [4] and the genomic constitution [8] suggest that GB
could be the earliest accessible stage in the development of a
malignant GCT.
There are strong indications that both GB and CIS are the
result of a disturbance in germ cell maturation. This model
is supported by epidemiological and morphological obser-
vations, as well as the presence of a number of immuno-
histochemical markers like germ cell/placental alkaline
phosphatase (PLAP) and the protooncogene receptor
c-KIT in CIS and GB [9-11]. Besides c-KIT and PLAP,
GBs were recently found to express TSPY (testis-specific
protein on the Y chromosome) in a limited number of cases
[12,13]. This is of particular interest, because development
of GBs has been linked to the presence of a specific part
of the Y chromosome, namely the GBY (GB on the
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Y chromosome) region [14-16]. A candidate gene in this
region is TSPY. Although its function is still unclear, a role
in the proliferation of germ cells has been suggested [13].
The model that CIS originates from an early germ cell,
either a primordial germ cell or a gonocyte, is strongly
supported by our recent finding that the octamer binding
transcription factor POU5F1, also known as OCT3/4, is
specifically found in CIS, seminoma, and EC [17]. OCT3/4
is a known marker for pluripotency. Its presence mimics the
expression pattern during embryogenesis, where this factor
is restricted to embryonic stem cells and early germ cells
(as discussed in Ref [17]). We recently found that OCT3/4 is
down-regulated during germ cell maturation both in male
and female gonadogenesis [18,19]. In a large series
investigating various malignancies, one case of GB was
positive for OCT3/4, as were all cases with testicular CIS
[17]. Recently, this was confirmed in larger series [20-25].
Presence of c-KIT, PLAP, OCT3/4, and TSPY proteins
has not been investigated systematically in a single study in
multiple GBs. To further investigate the pathogenesis of
GB, and to shed light on its pathogenetic relationship with
testicular CIS, we performed a detailed investigation of
these markers in a series of 6 GBs and adjacent invasive
tumor components. The findings were compared to those
obtained in testicular CIS and adjacent invasive GCTs. Our
results confirm that GB is a mixture of germ cells at
different stages of maturation, which can be identified by
morphology as well as the presence of various markers.
A process of selection of immature germ cells leads to the
precursor cells of invasive GCTs. This is demonstrated by
the consistent and homogenous staining pattern for both
OCT3/4 and TSPY in these cells, as well as in early invasive
tumor cells and CIS. Upon further progression, eventually
resulting in an invasive tumor, TSPY can be lost, whereas
OCT3/4 remains positive. These observations are in line
with the model that GB is an intermediate between normal
immature germ cells and CIS of the testis.
2. Materials and methods
2.1. Material
Use of tissues for scientific reasons has been approved
by an institutional review board (MEC 02.981). The
samples were used according to the bCode for Proper
Secondary Use of Human Tissue in the Netherlands,Q
developed by the Dutch Federation of Medical Scientific
Societies (FMWV) (version 2002).
Six dysgenetic gonads (including one individual with
bilateral dysgenetic gonads) containing GB with or without
an invasive tumor component were collected in the south-
western part of the Netherlands in collaboration with
pediatric surgeons, urologists, and pathologists (Table 1).
Furthermore, 21 seminomas and 38 nonseminomas of diffe-
rent, sometimes mixed, histologies (18 EC, 7 YSTs, 9 TEs,
4 CHs) of the adult testis were included, also, 31 cases of CIS
adjacent to invasive testicular germ cell tumors (TGCTs)
were retrieved from our archive. In addition, intratubular
seminoma and nonseminoma could be identified in a number
of cases. Two testicular CIS cases without the presence of an
invasive tumor were also included. Two normal testes from
fetuses of 16 and 21 weeks gestational age were obtained
after spontaneous miscarriages. The postmortem examina-
tions were carried out in our department. Tissues were
routinely formalin fixed and paraffin embedded. Diagnosis
of GB and invasive tumor parts was made according to the
World Health Organization classification by a pathologist
experienced in GCT pathology (JWO).
On the basis of morphology, the germ cells present in GBs
were classified as immature or mature. The immature cells are
characterized by their smaller size and a higher nuclear to
cytoplasmic ratio. These cells are similar to normal gono-
cytes/oogonia. The mature germ cells, which are larger with a
clear cytoplasm and which has a lower nuclear to cytoplasmic
ratio, are similar to oocytes/prespermatogonia.
Fig. 1 Representative examples of histology and immunohistochemistry of a GB included in this study (A-D, case 4, Table 1). Parallel
sections were used, allowing direct comparison of the different staining results. A, Hematoxylin and eosin staining. Note the presence of
supportive cells, Sertoli/granulosa cells (indicated by a black arrow) as well as germ cells, with various stages of maturation; immature germ
cells are small and show a high nuclear/cytoplasmic ratio (indicated throughout this figure with a red arrow), whereas mature germ cells show
the opposite characteristics (indicated throughout this figure with a green arrow). B, PLAP staining: the red cytoplasmic signal in
predominantly the immature germ cells, as well as in some stromal cells. C, OCT3/4 staining. Note the positive brown staining
predominantly in the immature and not the mature germ cells. None of the other cell types shows a positive staining. D, TSPY staining: the
red nuclear and cytoplasmic signal, predominantly in the mature compared to immature germ cells. In addition, supportive cells can be
positive. All images are at a magnification factor of 400. Representative example of immunohistochemistry for TSPYon a tissue section of
(E) seminiferous tubules with CIS and invasive testicular seminoma and (F) seminiferous tubule with CIS and invasive EC. Note that the CIS
cells are specifically stained, and note the absence of TSPY in the invasive tumor cells. G, Double staining for OCT3/4 (red) and TSPY (blue)
in an invasive seminoma (same case as shown in E). Note the double-positive CIS cells and the loss of TSPY, but only of OCT3/4 in the
invasive cells, that is, TSPY is lost upon invasive growth. Coexpression can result in a dark almost black signal. H, Representative example
of immunohistochemistry for TSPY on a tissue section of testicular parenchyma, containing both seminiferous tubules with normal
spermatogenesis (right part of the image) and CIS (left lower part of the image). Carcinoma in situ cells stain stronger than spermatogonia
(hematoxylin and eosin, original magnification 200).
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2.2. Immunohistochemistry
Staining was performed as described before [26]. For
immunohistochemistry, 3-lm-thick paraffin-embedded tis-
sue sections were incubated with the primary anti-
bodies overnight at 48C: PLAP (1:200, Cell Marque, Hot
Springs, Ark), c-KIT (1:500, Dako-Cytomation, Glostrup,
Denmark), and TSPY (1:3000, provided by C. Lau). Ki-67
(1:100, Dako-Cytomation) were incubated for 1 hour and
OCT3/4 (1:1000, Santa Cruz Bio-technology, Santa Cruz,
Calif) for 2 hours at room temperature. All slides of the
single-staining experiments were counterstained with hema-
toxylin. Alkaline phosphatase staining with new fuchsin
was used for the detection of PLAP, c-KIT, and TSPY,
resulting in a red signal of cytoplasmic, membranous, and
cytoplasmic/nuclear localization, respectively. Diaminoben-
zidine was used as chromogen in the peroxidase staining for
the detection of OCT3/4, resulting in a brown nuclear signal.
Double-staining experiments were performed using a
combination of the same detection methods but with
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different visualization methods: Fast Blue/Naphthol ASMX
phosphate (F3378 and N500; Sigma, Steinheim, Germany)
for a blue staining (TSPY) and 3-amino-9-ethyl-carbazole
(A.5754 and D4254; Sigma)/H2O2 for a red staining
(OCT3/4; Ki-67), without counterstaining. To reduce
background signal, endogenous peroxidase activity and
endogenous biotin were blocked using 3% H2O2 (for
5 minutes) and a blocking kit for endogenous biotin (Vector
Laboratories, Burlingame, Calif).
2.3. Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) was performed
as previously described [27] on paraffin-embedded tissue
sections using probes specific for the centromeric regions of
chromosomes X (DXZ1) and Y (DYZ3). Only whole nuclei
of intact cells were scored in 2 different tumor areas, both in
regions containing GB and DG, if present. The mean
number of spots per nucleus is indicated; minimum number
of cells assessed was 117.
3. Results
c-KIT and PLAP are established markers suitable for the
immunohistochemical detection of CIS cells of the adult
testis (for review, see Ref [28]). This also counts for OCT3/4
[17], of which multiple confirmative studies have been
reported [20-25], and for TSPY [29], although this is less
well established. Here we compare the staining pattern of
these markers in CIS with the findings in a series of GBs. In
total, 6 GBs were included of 5 independent patients with a
46,XY karyotype (one was bilateral). In 4 cases, an adjacent
invasive DG component was available for investigation.
Three of the invasive tumors showed an early stage of
invasiveness near the GB areas (termed early invasive
dysgerminoma, Table 1), and 1 case also contained large
invasive tumor areas at a distance from the precursor lesion
(termed progressed dysgerminoma, Table 1). The results of
the staining experiments are summarized in the Table 1, and
representative examples of staining results are shown in
Fig. 1. Double-staining experiments were performed for
TSPY and OCT3/4, and TSPY and Ki-67, of which repre-
sentative examples are shown in Figs. 1G and 2. To assess
the presence of chromosome X and Y, FISH analysis was
performed using centromere probes for these chromosomes.
Morphologically, GB lesions contain various cell types,
including somatic cells and germ cells (Fig. 1A). The first
show characteristics of Sertoli/granulosa cells (further
supported by a weak staining for vimentin using immuno-
histochemistry, data not shown), whereas the germ cells are
a mixture of cells at different stages of maturation. The
smaller cells with a high nuclear to cytoplasmic ratio are
immature germ cells, resembling gonocytes/oogonia. The
bigger cells with a large clear cytoplasm are mature germ
cells, which are similar to prespermatogonia/oocytes.
3.1. Results of single-staining experiments
c-KIT was the least consistent marker investigated in the
GBs in this study. It showed no staining in the 3 GBs and the
2 matched DGs. In contrast, PLAP was detected in all GBs
and adjacent invasive components, with a heterogeneous
pattern in the most advanced DG. However, not all germ
cells present in GBs were positive for PLAP (Fig. 1B).
Although most mature germ cell were negative, the
immature germ cells were mainly positive, although stromal
cells could show staining. Most of the tumor cells in invasive
DG showed a weaker signal intensity or were negative for
PLAP (Table 1). This indicates that PLAP is present in GB
but weaker to negative in invasive DG. A similar pattern has
been observed in testicular CIS and seminoma, in which
PLAP is down-regulated upon tumor progression (Table 1).
OCT3/4 was readily detectable as a nuclear staining in all
GBs (Fig. 1C), in which the protein was restricted to the
immature germ cells, although the more differentiated germ
cells were negative. In contrast to the heterogeneity seen in
GB, all tumor cells of DGs, both adjacent to and at distance
from GB areas, showed a homogenous staining for OCT3/4
(see also Fig. 2). Therefore, a selection of OCT3/4-positive
Fig. 2 Representative examples of double immunohistochemical staining experiments. Shown are TSPY (blue cytoplasmic and nuclear
signal) and OCT3/4 (red nuclear signal) in (A) early invasive DG (case 3, Table 1). Similar to seminoma, the vast majority of DG cells show
expression of both markers. Original magnification 400. B, Gonadoblastoma (case 1, Table 1). Note the heterogeneous staining pattern,
only a minority of cells shows a positive staining of both factors. The germ cells only positive for OCT3/4 are indicated by a red arrow, and
the germ cells only positive for TSPY by a green arrow. The double-positive cells are indicated by a red/green arrow. Original magnification
400. C, Normal fetal germ cells, gestational age 21 weeks. Note that whereas TSPY is predominantly expressed in prespermatogonia
(located on the basal membrane, green arrow), OCT3/4 is seen more frequently in gonocytes in a more central localization of the tubule
(red arrow). Only a minority of germ cells is positive for both factors (green/red arrow). Original magnification 400. D, CIS and early
(micro-)invasive seminoma. The CIS and early invasive seminoma cells (left and middle panel of the image) show expression of both
markers. Invasive seminoma cells at more distance (right panel of the image) show loss of TSPY but not of OCT3/4. Original magnification
200. E, CIS adjacent to an invasive tumor. Note the presence of CIS cells with both markers (red/green arrow) as well as CIS cells without
TSPY, but staining for OCT3/4 (red arrow). Original magnification 400. F, CIS before invasiveness. All cells show coexpression of both
factors. Original magnification 100. G, Double-staining for TSPY (blue cytoplasmic and nuclear signal) and Ki-67 (red nuclear signal) in
GB (case 5). Mature germ cells are TSPYpositive, whereas Ki-67 is mainly positive in immature cells. Only a minority of the cells is positive
for both factors, indicated by an arrow. Original magnification 400. H, Normal fetal germ cells (same case as shown in C). Only a minority
of germ cells (around 30%) is positive for both factors (indicated by a black arrow). Original magnification 400.
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cells takes place during development of an invasive tumor
from GB. These data are in accordance to observations in
CIS and TGCTs (see the following paragraphs and see Ref
[17] for discussion).
A heterogeneous staining pattern was found in GB for
TSPY. In contrast to OCT3/4, TSPY was detected in both a
nuclear localization and in the cytoplasm (Fig. 1D). The
protein was not detectable in somatic cells resembling
granulosa/Sertoli cells. Tumor cells of early invasive DG
closely adjacent to the GB areas consistently showed a strong
and homogenous staining for TSPY, similar to the pattern
seen for OCT3/4 (see Fig. 2 for examples). TSPYexpression
could be lost in invasive DG areas at distance from the
preinvasive lesion. A similar pattern was also detected in the
testis: TSPY was strongly expressed in CIS adjacent to
invasive tumors, both seminoma and nonseminoma (see
Table 1 and Fig. 1E-G). Intratubular seminoma was
consistently positive, whereas invasive seminoma, like DG,
can lose expression of TSPY. In contrast, all nonseminomas
lack TSPY. Interestingly, even the intratubular EC compo-
nent is already negative (data not shown). Because FISH
analysis revealed that the Y chromosome is not lost in these
tumors (data not shown), loss of TSPY protein is not due to
gross loss of Y-genetic material on progression.
In normal spermatogenesis, TSPY staining was predom-
inantly seen in spermatogonia and sometimes spermatocytes
(see Fig. 1H, right panel). However, the staining intensity of
TSPY in CIS was stronger than in spermatogonia (Fig. 1H,
left panel).
3.2. Results of double-staining experiments
To further investigate the observed heterogeneity in
expression of OCT3/4 and TSPY in GB, CIS and invasive
tumor components, double-staining experiments were per-
formed. The results for OCT3/4 and TSPY were in line with
the results of single-staining experiments. The early invasive
DG components showed a homogenous staining for both
OCT3/4 and TSPY, in which most tumor cells were positive
for both markers (Fig. 2A). In GB, however, the mature
germ cells were positive for TSPYand negative for OCT3/4,
whereas immature germ cells were mainly positive for
OCT3/4 only (Fig. 2B). Only a subpopulation of germ cells
in GB showed coexpression of both markers. To investigate
whether coexpression of OCT3/4 and TSPY is a physiolog-
ical event during normal intrauterine male germ cell
development, we stained 2 normal testes of fetuses of 16
and 21 weeks of gestational age. Most of the germ cells
were found to be positive for only one factor, either OCT3/4
or TSPY. A minority of OCT3/4-positive germ cells also
showed expression of TSPY (Fig. 2C). Interestingly, these
cells were located on the basal membrane of the seminif-
erous tubule. Whereas the overall number of OCT3/
4-positive cells decreased from weeks 16 to 21 of gestational
age, the fraction of germ cells showing expression of both
markers remained unchanged.
These results were compared to the samples of testicular
CIS and TGCTs, subjected to the same protocol for double
staining. In accordance with the single-staining results, CIS
and early invasive seminoma components were homoge-
nously positive for both OCT3/4 and TSPY (Fig. 2D, left
and middle panel). A more heterogeneous pattern was seen
in later stages of invasiveness of seminomas, where
expression of TSPY could be lost, but OCT3/4 remained
positive (Fig. 2D, right panel, and Fig. 1G). In all cases of
CIS adjacent to an invasive tumor, either seminoma or
nonseminoma (which were all negative for TSPY), CIS cells
without expression of TSPY but positive for OCT3/4 were
found (Fig. 2E). In 2 cases of CIS without invasive tumor,
all CIS cells expressed TSPY (Fig. 2F). These data indicate
that TSPY is lost upon invasiveness of GCT cells. This step
can already occur in the in situ stage (Fig. 2E).
Finally, to assess whether there is a correlation between
TSPY expression and proliferation, we performed double-
staining analyses for TSPY and Ki-67. In addition to CIS
and GB, the 2 normal fetal testes were investigated. Most
malignant germ cells (around 90%) of both CIS and
intratubular seminoma were positive for both TSPY and
Ki-67. Gonadoblastoma with an adjacent invasive tumor
component showed a similar pattern as CIS, whereas GB
without invasive tumor was much more heterogeneous
(case 5, Fig. 2G). In fact, less double-positive cells were
identified. In these cases, mature germ cells were mainly
TSPYpositive, whereas immature cells were mostly positive
for Ki-67 only, and coexpression of both markers was rarely
seen. This was similar to the pattern seen in fetal testes,
where the 2 factors were not frequently coexpressed. Only
around 30% (29% at 16 weeks; 32% at 21 weeks gestational
age) of germ cells positive for TSPYalso showed expression
of Ki-67 (see Fig. 2H).
4. Discussion
The term dysgenetic gonads is used to describe the
phenomenon of a disturbed gonadal sex determination or
differentiation. This condition is associated with an
increased risk for the development of malignant GCTs.
The invasive tumor components, referred to as DGs and
non-DGs, resemble those of the adult testis (TGCTs),
seminoma, and nonseminoma of various histologies. The
precursor lesion is known as GB [4]. Histologically, GBs
consist of aggregates of germ cells and sex cord elements,
including immature Sertoli and granulosa cells. Some of the
germ cells show similarities to CIS, the known precursor of
TGCTs [10]. Both CIS and GB are thought to be the result
of a maturation arrest of early germ cells, possibly due to a
disrupted gonadal environment or unknown pathogenetic
hits. Because CIS is highly similar to the invasive TGCTs
(ie, seminoma), and is suggested to be bonly one step behind
in the karyotypic evolutionQ [30,31], it might not be the best
target for the identification of the earliest steps in the
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development of TGCTs. This could, however, be the case
for GB [8]. We undertook the present study to further
understand the biology of this condition, and to compare
similarities and differences between GB and CIS.
Immunohistochemical analysis of both known (PLAP,
c-KIT) and recent markers of early male germ cells (OCT3/4,
TSPY) was performed in GBs and adjacent DGs. Gonado-
blastomas have previously been reported to be positive for
PLAP and c-KIT [9-11]. Our results are mainly in line with
these findings. PLAP can be present in GBs and is weakly
but homogenously positive in the invasive component.
However, c-KIT was not always detected. We therefore
conclude that c-KIT is not a reliable marker for the detection
of GB. A heterogeneous staining pattern was found for both
OCT3/4 and TSPY in all GBs investigated. Early invasive
DG cells closely adjacent to the GB component were
positive for both OCT3/4 and TSPY. A similar pattern was
found in most CIS cells and could be confirmed by double-
staining experiments. TSPY has previously been reported in
a few cases of GB [12,13], although, to our knowledge, the
presence of TSPY in early invasive DGs and the loss of
expression on tumor progression are novel. These findings
support a model in which progression from early GB to
invasive growth is associated with expression of both TSPY
and OCT3/4 in immature germ cells (see Fig. 3 for a
schematic representation). A similar pattern is present in
CIS and early stages of seminoma. This indicates that TSPY
might be involved in the initial selection of tumorigenic
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germ cells at different stages of development in a disturbed stromal environment, classifiable both morphologically and with regard to the
presence of the immunohistochemical markers OCT3/4 and TSPY (middle panel). In contrast, CIS (upper boxed panel) and early invasive
DG are much more homogeneous, both morphologically and with regard to the expression of OCT3/4 and TSPY. This suggests a process of
selection and clonal expansion and supports the model that GB is an earlier stage in the process of GCT formation than CIS.
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cells, possibly by playing a role in cell cycle regulation or
cell division [13]. We therefore assessed the fraction of cells
that were positive for both TSPY and Ki-67, a marker for
proliferation. Interestingly, coexpression was found in the
vast majority of CIS and early invasive seminoma cells, as
well as in GB with an adjacent invasive tumor. This
underlines the strong proliferative activity of both lesions.
Whereas the proliferative activity of CIS has been reported
before [32], little is known about proliferation in GB. TSPY
and Ki-67 were less frequently coexpressed in one GB case
that had not yet developed into an invasive tumor (case 5,
Table 1). In our view, this could indicate that this specific
GB case had not yet progressed to the next pathogenetic
step, that is, the expansion of one premalignant clone. In
fact, it could pathogenetically be one step behind CIS,
which is the obvious result of a clonal process. Whatever the
role of TSPY in preinvasive lesions, proliferation in the
invasive GCTs is no longer dependent on TSPY, as is
demonstrated by the loss of TSPY on tumor progression.
Like TSPY, OCT3/4 has been shown to be present in
GBs [17,18]. In the present series, OCT3/4 was readily
detectable in all GBs in the nuclei of cells showing
morphological features of immature germ cells. Further-
more, as OCT3/4 remained positive throughout all stages of
tumor development from GB to DG, it can serve as a marker
to identify cells showing a high risk for malignant
transformation. However, it is important to notice that the
coexpression of OCT3/4 and TSPY does not per se confer
neoplastic properties to germ cells. This is illustrated by the
fact that normal male fetal germ cells of the second trimester
can coexpress both TSPY and OCT3/4, although only in a
minority of all cells.
Results of the double-staining experiments support the
notion that GB consists of a heterogeneous group of mature
and immature germ cells, of which the immature cells show
the phenotype similar to premalignant cells, in line with
earlier findings [10]. Interestingly, we recently observed that
mature germ cells in GB resemble more the male germ cell
lineage than the female [33]. The higher incidence of these
tumors in males compared to females confirms the finding
of a crucial role of part of the Y chromosome in the
development of this tumor [14]. Our results are compatible
with the model that after a process of selection and
consecutive clonal expansion, immature germ cells in GB
expressing OCT3/4, PLAP, and TSPY progress to the next
pathogenetic step, eventually leading to invasive growth.
Whether the presence of TSPY is needed to maintain the
germ line commitment of these cells at an early stage, or
confers a growth advantage during the critical step to
invasiveness, remains to be elucidated.
In conclusion, our results show that GB consists of a
heterogeneous population of germ cells. Both in DG in
ovaries and in seminoma, its counterpart in the adult testis,
the step to an invasive GCT seems to involve selection and
clonal expansion of an immature germ cell, positive for
OCT3/4 and TSPY. At later stages of invasiveness, TSPY
can be lost, whereas OCT3/4 always remains present in
tumor cells exhibiting germ line characteristics, that is, DG
or seminoma. Our analysis places GB at a very early stage
of GCT development, making it an interesting entity to
elucidate changes involved in the early pathogenesis of this
disease in the future.
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Abstract
Human germ cell tumours (GCTs) have long fascinated investigators for a number of
reasons. Being pluripotential tumours, they can differentiate into both extra-embryonic and
embryonic (somatic) tissues. However, it has never been shown convincingly that, in humans,
these tumours are truly totipotent and can also give rise to the germ lineage, the third major
differentiation lineage occurring early during embryonic life. Using a number of newly
available, distinct, immunohistochemical markers, such as OCT3/4, VASA and TSPY, the
occurrence of germ cells was investigated in a number of germ cell tumours. Development
of germ cells was identified in three independent non-seminomas, including two pure yolk
sac tumours and one mixed tumour composed of yolk sac tumour and immature teratoma.
Our finding indicates a previously unknown totipotent potential of human GCTs and raises
the question of whether, under certain culture conditions, primordial germ cells could be
derived from human GCT cell lines.
Copyright  2005 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
Keywords: germ cell tumours; germ cell lineage; differentiation; totipotency; primordial
germ cells
Introduction
Germ cell tumours of adolescents and adults (GCTs)
are at the cross-roads of tumour and developmen-
tal biology. They are pluripotent tumours with mul-
tiple possible fates. Two subgroups can be distin-
guished, seminomatous and non-seminomatous GCTs
(for review, see [1]), and Figure 1 shows their devel-
opmental potential schematically. Seminomas resem-
ble early germ cells (primordial germ cells/gonocytes).
They show limited capacity to differentiate into
somatic or extra-embryonic tissues, although they
can switch to a non-seminomatous phenotype [2].
Non-seminomas mimic early embryonic development.
Embryonal carcinoma (EC) cells, the stem cells
of non-seminomas, are highly similar to embryonic
stem (ES) cells [3] and can give rise to embryonic
endo-, meso- and ectoderm and/or differentiate into
extra-embryonal yolk sac and trophoblast. As they
have never been shown to give rise to the germ
line in humans, they seem to fall one step short of
totipotency.
Recent studies show that germ cells can be derived
from mouse and human ES cells [4–6]. So far,
it has been impossible to identify the development
of germ cells in human GCTs. Recently, antibodies
against several markers present in early germ cells
of both sexes (OCT3/4, a marker for pluripotency,
which is also expressed in ES cells, and VASA, a
germ line-specific protein) or exclusively in male germ
cells (TSPY, the testis-specific protein, Y-encoded),
have been described [7–9]. Our search for germ
cell development in non-seminomas was significantly
supported by recent studies on the presence of these
proteins during normal testicular development [10].
Materials and methods
Research on human tumour samples has been per-
formed according to the Code for Proper Secondary
Use of Human Tissue in The Netherlands, as developed
by the Dutch Federation of Medical Scientific Soci-
eties (FMWV) (version 2002), and has been approved
by an institutional review board (MEC 02.981).
Formalin-fixed, paraffin-embedded tissue blocks
from germ cell tumours that had been collected
between 1991 and 2003, in close collaboration with
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Figure 1. Developmental potential of normal and malignant germ cells. Normal development after fertilization is depicted in
the boxed area on the left. Both embryonic (soma) and extra-embryonic tissues (trophoblast and yolk sac) develop from the
zygote. Cells from the proximal region of the epiblast contribute to the primordial germ cell (PGC) pool, the allantois and the
extra-embryonic mesoderm. The fate of epiblast cells becoming PGCs is not predetermined, but is specified by response to
localized signals. After puberty, the derivatives of PGCs, known as spermatogonia, will eventually give rise to mature germ cells
that can be fertilized and restart the life cycle (oocyte in females and spermatid in males). Due to as-yet unknown pathogenetic
hits during intrauterine life, developmentally arrested germ cells can give rise to germ cell tumours. In the post-pubertal testis,
this is thought always to involve an intermediate stage, termed carcinoma in situ/intratubular germ cell neoplasia unclassified
(CIS/ITGCNU). Seminomas resemble early germ cells and CIS/ITGCNU, whereas embryonal carcinoma (EC) cells that originate
after reprogramming of CIS/ITGCNU are highly similar to embryonic stem cells from the inner cell mass and can mimic early
intrauterine development after fertilization (see boxed area in the middle). EC can differentiate into choriocarcinoma (CH),
teratoma (TE) or yolk sac tumour (YST). Here we describe for the first time that tumour cells from non-seminomas containing
yolk sac histology can re-activate totipotency and show properties of immature and more mature germ cells (see boxed area to
the right)
urologists and pathologists in the south-western part of
The Netherlands, were retrieved from our archive. In
addition, tumour samples were obtained from patients
treated according to protocols led by the Department
of Hematology/Oncology, University of Tu¨bingen. All
cases were reviewed and diagnosed by J.W.O., accord-
ing to the WHO classification.
Histochemical and immunohistochemical staining
For immunohistochemistry, 3 µm sections were incu-
bated with the primary antibody, followed by
biotinylated secondary antibodies for 30 min and a
biotinylated streptavidin horseradish peroxidase- or
alkaline phosphatase-coupled complex. The antibod-
ies and conditions used are indicated in Table 1. All
stains were counterstained with haematoxylin.
Double-staining was performed by using a combi-
nation of the same detection method but with differ-
ent substrates: Fast Blue/Naphthol ASMX phosphate
(F3378 and N500, Sigma, Steinheim, Germany) for
blue staining and 3-amino-9-ethyl-carbazole (A.5754
and D4254, Sigma, Steinheim, Germany)/H2O2 for red
staining, without counterstaining. Endogenous perox-
idase activity and/or endogenous biotin was blocked
using 3% H2O2 (for 5 min) and/or a blocking kit for
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Table 1. Antibodies (source) and detection method used for immunohistochemistry
Antibody Company
Clone,
code Pretreatment
Dilutions,
incubation
time and
temperature
Secondary
antibody (1 : 200)
(biotinylated) Visualization
PLAP Cell Marque CMC203 HIAR∗ 1 : 200, overnight (o.n.),
4 ◦C
Rabbit anti-mouse
(Dako E0413)
ABCplx-ap1
c-KIT DakoCytomation A4502 HIAR 1 : 500, o.n., 4 ◦C Swine anti-rabbit
(Dako E0413)
ABCplx-ap
OCT3/4 Santa Cruz sc-8629 HIAR 1 : 1000, 120 min, room
temperature (RT)
Horse anti-goat
(Vector BA9500)
ABCplx-hrp2
VASA Provided by D. Castrillon HIAR 1 : 2000, overnight (o.n.),
4 ◦C
Swine anti-rabbit ABCplx-ap
TSPY Provided by Y. Lau None 1 : 3000, o.n., 4 ◦C Swine anti-rabbit ABCplx-ap
BMP4 Novocastra 3H2 None 1 : 100, o.n., 4 ◦C Rabbit anti-mouse ABCplx-ap
SCF Santa Cruz Biotechnology sc-1302 HIAR 1 : 400 o.n., 4 ◦C Horse anti-goat ABCplx-ap
CD30 DakoCytomation Ber-H2 HIAR 1 : 100 o.n., 4 ◦C Rabbit anti-mouse ABCplx-hrp2
CD34 Neomarkers QBEnd/10,
MS-363-S
None 1 : 20, 30 min, RT Rabbit anti-mouse ABCplx-hrp2
CD61 Immunotech SZ 21, 2116 HIAR 1 : 100, 30 min, RT Rabbit anti-mouse ABCplx-hrp2
Glycophorin C DakoCytomation M0820 HIAR 1 : 100, 120 min. RT Rabbit anti-mouse ABCplx-hrp2
Lysozyme DakoCytomation A0099 Pronase, 10 min 1 : 900, 30 min, RT Swine anti-rabbit ABCplx-hrp2
Myeloperoxidase DakoCytomation A0398 HIAR 1 : 5000, 30 min, RT Swine anti-rabbit ABCplx-hrp2
∗ Heat-induced antigen retrieval.
1 ABCplx-ap, streptavidin–biotin–alkaline phosphatase complex.
2 ABC-hrp, streptavidin–biotin–horseradish peroxidase complex.
endogenous biotin (Vector Laboratories, Burlingame,
CA, USA) to prevent background staining.
Results
Detection of cells with germ cell characteristics in
non-seminomas
Markers for immature germ cells and other factors
involved in fetal germ cell differentiation, e.g. germ
cell/placental-like alkaline phosphatases (PLAP), stem
cell factor receptor (c-KIT) and glycogen, were stud-
ied in a series of 34 GCTs of pure non-seminomatous
histology (YSTs, TEs and ECs): in other words,
none of these tumours contained a seminomatous
component, as judged by morphology and immuno-
histochemistry. In three cases, originating from the
testis, the mediastinum and the pituitary gland, respec-
tively, early germ cells were identified by morphol-
ogy and marker expression (see Figure 2). In two
cases, germ cells were found loosely distributed in
clusters throughout the yolk sac component of the
tumours (Figure 2A–E), whereas in the third case
they were localized in tube-like structures (this tumour
contained both yolk sac and immature teratoma com-
ponents). The germ cells showed consistent staining
for OCT3/4 (Figure 2C), PLAP (Figure 2D), c-KIT,
TSPY (Figure 2E) and glycogen. CD30 was absent
(Figure 2B insert), ruling out that these cells are EC
cells rather than embryonic germ cells [11]. The pres-
ence of VASA (Figure 2F and lower insert), spe-
cific for late migratory and postmigratory germ cells
[8], indicates that a number of these cells have pro-
gressed beyond the earliest stage of germ line com-
mitment. While the majority of cells were positive
for either OCT3/4 or VASA (Figure 2F), double stain-
ing revealed co-expression of both markers in only a
minority of cells (lower insert), which was also the
case for OCT3/4 and TSPY (Figure 2F, upper insert).
The observation that the cells of interest are negative
for OCT3/4 demonstrate that they are not seminoma
cells.
Detection of cells with characteristics of early
haematopoietic cells
Staining for c-KIT, CD34, lysozyme, myeloperoxi-
dase, Glycophorin C and CD61 showed the presence
of cells with characteristics of early haematopoiesis. In
two cases, nests of cells resembling angiogenetic clus-
ters (so-called haemangioblasts) could be identified by
the presence of c-KIT, CD34 (Figure 2G insert), a
marker for pluripotent haematopoietic stem cells, and
glycophorin C, a marker for red cells and their precur-
sors (Figure 2H insert). A number of other factors for
haematopoietic differentiation (ie lysozyme, myeloper-
oxidase and CD61) were occasionally present. How-
ever, the cells lacked the morphological characteristics
of haematopoietic differentiation, such as blast forma-
tion (data not shown).
All three cases showed the presence of bone mor-
phogenetic protein 4 (BMP4) in the YST component
(Figure 2G), mainly in areas showing hepatoid histol-
ogy. BMP4 was not restricted to the areas contain-
ing germ cells. Moreover, BMP4 was also observed
in non-seminomas (ie yolk sac tumours) without the
presence of germ cell lineage differentiation (data not
shown). Therefore it cannot be considered as a spe-
cific marker. Stem cell factor (SCF), the ligand for
c-KIT, was found in the yolk sac component, most
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often in close association with the developing germ
cells (Figure 2H).
Discussion
An extensive immunohistochemical analysis was per-
formed to study the developmental potential and cell
fate commitment of non-seminomas. We describe
the novel finding of germ cell development in non-
seminomas. In three cases, small groups of cells show-
ing characteristics of fetal germ cell differentiation, ie
loss of OCT3/4 and increased staining for VASA and
TSPY, were found. The same pattern of OCT3/4 and
VASA expression was recently described upon spon-
taneous differentiation of germ cells from human ES
cells in vitro [6] and during normal germ cell develop-
ment in humans [10]. Our findings indicate that germ
cells can develop in non-seminomas, in particular
YSTs showing expression of supporting factors, such
as BMP4 and SCF. It is unknown whether the YST
is the direct precursor of the germ cells or whether
both lines co-develop from one common ancestor. This
seems a rather semantic question; however, as all non-
seminomas originate from a common stem cell, ie the
EC cell (for review, see [1]; see also Figure 1).
Mammalian germ cells originate from the proximal
region of the epiblast. In mouse experiments, ES
cells can be stimulated to differentiate into germ cells
and extra-embryonic mesoderm when grafted to the
proximal epiblast [12]. This indicates that the potential
to become a germ cell may not be restricted to
predetermined progenitor cells but can be induced by
extracellular factors [13]. The nature of these factors is
largely unknown. Recent findings indicate that BMP4
might play a crucial role [4].
In two of the three cases, haematopoietic differen-
tiation was found, underlining the close developmen-
tal relationship between germ cells and haematopoi-
etic precursor cells. In fact, it has been hypothesized
that primordial germ cells could be haematopoiesis-
initiating cells [14], a process in which BMP4 could be
an important signal [4,15]. Clinically, the relationship
between mediastinal GCTs with yolk sac histology and
acute myeloid leukemias is well established [16,17].
The haematopoietic precursor cells in these tumours
are likely the origin of the leukaemias [18]. The clonal
origin of mediastinal GCTs and haematological malig-
nancies indicate a common malignant stem cell [19].
Failure to demonstrate germ cell development in
non-seminomas so far might have been due to a
number of reasons. It is probably a rare event (so far
found in 3/34 non-seminomas), possibly due to the
absence of crucial factors. Alternatively, development
of germ cells may be hampered by the fact that
these cells are highly susceptible to apoptotic stimuli,
leading to early death. Most important, however, could
be the fact that so far the markers to identify germ
lineage differentiation were lacking. Only the use
of a combination of the markers OCT3/4, VASA
and TSPY has enabled us to identify germ cell
development in non-seminomas. It is highly unlikely
that the presence of these markers is due to aberrant
expression, because of the consistency in loss of
OCT3/4 and increase in VASA, as found during
normal germ cell development. In addition, GCTs
are known to show expression of various markers in
accordance with their physiological pattern, dependent
on their specific lineage of differentiation (for review,
see [1]).
The fact that non-seminoma cells can differentiate
into germ cells is exciting and should be exploited
in vitro using pluripotent GCT cell lines, under cul-
ture conditions that enhance formation of germ cells
[4,6,20]. The resulting germ cells could be traced using
a specific reporter system [4,5] and studied for their
expression profile [6].
Deriving germ cells from human GCTs would be
more than a mere technical exercise. Even though
the cells of origin show neoplastic properties (eg
they are aneuploid), the system would clearly reflect
many aspects of normal germ cell development. It
could therefore provide a readily accessible tool for
the investigation of mechanisms of human germ cell
Figure 2. Representative illustrations of the various immunohistochemical markers identified in the germ cell tumours showing
germ cell differentiation. (A) Testicular yolk sac tumour, haematoxylin and eosin staining (magnification ×10; insert ×40). (B) Same
case: α-fetoprotein (AFP) staining is seen as a red cytoplasmic signal. Note the stronger staining intensity in more solid yolk sac
tumour areas, showing a hepatoid pattern (magnification ×10). Insert is staining for CD30, being negative (magnification ×20).
(C) Same case: OCT3/4 (brown nuclear signal)-positive cells are scattered throughout the tumour (magnification ×10; insert
×40). (D) Same case: single cells show a red positive cytoplasmatic staining reaction for placental alkaline phosphatase (PLAP)
(magnification ×10; insert ×40). (E) Same case: single cells show a red positive nuclear and cytoplasmic staining reaction for
testis-specific protein on the Y chromosome (TSPY). Note also the weaker staining intensity in more solid yolk sac tumour
areas, showing a hepatoid pattern (magnification ×10; insert 40×). (F) Same case: double staining for OCT3/4 (red nuclear signal)
and VASA (blue cytoplasmic signal). Immature germ cells show strong signal intensity for OCT3/4, but are negative for VASA.
This germ cell-specific marker is exclusively seen in more mature germ cells. The VASA-positive cells are negative for OCT3/4,
and are therefore not seminoma cells (magnification ×40). Upper insert: double-staining for OCT3/4 (red nuclear signal) and
TSPY (blue cytoplasmic signal). Note the double positive cells, and the single OCT3/4-positive cells (magnification ×40). Lower
insert: double-staining for OCT3/4 (red nuclear signal) and VASA (blue cytoplasmic signal), showing some double positive cells
for OCT3/4 and VASA. (G) Mediastinal yolk sac tumour, bone morphogenetic protein 4 (BMP4) staining (red cytoplasmic signal).
Note the stronger staining intensity in more solid yolk sac tumour areas (magnification ×10). Insert: same case staining for
CD34 (magnification ×20). (H) Testicular yolk sac tumour, same case as shown in A–F. Stem cell factor (SCF) is seen as a red
cytoplasmic and membranous signal in the majority of yolk sac tumour cells (magnification ×10). Insert: same case, staining for
glycophorin C (magnification ×40)
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development, yet avoiding the ethical issues and
legal restrictions associated with the use of normal
primordial germ cells derived from human embryos
or human ES cells.
Acknowledgements
We thank the urologists and pathologists in the south-western
part of The Netherlands for their cooperation in collecting the
tumour samples. This work was supported by the Dutch Cancer
Society (H.S., J.W.O., L.H.J.L.) and the Deutsche Krebshilfe,
Dr Mildred Scheel Stiftung (F.H.)
References
1. Oosterhuis JW, Looijenga LHJ. Testicular germ cell tumors in a
broader perspective. Nat Rev Cancer 2005;5:210–222.
2. Oosterhuis JW, Kersemaekers AM, Jacobsen GK, Timmer A,
Steyerberg EW, van Weeren PC, et al. Morphology of testicular
parenchyma adjacent to germ cell tumours; an interim report.
APMIS 2003;111:32–42.
3. Donovan PJ, de Miguel MP. Turning germ cells into stem cells.
Curr Opin Genet Dev 2003;13(5):463–471.
4. Toyooka Y, Tsunekawa N, Akasu R, Noce T. Embryonic stem
cells can form germ cells in vitro. Proc Natl Acad Sci USA
2003;100:11 457–11 462.
5. Hubner K, Fuhrmann G, Christenson LK, Kehler J, Reinbold R,
De La Fuente R, et al. Derivation of oocytes from mouse
embryonic stem cells. Science 2003;300:1251–1256.
6. Clark AT, Bodnar MS, Fox M, Rodriquez RT, Abeyta MJ,
Firpo MT, et al. Spontaneous differentiation of germ cells
from human embryonic stem cells in vitro. Hum Mol Genet
2004;13:727–739.
7. Looijenga LHJ, Stoop H, De Leeuw PJC, De Gouveia Brazao CA,
Gillis AJM, Van Roozendaal KEP, et al. POU5F1 (OCT3/4)
identifies cells with pluripotent potential in human germ cell
tumors. Cancer Res 2003;63:2244–2250.
8. Castrillon DH, Quade BJ, Wang TY, Quigley C, Crum CP. The
human VASA gene is specifically expressed in the germ cell
lineage. Proc Natl Acad Sci USA 2000;97:9585–9590.
9. Lau Y, Chou P, Iezzoni J, Alonzo J, Komuves L. Expression
of a candidate gene for the gonadoblastoma locus in
gonadoblastoma and testicular seminoma. Cytogenet Cell Genet
2000;91:160–164.
10. Honecker F, Stoop H, De Krijger R, Lau Y-FC, Castrillon DH,
Bokemeyer C, et al. Pathobiological implications of the expression
of markers of testicular carcinoma in situ by fetal germ cells. J
Pathol 2004;203:849–857.
11. Latza U, Foss H-D, Durkop H, Eitelbach F, Dieckmann K-P,
Loy V, et al. CD30 antigen in embryonal carcinoma and
embryogenesis and release of the soluble molecule. Am J Pathol
1995;146:463–471.
12. Tam PP, Zhou SX. The allocation of epiblast cells to ectodermal
and germ-line lineages is influenced by the position of the cells in
the gastrulating mouse embryo. Dev Biol 1996;178:124–132.
13. Lawson KA, Dunn NR, Roelen BA, Zeinstra LM, Davis AM,
Wright CV, et al. Bmp4 is required for the generation of
primordial germ cells in the mouse embryo. Genes Dev
1999;13:424–436.
14. Rich IN. Hemopoietic-initiating cells. J Perinat Med
1995;23:31–38.
15. Chadwick K, Wang L, Li L, Menendez P, Murdoch B, Rouleau A,
et al. Cytokines and BMP-4 promote hematopoietic differentiation
of human embryonic stem cells. Blood 2003;102:906–915.
16. Nichols CR, Roth BJ, Heerema N, Griep J, Tricot G. Hematologic
neoplasia associated with primary mediastinal germ-cell tumors. N
Engl J Med 1990;322:1425–1429.
17. Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A,
Fossa SD, et al. The relative risk of second nongerminal
malignancies in patients with extragonadal germ cell tumors.
Cancer 2000;88:2629–2635.
18. Lee KC. Hematopoietic precursor cells within the yolk sac
tumor component are the source of secondary hematopoietic
malignancies in patients with mediastinal germ cell tumors. Cancer
1994;73:1535.
19. Woodruff K, Wang N, May W, Adrone E, Denny C, Feig SA.
The clonal nature of mediastinal germ cell tumors and acute
myelogenous leukemia. A case report and review of the literature.
Cancer Genet Cytogenet 1995;79:25–31.
20. Geijsen N, Horoschak M, Kim K, Gribnau J, Eggan K, Daley GQ.
Derivation of embryonic germ cells and male gametes from embry-
onic stem cells. Nature 2004;427:148–154.
  
 
 
 
 
Chapter 6 
 
 
INVOLVEMENT OF E-CADHERIN AND β-CATENIN IN GERM CELL TUMOURS AND 
IN NORMAL MALE FETAL GERM CELL DEVELOPMENT 
 
 
 
JOURNAL OF PATHOLOGY 204: 167-174, 2004 
 
 
 
 
 
By Friedemann Honecker, Anne-Marie F. Kersemaekers, Michel Molier, Pascale C. van Weeren, 
Hans Stoop, Ronald R. de Krijger, Katja P. Wolffenbuttel, Wolter Oosterhuis, Frank Mayer, Carsten 
Bokemeyer,  and Leendert H.J. Looijenga 
 
 
 E-cadherin and β-catenin in germ cell tumours and normal germ cells 
71 
 
Original Paper
Involvement of E-cadherin and β-catenin in germ cell
tumours and in normal male fetal germ cell development
Friedemann Honecker,1,2 Anne-Marie F Kersemaekers,1 Michel Molier,1 Pascale C van Weeren,1 Hans Stoop,1
Ronald R de Krijger,1 Katja P Wolffenbuttel,3 Wolter Oosterhuis,1 Carsten Bokemeyer2
and Leendert HJ Looijenga1*
1Department of Pathology, Josephine Nefkens Institute, Rotterdam, The Netherlands
2Department of Haematology/Oncology, University of Tu¨bingen, Tu¨bingen, Germany
3Department of Paediatric Urology, Erasmus MC-University Medical Centre Rotterdam, Daniel den Hoed Cancer Center and Sophia Children’s
Hospital, Rotterdam, The Netherlands
*Correspondence to:
Leendert HJ Looijenga, PhD,
Department of Pathology,
Erasmus MC-University Medical
Centre Rotterdam, Josephine
Nefkens Institute, Room 430b,
PO Box 1738, 3000 DR
Rotterdam, The Netherlands.
E-mail: l.looijenga@erasmusmc.nl
Received: 6 April 2004
Revised: 27 May 2004
Accepted: 4 June 2004
Abstract
Intercellular contacts, mediated by E-cadherin, are essential for germ cell migration and
maturation. Furthermore, it has been suggested that decrease or loss of E-cadherin corre-
lates with tumour progression and invasive behaviour. β-catenin is involved in a number of
different processes, including cell–cell interaction when bound to cadherins, and determina-
tion of cell fate in pluripotent cells when activated via the Wnt signal-transduction pathway.
To shed more light on the role of these factors in normal fetal germ cell development and
the pathogenesis of germ cell tumours (GCTs), the present study investigated the presence
and localization of E-cadherin and β-catenin by immunohistochemistry. E-cadherin was
only weakly expressed in or absent from fetal germ cells of the second and third trimesters,
and was not expressed in carcinoma in situ/intratubular germ cell neoplasia unclassified
(CIS/ITGCNU) and gonadoblastoma, the precursor of an invasive GCT in dysgenetic gonads.
In GCTs, it was generally not expressed in seminoma and dysgerminoma, but was found
in the vast majority of non-seminoma cells. β-catenin was found in the cytoplasm of fetal
germ cells at all gestational ages and in spermatogenesis in post-pubertal testes. It was also
present in CIS/ITGCNU and gonadoblastoma. Whereas seminomas and dysgerminoma were
negative, non-seminoma cells were frequently found to express β-catenin. Expression of both
factors therefore reflects the degree of differentiation of these tumours. No differences for
either E-cadherin or β-catenin were observed between samples of tumours resistant or sen-
sitive to chemotherapy, and E-cadherin expression did not correlate with vascular invasion.
E-cadherin and β-catenin therefore play a role in both normal and malignant germ cell
development and differentiation that warrants further investigation, but they seem to be of
limited value as predictive or prognostic factors in GCTs.
Copyright  2004 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
Keywords: E-cadherin; β-catenin; fetal gonads; germ cell tumours; carcinoma in situ/
intratubular germ cell neoplasia unclassified (CIS/ITGCNU); gonadoblastoma; chemother-
apy resistance; vascular invasion
Introduction
Epithelial (E-) cadherin is a transmembrane glycopro-
tein that is involved in Ca2+-dependent intercellular
adhesion. Through a cytoplasmic domain, it binds via
catenins (α-, β-, and γ -catenin) to the actin cytoskele-
ton. The cadherin–catenin complex is involved in sig-
nal transduction from the cell surface to the cytoskele-
ton and the nucleus. Little is known about E-cadherin
expression during human intrauterine germ cell devel-
opment. In tumour cells, E-cadherin has shown prop-
erties of a tumour suppressor, as cells become more
invasive if E-cadherin expression is down-regulated
[1].
Besides a role in cadherin–catenin complexes,
β-catenin has been found to be involved in embry-
onic stem (ES) cell differentiation of the mouse via the
Wnt signal-transduction pathway [2]. Stabilization of
β-catenin by mutation or disturbed degradation leads
to accumulation in the nucleus, a process implicated
in cancer development [3].
An extensive immunohistochemical analysis was
undertaken to assess whether the E-cadherin/β-catenin
complex is involved in the pathogenesis of GCTs.
Data from the literature on this topic are not conclu-
sive [4,5]. Since testicular germ cell tumours (TGCTs)
originate from CIS/ITCGNU, which is most likely
composed of the malignant counterpart of an early
germ cell [6], we also included normal fetal testes in
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our investigations of both factors. Like CIS/ITGCNU,
gonadoblastoma, the precursor lesion of the dysgenetic
gonad, shows the potential to progress to an invasive
GCT, mainly dysgerminoma [7]. The presence and
localization of E-cadherin and β-catenin were exam-
ined both during normal fetal germ cell development
and in GCTs of different stages and histological types,
including CIS/ITGCNU, gonadoblastoma, intratubular
and invasive seminoma, dysgerminoma, and intratubu-
lar and invasive non-seminoma. The results were cor-
related with treatment outcome (tumours refractory or
sensitive to chemotherapy) and vascular invasion to
assess the potential value of these factors as prognostic
or predictive markers.
Materials and methods
Materials
The use of tissues for scientific reasons was approved
by an institutional review board (MEC 02.981). The
samples were used according to the ‘Code for Proper
Secondary Use of Human Tissue in The Netherlands’,
as developed by the Dutch Federation of Medical
Scientific Societies (FMWV) (version 2002).
Fetal gonads
Human gonads of 11 males from the second and third
trimesters were obtained after spontaneous miscar-
riages (n = 8; gestational ages 16, 17, 21, 2 × 24, 27,
32, 35 weeks) or from term neonates (n = 3) that had
died shortly after birth. Tissues were collected within
24 h of death and post-mortem examinations were
carried out in our department. Testes were dissected
and fixed in 10% formalin and processed into paraf-
fin wax. Cases showing conditions potentially affect-
ing gonadal development, such as chromosomal aber-
rations, hydrocephalus, malformations of the genito-
urinary tract, or gross intrauterine growth retardation,
were excluded from the study. Gestational ages were
calculated in relation to the mother’s last menstrual
cycle and were in accordance with the foot length
and the crown–heel length measurements at autopsy,
showing a maximum variation of 2 weeks.
Unselected GCT-patient group
To correlate vascular invasion and E-cadherin expres-
sion, fresh frozen or formalin-fixed, paraffin wax-
embedded tissues that had been collected between
1991 and 2000 in close collaboration with urologists
and pathologists in the south-western part of The
Netherlands were retrieved from our archive. Forty
patients with a GCT TNM stage 1 or 2 with the fol-
lowing histological diagnosis were included: 18 non-
seminomas, 13 seminomas, seven combined tumours,
and two only CIS/ITGCNU. The presence of vas-
cular invasion (both lymphatic and angio-invasion)
was assessed by an experienced pathologist (JWO).
In addition, paraffin wax-embedded tissue from four
patients with gonadoblastoma, the precursor lesion of
an invasive GCT in dysgenetic gonads, was available
for investigation. In two of the samples, a component
of invasive dysgerminoma histology was also present.
Selected GCT-patient group
Tumour samples were obtained from patients treated
according to protocols followed by the Department of
Haematology/Oncology, University of Tu¨bingen. This
series has been reported before [8]. In the chemo-
sensitive group, samples collected before therapy from
12 high-risk patients were investigated. Only patients
with complete remission or a marker-negative partial
remission after high-dose chemotherapy and a relapse-
free follow-up of more than 1 year were included.
The series consisted of 11 non-seminomas and one
seminoma. In the refractory group, 23 samples from
22 patients with chemotherapy-refractory disease were
investigated. Patients were considered refractory when
progression or relapse occurred despite adequate ini-
tial and/or salvage treatment. The material from 14
patients was obtained at initial diagnosis; in nine cases,
the material was sampled at relapse after exposure
to chemotherapy. In one case, material from both the
primary tumour and a metastasis at relapse was avail-
able. The series consisted of 22 non-seminomas and
one seminoma. Table 1 summarizes the characteris-
tics of the patients with refractory and chemo-sensitive
tumours. All cases were reviewed and diagnosed by
JWO according to the WHO classification.
Immunohistochemistry
Immunohistochemistry was performed on 3-µm-thick
paraffin wax sections. Sections were dewaxed in
xylene and rehydrated; frozen tissue sections were
fixed in acetone for 5 min and dried. Pressure cook-
ing in 0.01 M citrate buffer, pH 6.0 (1.2 bar) was
used for antigen retrieval on paraffin wax sections. All
antibodies were diluted in phosphate-buffered saline
(PBS), pH 7.4, with 1% bovine serum albumin (BSA).
Primary antibodies [E-cadherin (HE-CADHERIN-1,
1 : 300; Zymed Laboratories, San Francisco, CA,
USA), and β-catenin (CAT-5H10, 1 : 2000; Zymed
Laboratories)] were incubated at 4 ◦C overnight or
on frozen tissue sections for 1 h at room temper-
ature. OCT3/4 (sc-8629, 1 : 1000; Santa Cruz Bio-
Technology, Santa Cruz, CA, USA) was incubated for
2 h at room temperature. After washing in PBS, slides
for E-cadherin and β-catenin were incubated with
biotin-labelled rabbit anti-mouse (Dako-Cytomation,
Glostrup, Denmark), and slides for OCT3/4 with
biotin-labelled horse anti-goat (Vector BA9500; Vector
Laboratories, Burlingame, CA, USA) immunoglobu-
lins for 30 min. Subsequently, all slides were incu-
bated with a biotinylated streptavidin horseradish per-
oxidase complex (Dako-Cytomation, Glostrup, Den-
mark) for 30 min. DAB solution (Fluka Chemie,
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Table 1. Overall results of immunostaining and characteristics
of patients with proven chemo-sensitive or -resistant GCTs
(selected group)
Chemo-sensitive
(n = 12)
Refractory
(n = 22)
Age, years
Median 28 29
Range 20–47 17–56
Histology
Seminoma 1 1
Non-seminoma 11 22
Stage at diagnosis (according to UICC)
I 0 3
II 0 7
III 12 12
Initial treatment after surgery
Surveillance 0 2
Chemotherapy 12 20
Follow-up, months
Median 49 39
Range 12–67 11–180
Relapse-free survival, months
Median NR 7.1
Range 0–150
Response to initial treatment
Complete remission 8 5
Partial remission, 4 8
marker negative
Partial remission, 0 3
marker positive
Progressive disease 0 3
Unknown 0 3
No of regimens in relapse
Median 0 3
Range 0 1–9
% of cases showing NS: 92% NS: 100%
β-catenin staining SE:– SE:–
% of cases showing NS: 89% NS: 80%
E-cadherin staining SE: – SE: –
Co-localization of
E-cadherin and β-catenin
staining in >80% of
tumour cells
5/8 (42%) 11/22 (50%)
UICC = International Union Against Cancer; NR = not reached;
NS = non-seminoma; SE = seminoma.
Buchs, Switzerland) with H2O2 was used to visu-
alize the immune aggregates. Slides were counter-
stained with Mayer’s haematoxylin. Omitting the pri-
mary antibody served as a negative control in all
experiments, whereas positive staining of epithelial
structures (eg rete testis) served as a positive internal
control.
Statistical analysis
A chi-squared test was performed to evaluate a pos-
sible correlation between E-cadherin expression and
vascular invasion. Two-sided testing was applied and
p < 0.05 was considered statistically significant.
Results
Expression of E-cadherin and β-catenin in normal
fetal germ cells, adult germ cells, gonadoblastoma,
and CIS/ITGCNU
During fetal development, weak membranous stain-
ing for E-cadherin was seen (see Figure 1A) in three
of 11 cases containing germ cells. Two of the four
gonadoblastomas were weakly positive for E-cadherin,
but no expression was detectable at any stage of sper-
matogenesis in normal adult testis or in CIS/ITGCNU
(data not shown). β-catenin was strongly positive at all
stages during fetal germ cell development, showing a
distinct staining pattern in germ cells: central perinu-
clear areas of the cytoplasm did not show any signal,
but strong staining was detected in a submembranous
location (see Figure 1B). In normal adult testis, β-
catenin was mainly expressed in the cytoplasm of
germ cells at earlier stages of spermatogenesis (ie sper-
matogonia A and B), but was no longer detectable
in spermatids and spermatozoa. Both CIS/ITGCNU
and gonadoblastoma showed a staining pattern com-
parable to that seen in fetal germ cells, with a clear
cytoplasmic and submembranous signal location (cf
Figures 1B and 1D).
Expression of E-cadherin and β-catenin in invasive
GCTs
To assess a possible correlation between the pres-
ence of E-cadherin, β-catenin, and clinical outcome,
we investigated samples of GCTs with known clin-
ical course. Clinical information and staining results
are summarized in Table 1. Overall, no differences
were found between the two groups. Both E-cadherin
and β-catenin were found in the vast majority of
non-seminomas, but not in seminomas (see Tables 1
and 2). No expression of E-cadherin and β-catenin
was seen in two dysgerminomas arising in dysgenetic
gonads (data not shown). 92% of the chemo-sensitive
non-seminomas and 100% of the chemo-resistant non-
seminomas showed expression of β-catenin. Expres-
sion of E-cadherin was seen in 89% and 80% of
the non-seminomas, respectively. Whereas intratubular
seminoma and invasive seminoma were negative for
E-cadherin, intratubular non-seminoma and embryonal
carcinoma (EC) were strongly positive, and yolk sac
tumour (YS) was moderately to strongly positive. In
teratomas, strong signal intensity for E-cadherin was
seen in components showing epithelial differentiation.
β-catenin was mainly seen in a membranous loca-
tion with differing signal intensity in GCTs of
different histological types and stages of invasion
(see Figures 1E and 2B). Intratubular seminoma was
weakly positive, whereas invasive seminoma was neg-
ative. Intratubular non-seminoma and EC showed
moderate staining intensity, and YS moderate to strong
staining intensity. Using OCT3/4 to identify EC cells
in tumours with mixed histology, the signal intensity
of β-catenin was found to be stronger in YS cells than
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Figure 1. (A) Fetal testis (16 weeks of development); E-cadherin (brown signal) is seen as a very weak membranous signal in
germ cells (arrow). Some staining is also seen in Leydig cells (arrow-head). (B) Same case, showing strong signal intensity for
β-catenin in a cytoplasmic and membranous location in germ cells and Sertoli cells. Some signal is seen in Leydig cells. Note
that endothelial cells are also positive for β-catenin (arrow). (C) Germ cell tumour showing seminoma and CIS/ITGCNU. Note
the brown β-catenin signal in tubules containing CIS/ITGCNU, but absence of staining in the invasive seminoma component.
(D) Gonadoblastoma, positive for β-catenin (brown membranous and cytoplasmic signal). Note the similarity of the staining
pattern to that of fetal germ cells (cf B). (E) Yolk sac tumour with solid growth pattern; membranous staining for β-catenin is seen
(brown signal). (F) Papillary yolk sac tumour showing mainly cytoplasmic and, in a minority of tumour cells, also nuclear β-catenin
staining (brown signal, arrow)
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Table 2. Results of immunostaining, differentiated by histological subtype; note that one
tumour sample can contain more than one histological type
Histology No
Overall
E-cadherin
staining
(%)
>20%
tumour
cells
positive (%)
Overall
β-catenin
staining
(%)
>20%
tumour cells
positive
(%)
Refractory series
CIS/ITGCNU 7 0 0 100 100
ITSE 3 0 0 0 0
SE 2 0 0 0 0
YS 16 75 44 100 100
CC 3 100 100 100 100
TE 3 100 100 100 100
ITNS (EC) 2 100 100 100 100
EC 8 87.5 87.5 100 100
Sensitive series
CIS/ITGCNU 4 0 0 100 100
ITSE 1 0 0 0 0
SE 3 0 0 0 0
YS 4 100 75 100 75
CC 0 0 0 0 0
TE 3 66 66 100 100
ITNS (EC) 1 100 100 100 100
EC 7 86 86 86 71
CIS/ITGCNU = carcinoma in situ/intratubular germ cell neoplasia unclassified; ITSE = intratubular
seminoma; SE = seminoma; YS = yolk sac tumour; CC = choriocarcinoma; TE = teratoma; ITNS =
intratubular non-seminoma; EC = embryonal carcinoma.
in EC cells (see Figures 2A–2C). Strong staining was
also observed in teratomas, mainly in epithelial com-
ponents.
In both groups, co-localization of E-cadherin and
β-catenin in the majority of tumour cells (judged
by comparing tumour areas in adjacent slides) was
seen in approximately 50% of the cases (see Table 1).
Nuclear localization of β-catenin was observed in a
maximum of 10% of all tumour cells in two tumours
from the refractory group, one before and one after
exposure to chemotherapy, and in one tumour in the
sensitive group, prior to chemotherapy treatment (see
Figure 1F).
Correlation of E-cadherin expression and vascular
invasion and metastasis
All of the chemo-sensitive cases and 19 of the 22
refractory cases (selected patient group) had metas-
tases at the time the tumour sample was obtained.
No correlation between vascular invasion or metastatic
behaviour and E-cadherin expression was seen: of the
three refractory cases without metastases, two showed
E-cadherin expression, and one did not. In several
cases, vascular invasion by non-seminoma (mostly EC
cells) expressing E-cadherin was seen.
To extend our analysis of a possible correlation
between E-cadherin expression and vascular inva-
sion, a series of 40 tumour samples (unselected
patient group) from patients with early-stage GCT
was assessed. In the group without vascular invasion
(n = 29), 13 samples were E-cadherin-negative and
16 samples were positive. In the group with vascular
invasion (n = 11), E-cadherin expression was absent
from three and present in eight samples (p = 0.31,
statistically not significant).
Discussion
GCTs are at the crossroads of developmental and
tumour biology, and are of interest from both points
of view. Comparative analyses of tumour samples
and normal counterparts can help to define events
related to the pathogenesis of these tumours. This
is also documented by our study investigating the
expression and localization of E-cadherin and β-
catenin in both normal early germ cells and GCTs
of different histological types. Besides interpreting
our findings from the point of view of development
of germ cells, both normal and malignant, we will
also discuss our results with regard to clinically
important issues, including tumour invasiveness and
chemotherapy resistance.
Aspects of developmental biology
Characteristics of early germ cell development
The cadherin–catenin complex plays an important role
in the very early stages of embryonal development. E-
cadherin has been described in early blastomeres [9]
and on human EC cell lines, which closely resemble
ES cells. E-cadherin is essential for the migration and
homing of mouse primordial germ cells (PGCs) from
the hindgut to the genital ridges [10,11]. Whereas
little is known about the expression of E-cadherin on
human migratory and post-migratory germ cells of
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Figure 2. (A) Germ cell tumour showing a combination of
embryonal carcinoma and yolk sac tumour. Note the brown
nuclear signal for OCT3/4 in embryonal carcinoma, but not in
the cells showing yolk sac features. (B) Same case; E-cadherin
staining is seen in embryonal carcinoma, but not in yolk sac
tumour. (C) Same case; β-catenin is seen predominantly in yolk
sac areas and is much weaker in embryonal carcinoma
the male, we recently described the presence of E-
cadherin in both early and maturing female germ cells
(unpublished observations). β-catenin has been shown
to play a major role in the stem cell compartment of
germ cells in vertebrates and non-vertebrates [12,13].
Our data show that E-cadherin is only weakly
expressed on or absent from the surface of male
germ cells at different stages of fetal development
and during spermatogenesis. In contrast, β-catenin is
present throughout all stages of intrauterine germ cell
maturation. Interestingly, the expression pattern and
intensity of both factors seen in gonadoblastoma and
CIS/ITGCNU show a close resemblance to male fetal
germ cells. The weak expression of E-cadherin in
gonadoblastoma present in dysgenetic gonads of XY
individuals with a female phenotype resembles imma-
ture male germ cells more than immature female germ
cells, as these are strongly positive for E-cadherin
(unpublished observations). These results add further
evidence to the model that both gonadoblastoma and
CIS/ITGCNU originate early during fetal development
[14,15]. An interesting, yet unexplained, observation is
the phenomenon that β-catenin is present in all precur-
sor lesions, but is lost consistently upon progression
to an invasive tumour showing germ cell character-
istics. This was observed in the progression of both
gonadoblastoma to dysgerminoma and CIS/ITGCNU
to seminoma.
Characteristics of early embryonal development
Seminoma and dysgerminoma cells, resembling early
germ cells, are mainly negative for E-cadherin,
whereas ES-like properties of EC are reflected by their
strong expression of E-cadherin. This is illustrated by
the similar expression pattern of OCT3/4, a marker
specific for pluripotent germ cell tumour cells such as
EC [16], and E-cadherin in tumours of different his-
tological types (see Figures 2A and B). Low levels
or the absence of E-cadherin in seminomas and some
YS is not accompanied by nuclear translocation of β-
catenin in the majority of the tumours investigated, in
contrast to findings from functional knock-out stud-
ies of E-cadherin in ES cells [17]. Furthermore, the
switch from pluripotent EC cells to extra-embryonic
or somatic tissues such as YS and teratoma leads
to an increase in the signal intensity of cytoplasmic
β-catenin (see Figure 2C). In teratomas, both factors
are strongly expressed in epithelial structures, most
likely reflecting changes in gene expression induced
by somatic differentiation. Our results confirm the ear-
lier observation that the expression of E-cadherin and
β-catenin in GCTs correlates with the degree of dif-
ferentiation of these tumours [5].
Pathobiological implications
Correlation of E-cadherin and β-catenin expression
with treatment outcome
A role for E-cadherin and β-catenin has been pos-
tulated in cancer invasion, aggressiveness of the
tumour, and metastasis [18]. E-cadherin has been
viewed as a tumour suppressor, mainly by main-
taining cell–cell adhesion and anchoring β-catenin
in a submembranous location [19]. Mutations of E-
cadherin have been found in a number of tumours,
including breast and gastric cancer, but not in testic-
ular cancer [20]. Adriamycin, a cytotoxic drug, has
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been shown to induce E-cadherin-mediated cell–cell
adhesion in vitro [21], and in another in vitro model,
expression of E-cadherin led to reduced BCL-2 expres-
sion and increased sensitivity to etoposide, an impor-
tant drug in the treatment of GCTs. β-catenin, a target
of the Wnt-signalling pathway, has been identified as a
potential candidate for targeted therapy [22]. As little
is known about these factors in treatment resistance
in GCT, we investigated E-cadherin and β-catenin in
samples from tumours both resistant and sensitive to
chemotherapy.
Although expression of both factors correlated with
different histological subtypes, and was seen in non-
seminomas but not in seminomas, no differences in
treatment outcome could be detected. Our data suggest
that the detection of E-cadherin or β-catenin by
immunohistochemistry has no prognostic or predictive
value for patients with newly diagnosed GCTs. The
overall prevalence of nuclear translocation of β-
catenin was low in our series. Although the factors
were not co-localized in approximately 50–60% of
all tumours, events leading to nuclear translocation of
β-catenin seem to be relatively rare in GCTs.
Correlation of E-cadherin expression and vascular
invasion in GCTs
It has been speculated that loss of cell adhesion
might help cells to detach from a primary tumour
and become invasive. For GCTs, a correlation between
loss of E-cadherin and lymph node metastases in
stage I non-seminomas has been implicated [4]. Yet,
given that E-cadherin is essential for the migration
and homing of mouse PGCs, a different function for
E-cadherin in GCTs is conceivable. In GCT cells
showing characteristics of early germ cells, E-cadherin
could actually enhance motility and the capacity
to penetrate tissues, or enable circulating tumour
cells to attach to vessel walls and ‘home’ in a new
environment. In seminomas, which show no or only
weak E-cadherin expression, vascular invasion is not
a frequent event. On the other hand, ECs, which in the
vast majority of cases show high levels of E-cadherin
expression, are frequently angio-invasive [23]. In fact,
the presence of EC is associated with an odds ratio of
2.9 for developing occult metastases [24].
Our results from the tumour samples from the
selected group of patients suggest that neither vascular
invasion nor the frequency of metastatic spread cor-
relate with E-cadherin expression. Yet, as this series
was highly biased towards later stages of GCTs and
contained almost no cases without metastases at diag-
nosis, we expanded our series by including samples
of tumours of earlier stages without metastases. In a
cohort of 40 cases, 29 without and 11 with vascular
invasion, no statistically significant correlation of E-
cadherin expression and vascular invasion was seen, in
line with the results of our selected patient group. This
suggests that, unlike in other tumour entities, vascu-
lar invasion and E-cadherin expression do not seem to
correlate in GCTs. However, our results must be inter-
preted with caution, as the sample size investigated
was rather small. Further investigation of this topic
should ideally be performed as part of a multivari-
ate analysis of prognostic factors within large clinical
trials.
In summary, our results allow a number of con-
clusions: (1) The majority of immature male germ
cells of the second and third trimesters show no or
very weak expression of E-cadherin, but consistently
express β-catenin. (2) E-cadherin is not expressed in
gonadoblastoma, CIS/ITGCNU, or intratubular and
invasive seminoma; in contrast, β-catenin is expressed
in gonadoblastoma and CIS/ITGCNU, but is lost dur-
ing progression to intratubular seminoma and inva-
sive seminoma or dysgerminoma. (3) Both factors are
expressed in the vast majority of intratubular and inva-
sive non-seminomas. Expression therefore seems to be
regulated during differentiation. (4) Nuclear transloca-
tion of β-catenin is a rare event in GCTs. (5) No differ-
ences in the presence of either E-cadherin or β-catenin
were observed between samples of tumours refractory
or sensitive to chemotherapy, and E-cadherin expres-
sion did not correlate with vascular invasion.
E-cadherin and β-catenin therefore play a role in
both normal and malignant germ cell development
and differentiation that warrants further investigation,
but they seem to be of limited value as predictive or
prognostic factors in GCTs.
Acknowledgements
We thank the pathologists and urologists in the south-western
part of The Netherlands for their cooperation in collecting
the tumour samples, and R Fodde (Rotterdam) for critically
reading the manuscript. This work was supported by the Dutch
Cancer Society (grant numbers KWF DDHK 99-1876 (AMFK)
and 2002-2682; HS, LHJL) and the Deutsche Krebshilfe, Dr
Mildred Scheel Stiftung (FH).
References
1. Comijn J, Berx G, Vermassen P, et al. The two-handed E box
binding zinc finger protein SIP1 downregulates E-cadherin and
induces invasion. Mol Cell 2001; 7: 1267–1278.
2. Kielman MF, Rindapaa M, Gaspar C, et al. Apc modulates
embryonic stem-cell differentiation by controlling the dosage of
beta-catenin signaling. Nature Genet 2002; 32: 594–605.
3. Nollet F, Berx G, van Roy F. The role of the E-cadherin/catenin
adhesion complex in the development and progression of cancer.
Mol Cell Biol Res Commun 1999; 2: 77–85.
4. Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW. Prognostic
risk factors that identify patients with clinical stage I
nonseminomatous germ cell tumors at low risk and high risk for
metastasis. Cancer 1998; 83: 1002–1011.
5. Saito T, Katagiri A, Watanabe R, et al. Expression of E-cadherin
and catenins on testis tumor. Urol Int 2000; 65: 140–143.
6. Skakkebæk NE, Berthelsen JG, Giwercman A, Mu¨ller J.
Carcinoma-in-situ of the testis: possible origin from gonocytes and
precursor of all types of germ cell tumours except spermatocytoma.
Int J Androl 1987; 10: 19–28.
7. Scully RE. Gonadoblastoma. A review of 74 cases. Cancer 1970;
25: 1340–1356.
Chapter 6   
 
78
8. Honecker F, Mayer F, Stoop H, et al. Xeroderma pigmentosum
group A protein and chemotherapy-resistance in human germ cell
tumors. Lab Invest 2003; 83: 1489–1495.
9. Geiger B, Ayalon O. Cadherins. Annu Rev Cell Biol 1992; 8:
307–332.
10. Bendel-Stenzel MR, Gomperts M, Anderson R, Heasman J,
Wylie C. The role of cadherins during primordial germ cell
migration and early gonad formation in the mouse. Mech Dev
2000; 91: 143–152.
11. Di Carlo A, De Felici M. A role for E-cadherin in mouse
primordial germ cell development. Dev Biol 2000; 226: 209–219.
12. Yamashita YM, Jones DL, Fuller MT. Orientation of asymmetric
stem cell division by the APC tumor suppressor and centrosome.
Science 2003; 301: 1547–1550.
13. Tiedemann H, Asashima M, Grunz H, Knochel W. Pluripotent
cells (stem cells) and their determination and differentiation in
early vertebrate embryogenesis. Dev Growth Differ 2001; 43:
469–502.
14. Jørgensen N, Muller J, Jaubert F, Clausen OP, Skakkebaek NE.
Heterogeneity of gonadoblastoma germ cells: similarities with
immature germ cells, spermatogonia and testicular carcinoma
in situ cells. Histopathology 1997; 30: 177–186.
15. Rajpert-De Meyts E, Bartkova J, Samson M, et al. The emerging
phenotype of the testicular carcinoma in situ germ cell. APMIS
2003; 111: 267–278; discussion 278–269.
16. Looijenga LHJ, Stoop H, De Leeuw PJC, et al. POU5F1
(OCT3/4) identifies cells with pluripotent potential in human germ
cell tumors. Cancer Res 2003; 63: 2244–2250.
17. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R. E-cadherin
binding prevents beta-catenin nuclear localization and beta-
catenin/LEF-1-mediated transactivation. J Cell Sci 1999; 112:
1237–1245.
18. Jiang WG. E-cadherin and its associated protein catenins, cancer
invasion and metastasis. Br J Surg 1996; 83: 437–446.
19. Berx G, Cleton-Jansen A-M, Nollet F, et al. E-cadherin is a
tumour/invasion suppressor gene mutated in human lobular breast
cancers. EMBO J 1995; 14: 6107–6115.
20. Huiping C, Kristjansdottir S, Jonasson JG, Magnusson J, Egils-
son V, Ingvarsson S. Alterations of E-cadherin and beta-catenin
in gastric cancer. BMC Cancer 2001; 1: 16.
21. Yang SZ, Kohno N, Kondo K, et al. Adriamycin activates E-
cadherin-mediated cell–cell adhesion in human breast cancer cells.
Int J Oncol 1999; 15: 1109–1115.
22. Li H, Pamukcu R, Thompson WJ. Beta-catenin signaling: thera-
peutic strategies in oncology. Cancer Biol Ther 2002; 1: 621–625.
23. Oosterhuis JW, Kersemaekers AM, Jacobsen GK, et al. Morphol-
ogy of testicular parenchyma adjacent to germ cell tumours; an
interim report. APMIS 2003; 111: 32–42.
24. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Albers P,
Habbema JD. Predictors of occult metastasis in clinical stage
I nonseminoma: a systematic review. J Clin Oncol 2003; 21:
4092–4099.
  
 
 
 
 
Chapter 7 
 
 
XERODERMA PIGMENTOSUM GROUP A PROTEIN AND CHEMOTHERAPY 
RESISTANCE IN HUMAN GERM CELL TUMORS 
 
 
 
LABORATORY INVESTIGATION 83: 1489-1495, 2003 
 
 
 
 
 
By Friedemann Honecker, Frank Mayer, Hans Stoop, J. Wolter Oosterhuis, Sandra Koch, Carsten 
Bokemeyer, and Leendert H.J. Looijenga 
 
 

 XPA and chemotherapy resistance in germ cell tumors  
81 
Xeroderma Pigmentosum Group A Protein and
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Sandra Koch, Carsten Bokemeyer, and Leendert H. J. Looijenga
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Netherlands; and Department of Hematology-Oncology (FH, FM, SK, CB), University of Tübingen, Tübingen, Germany
SUMMARY: The exceptional sensitivity of germ cell tumors (GCTs) of adolescents and adults to chemotherapy, in particular to
cisplatin, has been attributed to low levels of xeroderma pigmentosum group A protein (XPA), a crucial component of the
nucleotide excision repair DNA repair pathway. In different types of solid tumors, resistance to cisplatin has been associated with
enhanced expression of XPA. To assess the role of XPA levels in clinical sensitivity and resistance of GCTs to chemotherapy,
immunohistochemistry was performed on tumor samples of both unselected patients before therapy and patients with fully
documented clinical course before and after therapy. In the case of high XPA levels, fluorescent in situ hybridization was applied
to assess the possibility of gene amplification. XPA protein levels were investigated by Western blot analysis after repeated
exposure to cisplatin in different GCT-derived cell lines. Finally, XPA levels of both sensitive and cisplatin-resistant GCT cell lines
were compared with cell lines derived from other neoplasms. We found that the presence of XPA protein as assessed by
immunohistochemistry differs among the various histologies of GCTs. It is found more frequently and with a more homogenous
staining pattern in histologic subtypes showing a more differentiated phenotype. Overall, no differences in the presence of XPA
was observed between samples of tumors refractory or sensitive to chemotherapy. No XPA gene amplification was found.
Interestingly, all tumors resected in relapse after chemotherapy in the refractory group stained positive for XPA. However, XPA
was not induced by repeated courses of sublethal doses of cisplatin in GCT-derived cell lines in vitro, and no correlation between
XPA protein levels and sensitivity to cisplatin in three GCT-derived cell lines was observed. We therefore conclude that XPA does
not play a critical role in overall treatment resistance of GCTs. (Lab Invest 2003, 83:1489–1495).
G erm cell tumors (GCTs) of the testis are the mostfrequent solid tumor in Caucasian men between
20 and 45 years of age (Adami et al, 1994). Histolog-
ically, they display patterns that resemble stages of
embryonal development (Looijenga and Oosterhuis,
1999, 2002). Seminomas show characteristics of early
germ cells (primordial germ cells or gonocytes),
whereas nonseminomas can contain different, both
embryonic and extra-embryonic, elements. The em-
bryonal carcinoma is the stem cell component of
nonseminomas, which may differentiate into yolk sac
tumor, choriocarcinoma, and teratoma.
Seminomas and nonseminomas are highly sensitive
to chemotherapy, notably to cisplatin (Einhorn, 2002).
Presently, more than 80% of patients with metastatic
disease can be cured by cisplatin-based combination
chemotherapy. However, mature teratomas are intrin-
sically resistant to chemotherapy. This histology is
found in about 40% of residual lesions after chemo-
therapy and should be resected to prevent malignant
transformation and development of secondary non–
germ cell malignancies (Fizazi et al, 2001; Oosterhuis
et al, 1983). The biological basis of the overall high
sensitivity to chemotherapy and the infrequent but
mostly lethal occurence of resistant phenotypes re-
mains unclear.
Different mechanisms of cellular resistance to cis-
platin have been described, including inhibition of
drug uptake and increased efflux, inactivation by
sulfur-containing proteins, enhanced replicative by-
pass of platinum DNA adducts, changes in concen-
trations of regulatory proteins, and enhanced repair of
DNA crosslink lesions caused by cisplatin (Kartalou
and Essigmann, 2001; Mayer et al, 2003; Reed, 1998).
Nucleotide excision repair (NER) is believed to be the
main mechanism by which damage caused by cispla-
tin through formation of bulky DNA adducts is repaired
in mammalian cells (Chaney and Sancar, 1996;
Zamble and Lippard, 1995). Xeroderma pigmentosum
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group A protein (XPA), involved in the NER system, is
a zinc finger protein that is absent or aberrant in cells
of patients with xeroderma pigmentosum complemen-
tation group A (Bootsma et al, 2001). Binding of XPA
to the replication protein A is the initiating and rate-
limiting step of NER (Matsuda et al, 1995). It subse-
quently recruits other factors to damaged substrates
(Buschta-Hedayat et al, 1999). GCT-derived cell lines
were found to have low XPA levels and a low NER
capacity. This finding was proposed as the major
reason for the high sensitivity of GCTs to chemother-
apy (Koberle et al, 1999). The XPA gene maps to
chromosome 9q22, one of the regions found to be
specifically amplified in GCTs showing chemotherapy
resistance (Rao et al, 1998).
The objective of the present study is to investigate
the presence of XPA in GCTs and clarify its role in
sensitivity and resistance to cisplatin-based chemo-
therapy. XPA status was assessed by immunohisto-
chemistry in tumor samples from patients with histo-
logically defined GCTs without information on clinical
outcome. To correlate immunohistochemical findings
with clinical outcome, tumors from patients with fully
documented clinical course, including chemotherapy-
sensitive and refractory cases, were investigated. In
addition, the correlation between XPA protein levels
and cisplatin sensitivity was investigated by immuno-
blotting in different cell lines, including GCT cell lines
with defined sensitivity and resistance to cisplatin.
Results
The presence of XPA protein was investigated in
different histological elements of GCTs, including car-
cinoma in situ (CIS), their obligatory precursor lesion in
the testis. Immunohistochemistry was performed on
paraffin-embedded tissue sections of 85 unselected
tumors of all histologic variants (Table 1). XPA showed
a nuclear localization in the tumor cells with differing
frequency and intensity in the different subtypes and
histologic elements. Figure 1 shows representative
examples, including normal spermatogenesis. Embry-
onal carcinomas showed staining in 26% of cases (4
of 15), followed by seminomas (16 of 33, 48%),
choriocarcinoma (2 of 4, 50%), and yolk sac tumors
(11 of 18, 61%). Interestingly, all teratomas (19 primary
cases and 4 residual mature teratomas) were strongly
positive. The overall percentage of positive tumor cells
varied between different subtypes and histologies.
Seminomas and embryonal carcinomas displayed a
heterogenous staining pattern with only a few tumors
(n  8/33 and 2/15, respectively) showing more than
50% positivity. Yolk sac tumors, choriocarcinomas,
and teratomas revealed a much more homogenous
staining, with up to 100% of nuclei being positive.
About 25% of the CIS cells, as present in adjacent
testicular parenchyma of invasive seminomas or non-
seminomas (n  5), showed a positive staining for
XPA. This positivity was confirmed using a double-
staining for c-KIT and XPA (Fig. 1B).
To assess a possible correlation between the pres-
ence of XPA and clinical outcome, we investigated
samples of GCTs from patients with chemotherapy-
sensitive (n  12) and refractory (n  23) tumors.
Clinical information is given in Table 2. The immuno-
histochemical results demonstrated no difference be-
tween the two groups: 9 of 12 (75%) tumors in the
chemosensitive and 16 of 23 (70%) tumors in the
refractory group stained positive for XPA (Table 2).
However, all tumors sampled after chemotherapy (n
9) in the refractory group were positive for XPA. The
histologies found in these cases were yolk sac tumor
(n  7), teratoma (n  2), and choriocarcinoma (n  2;
some of the tumors exhibited more than one histologic
subtype). No gene amplification of XPA was found
using double-color fluorescent in situ hybridization
(FISH) on tumors showing strong XPA expression in
the refractory group (n  9 cases).
To investigate possible mechanisms related to the
consistent presence of XPA in the refractory GCTs
after cisplatin exposure, we investigated the total
amount of XPA protein in three well-characterized
GCT-derived cell lines (NT2, 2102Ep, and NCCIT) by
Western blotting. Whereas NCCIT showed a low and
2102Ep an intermediate expression level, NT2 con-
tained XPA at a level comparable to that of various
other tumor cell lines (Fig. 2A). Furthermore, in cyto-
toxicity assays no correlation between XPA level and
cisplatin sensitivity was observed (Fig. 2B). Continu-
ous treatment with 0.5 M and 1.5 M cisplatin,
respectively, for up to 48 hours did not result in
up-regulation of XPA in NT2 or 2102Ep (Fig. 2C).
Subsequently, NT2 and 2102Ep cells were repeatedly
treated with sublethal doses of cisplatin, resulting
(after 18 cycles of treatment) in cell lines relatively
resistent to cisplatin. The NT2 subline (NT2/CDDP)
showed a 2.2-fold and the 2101EP subline (2102EP/
CDDP) a 2-fold resistance to cisplatin at the IC50 (Fig.
2B). However, this was not accompanied by an in-
crease in the level of XPA in these sublines (Fig. 2A).
Table 1. Immunohistochemical detection of xeroderma
pigmentosum group A protein in CIS and in GCTs of
different histologies (unselected tumor samples)a
Histology
Cases
showing any
positivity, %
Cases with  50%
positive nuclei, %
EC (n  15) 26 13
SE (n  33) 48 24
CC (n  4) 50 50
YS (n  18) 61 44
TE (n  23, including 4
RMT)
100 95
CIS containing samples
(n  5)b
CC, choriocarcinoma; CIS, carcinoma in situ; EC, embryonal carcinoma;
GCTs, germ cell tumors; RMT, residual mature teratoma; SE, seminoma; TE,
teratoma; YS, yolk sac tumor.
a The majority of cases showed more than one histological subtype.
b 25% positivity of all CIS cells.
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Discussion
The unique chemosensitivity of GCTs is poorly under-
stood on a molecular level so far (Mayer et al, 2003).
Based on studies on the mouse teratocarcinoma cell
line P19, it has been assumed that a high level of
wild-type p53 results in a low threshold for induction
of apoptosis (Lutzker and Levine, 1996; Lutzker et al,
2001). However, this model differs from human GCTs
in various parameters, and we recently demonstrated
that treatment outcome in patients with GCTs does
not correlate with p53 status (Kersemaekers et al,
Figure 1.
Representative examples of the immunohistochemical stainings for xeroderma pigmentosum group A protein (XPA) in normal testis and germ cell tumors (GCTs)
of different histologic subtypes. All sections have been lightly counterstained with hematoxylin with exception of B (double-staining), which was not counterstained
to allow identification of both stainings. (A) Normal testicular parenchyma. Note positivity of germ cells at various stages of maturation as reported before (Stoop
et al, 2001). Primary and pachytene spermatocytes (Pps) are XPA positive, whereas spermatogonia (Spa) and spermatids (Sp) are negative. Insert: Negative control
(primary antibody omitted). (B) Seminiferous tubules containing carcinoma in situ (CIS) cells. Double-staining for c-KIT (red membrane-bound staining) and XPA
(blue nuclear staining). All CIS cells show positivity for c-KIT and can be either positive or negative for XPA. (C) Seminoma, negative for XPA. Note positivity of
infiltrating lymphocytes (Ly). (D) Nonseminoma containing both teratoma (Te) showing epithelial differentiation positive for XPA and embryonal carcinoma (EC)
negative for XPA. Note that stromal cells and infiltrating lymphocytes can be positive for XPA. (E) Choriocarcinoma showing a heterogeneous staining for XPA. Note
the varied staining reaction of the multinucleated syncytiotrophoblasts. (F) Yolk sac tumor positive for XPA.
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2002). It has also been suggested that the unique
treatment sensitivity of GCTs could be explained by a
defective repair of cisplatin-induced DNA damage
related to low XPA (Koberle et al, 1999). Several
observations seem to support this model. For exam-
ple, mammalian cells deficient in NER are more sen-
sitive to cisplatin than corresponding wild-type cells
(Dijt et al, 1988; Poll et al, 1984). Expression of a
truncated XPA protein exerting a dominant-negative
effect sensitizes human tumor cells to UV light and
cisplatin (Rosenberg et al, 2001). Moreover, an en-
hanced XPA expression is associated with resistance
to cisplatin treatment in human ovarian cancer (Dab-
holkar et al, 1994). However, studies correlating NER
with clinical data result in conflicting data for different
tumor entities. For example, expression of several
NER factors in patients with chronic lymphocytic leu-
kemia did not correlate with resistance to nitrogen
mustard (Bramson et al, 1995), while an increased
NER capacity in patients with non–small-cell lung
cancer may be associated with poorer survival
(Bosken et al, 2002). It is of specific interest that a link
between NER and differentiation has been observed in
normal tissues; somatic stem cells are highly sensitive
to the effects of physical and chemical mutagens (Ijiri
and Potten, 1987; Potten, 1977) and avoid certain
forms of potentially error-prone DNA damage repair
(Roth and Samson, 2002). It has been suggested that
the choice of death rather than defective DNA repair in
case of damage serves to avoid accumulation of
replication errors with fatal consequences for the
progeny (Cairns, 2002). So far, however, no data are
available regarding NER and clinical outcome in
GCTs.
The aim of this study is to assess the role of XPA in
clinical resistance of GCTs. Immunohistochemistry in
the unselected group of patients revealed that the
staining pattern of XPA correlated with histology. In
seminomas and in embryonal carcinoma, only a mi-
nority of cells contained detectable levels of XPA. In
contrast, the majority of cells from choriocarcinomas,
Table 2. Characteristics of patients with proven
chemosensitive or refractory germ cell tumors
Chemosensitive
(n  12)
Refractory
(n  22)
Age, years
Median 28 29
Range 20–47 17–56
Histology
Seminoma 1 1
Nonseminoma 11 21
Stage at diagnosis
(per UICC)
I 0 3
II 0 7
III 12 12
Initial treatment after
surgery
Surveillance 0 2
Chemotherapy 12 20
Follow-up, months
Median 49 39
Range 12–67 11–180
Relapse-free survival,
months
Median NR 7.1
Range 0–150
Response to initial
treatment
Complete remission 8 5
Partial remission, marker
negative
4 8
Partial remission, marker
positive
0 3
Progressive disease 0 3
Unknown 0 3
No. of regimens in relapse
Median 0 3
Range 0 1–9
Cases showing XPA
positivity
75% (9/12) 70% (16/23)
NR, not reached; UICC, International Union Against Cancer; XPA, xeroderma
pigmentosum group A protein.
Figure 2.
(A) Immunoblot analysis for xeroderma pigmentosum group A protein (XPA)
and -actin on different cell lines derived from germ cell tumors (GCTs),
including NT2/CDDP and 2102Ep/CDDP cell lines with acquired resistance to
cisplatin following repeated sublethal exposure. SKOV, HeLa, MCF7, and Jurkat
are cell lines derived from ovarian cancer, cervical cancer, breast cancer, and
leukemia cells. (B) Cytotoxicity assay for selected GCT-cell lines. Note the lack
of correlation between CDDP sensitivity and XPA level. (C) Immunoblot for
XPA and -actin on NT2 and 2102Ep cells during initial treatment with cisplatin
(NT2: 0.5 M cisplatin, 2102Ep: 1.5 M cisplatin).
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yolk sac tumors, or teratomas were positive for XPA.
Three teratomas and yolk sac tumors of infants and
neonates that were included in this series showed a
similar staining pattern as the tumors in histologic
counterparts found in testis of the adults (data not
shown). No differences in the presence of XPA was
evident comparing tumors of patients with cisplatin-
sensitive and refractory disease. The overall picture
was heterogenous, as high expression of XPA was
observed in several tumor samples of chemosensitive
cases on the one hand, and lack of expression of XPA
was seen in some refractory cases on the other hand.
Results were in the same range as in the unselected
group. Therefore, we conclude that XPA detection by
immunohistochemistry has no prognostic or predic-
tive value for patients with newly diagnosed GCTs.
None of the resistant tumors with detectable levels
of XPA showed amplification of the respective locus
using FISH analysis. This excludes amplification of the
XPA gene as a common mechanism of chemotherapy
resistance in GCTs. However, it is noteworthy that all
tumors sampled at relapse in the refractory group, ie,
after exposure to chemotherapy, were positive for
XPA. This could simply be due to the particular histol-
ogy (yolk sac tumors, choriocarcinoma, and teratoma)
found in this limited series. Alternatively, induction of
XPA or selection for XPA-positive cells could have
occurred during treatment. To test this hypothesis, an
in vitro model was used, which showed no correlation
between XPA levels and sensitivity to cisplatin in the
three GCT-derived cell lines investigated. We found a
low level of XPA only in NCCIT, the cell line with the
lowest sensitivity to cisplatin, whereas the levels of
2102Ep and NT2 were only slightly lower or compa-
rable to that found in cell lines derived from other
neoplasms. In addition, XPA expression was not in-
duced in GCT cells that acquired cisplatin resistance
by repeated exposure to the drug, differing from
findings reported from ovarian cancer–derived cell
lines (Hector et al, 2001). In this context it is of interest
that even a low level of XPA expression in deficient
cells is sufficient for total complementation of cellular
sensitivity and DNA repair activity (Muotri et al, 2002).
In accordance with this, it has been reported that
sensitivity to 170 different compounds, including cis-
platin, tested in a cytotoxicity assay did not correlate
with XPA levels in 60 human tumor cell lines (Xu et al,
2002).
In conclusion, we demonstrated that the presence
of XPA protein as assessed by immunohistochemistry
differs between the various histologies of GCTs. XPA
is found more frequently and with a more homoge-
nous staining pattern in the histologic subtypes with a
more differentiated phenotype. Overall, no differences
in the presence of XPA were observed between sam-
ples of tumors refractory or sensitive to chemother-
apy. Furthermore, we did not find a correlation be-
tween XPA protein levels and sensitivity to cisplatin in
three GCT-derived cell lines. We therefore conclude
that XPA does not play a critical role in overall treat-
ment resistance of GCTs. Further research is needed
to elucidate the mechanisms of chemotherapy sensi-
tivity and resistance in these tumors.
Materials and Methods
Patient Material
Unselected Group: Formalin-fixed paraffin-
embedded tissue blocks were retrieved from the ar-
chive of the Laboratory for Experimental Patho-
Oncology, Department of Pathology, Erasmus MC,
Rotterdam. The material was collected between 1991
and 2001 in close collaboration with urologists and
pathologists in the Southwest of the Netherlands.
Eighty-one tumors were collected before therapy. In
four cases residual mature teratomas were removed
after chemotherapy. No data on the clinical course of
the patients were available.
Chemosensitive Group: Formalin-fixed, paraffin-
embedded samples collected before therapy from 12
patients diagnosed between 1995 and 1998 were
investigated. Only patients with a complete remission
or a marker negative partial remission after high-dose
chemotherapy and a relapse-free follow-up of more
than 1 year were included. The series consisted of 11
nonseminomas and one seminoma.
Refractory Group: Twenty-three formalin-fixed
paraffin-embedded samples from 22 patients with
chemotherapy-refractory disease diagnosed between
1991 and 1998 were investigated. Patients were con-
sidered refractory when progression or relapse oc-
curred despite adequate initial or salvage treatment,
including high-dose chemotherapy in some cases.
The material of 14 patients was obtained at initial
diagnosis; in nine cases, the material was sampled
after exposure to chemotherapy from metastatic le-
sions in relapse. In one case, material from both the
primary tumor and a metastatic tumor at relapse was
available. The series consisted of 22 nonseminomas
and one seminoma. Table 2 summarizes the charac-
teristics of the patients with refractory and chemosen-
sitive tumors. All cases were reviewed and diagnosed
by J.W.O. according to the World Health Organization
classification, and the fully documented clinical course
was available for these patients.
Cell Lines and Culture Conditions
The GCT-derived cell lines NT2 and NCCIT were
purchased from the American Type Tissue Culture
(Manassas, Virginia). 2102Ep was a kind gift from M.
Pera. MCF-7 (breast cancer), SKOV-3 (ovarian can-
cer), and HeLa (cervical cancer) were gifts from P.
Brossart. Jurkat (human T cell leukemia) was a gift
from T. Brümmendorf (University of Tübingen Medical
Center). Cells were grown as monolayer and main-
tained at 37° C in a humidified cell culture incubator
with 5% carbon dioxide. NT2 were cultured in DMEM/
glutamax supplemented with 10% FCS (Gibco BRL,
Paisly, United Kingdom), penicillin (Biochrom), and
streptomycin (Biochrom). NCCIT and 2102Ep were
cultured in DMEM/nut mix F12 supplemented with
10% FCS, pencillin, streptomycin, and glutamin. All
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other cell lines were kept in HEPES-buffered RPMI
(Gibco).
Immunohistochemistry
Paraffin sections of 3-m thickness were mounted on
Starfrost slides (Knittel Gläser, Germany), dried at
50° C overnight, deparaffinized, and rehydrated. For
antigen retrieval, pressure cooking at 1.0 bar in citrate
buffer 0.01 mol/L pH 6.0 was used. All antibodies were
diluted in PBS with 1% BSA (Sigma, Zwijndrecht, the
Netherlands). The primary antibody anti-XPA (mouse
mAb, Ab-1 Clone 12F5; NeoMarkers, Freemont, Cali-
fornia) was used in a dilution 1:100, and incubation
time was 60 minutes at room temperature. Biotin-
labeled rabbit-antimouse immunoglobulins and an
avidin-biotin-HRP complex (both DAKO A/S, Glostrup,
Denmark) were subsequently applied for 30 minutes
each. DAB (Fluka, Switzerland) was used as a chro-
mogen, and slides were lightly counterstained with
Mayer’s hematoxylin stain. Double-staining for CIS
cells was performed incubating slides sequentially
with c-KIT (rabbit polyclonal antibody, C-19, Santa
Cruz Biotechnology, California) after pretreatment in a
dilution 1:300 overnight at 4° C and XPA as described
above. XPA was visualized using avidin-biotin-alkaline
phosphatase complex with Fast blue (Sigma) as chro-
mogen. Detection of the c-KIT specific antibody was
done using the peroxidase-anti-peroxidase method
with 3-amino-9-ethyl-carbazole (AEC) (Sigma) as
chromogen. For a negative control, the primary anti-
body was omitted; lymphocytes and normal spermat-
ogenesis (pachytene spermatocytes) as present in the
histological sections under investigation were used as
positive control. Two investigators (F.H. and F.M. or
H.S.) assessed samples independently. For evaluation
of percentage of positive cells, 200 cells were scored
in three randomly selected high-power fields. Only
clearly nuclear staining of intact cells was considered
positive.
Western Blotting and Amplification Analysis for XPA
Using FISH
Protein harvest, Western blotting procedure, and FISH
were performed as previously described (Kersemaek-
ers et al, 2002). The XPA probe for FISH was derived
from BAC clone RP11–414C23. A cut-off level of 10
signals per nucleus was chosen to assess amplifica-
tion of the gene locus. Only intact nuclei of a minimum
of 20 cells were scored.
Cisplatin Treatment and Toxicity, Resistance Assay, and
Cytotoxicity Assay
In vitro cytotoxicity was determined by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide-
(MTT-)assay (MTT-assay), which was performed ac-
cording to standard protocols. One-thousand cells/
well were seeded in 96-well plates 8-fold, left to attach
overnight, and were exposed to cisplatin in increasing
concentration continuously for further 72 hours. The
cisplatin-containing medium was carefully removed,
replaced by medium containing MTT (Sigma), and
incubated for 4 hours at 37° C. The tetrazolium salt
was dissolved in DMSO, and the extinction was mea-
sured at 570 nm on a Bio-Rad ELISA-reader. The
results are expressed relative to the extinction of the
cells grown in the absence of cisplatin.
Induction of Drug Resistance
Cells were treated in increasing sublethal doses of
cisplatin (ranging from 0.6 M to 2.0 M) for 2 hours,
transferred to normal medium, and grown for 2 weeks
before re-exposure to cisplatin. Exposure at each
dose level was repeated three times.
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Human GCTs are fascinating tumours, as they can be regarded as naturally occurring experiments 
revealing aspects of both developmental and tumour biology. However, with regards to some aspects, 
this can also be a limiting factor, as the observed findings can be either due to the process of 
tumourigenesis, or simply reflect normal development. Depending on their histology, GCTs can show 
significant similarities with early germ cells. Comparative analysis of the tumours and representative 
normal foetal counterparts, both female and male, can therefore help to define events related to the 
pathogenesis of this cancer. In the present work, therefore, a thorough analysis of changes in the 
marker profile during foetal germ cell development is presented (Chapters 2, 3, 4, and 6). Furthermore, 
the potential of GCTs to differentiate is explored, and the surprising finding of germ cell lineage 
differentiation in non-seminomas is presented (Chapter 5). Finally, aspects of treatment 
sensitivity/resistance of GCTs, most likely reflecting the intrinsic characteristics of the cell of origin 
and their derivatives, are discussed (Chapters 6 and 7).   
 
8.1. Defining normal germ cell development 
The common model of germ cell development in mammals holds that embryonic precursors of the 
gametes known as PGCs are set aside to an extra-embryonic localization during early embryonic 
development, and migrate to the area where the genital ridge will be formed around the 5th and 6th 
week of human development (1). Mammalian germ cells are known to first originate in the proximal 
region of the epiblast. In mouse experiments, cells that normally never would give rise to the germ 
lineage can differentiate into germ cells and extra-embryonic mesoderm when grafted to the proximal 
epiblast (2). This indicates that germ cell differentiation, rather than being an intrinsic quality of a 
predetermined progenitor cell, can be induced by extracellular factors and/or cell-cell interactions (3). 
Which of these factors are indispensable to induce commitment of an undetermined human ES cell to 
germ line fate is largely unknown. Recent findings indicate that co-aggregate culture of mice ES cells 
on feeder cells expressing bone morphogenetic protein 4 (BMP4) greatly enhances the population of 
germ cells (2).  
In humans, the female germ cell pool expands until the second trimester, and then begins to decline in 
number until birth (4). Postnatal development and expansion of female germ cells has largely been 
ruled out. Recently, however, this dogma has been challenged, and oocyte generation in adult ovaries 
in the mouse has been described (5), although this needs to be confirmed. A pool of stem cells with 
germline characteristics has been identified in the bone marrow and in the peripheral blood (6). 
Interestingly, germ cell markers and markers of pluripotency like NANOG have been isolated from 
human adult bone marrow and peripheral blood (7, 8, 6). This could indicate that a respective pool of 
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committed germline stem cells also exists in humans beyond the foetal period in extragonadal 
localizations.  
Even though male and female foetal germ cells show a number of differences, such as the timing of 
the onset of meiosis, there are also remarkable similarities. In both sexes, immature germ cells (called 
gonocytes in males and oogonia in females) can morphologically be distinguished by their large size, 
big nuclei, and clear cytoplasm. These cells eventually become more mature germ cells called 
prespermatogonia and oocytes. In humans, the process of maturation is not synchronized, and germ 
cells at different developmental stages can be detected at the same time in prenatal gonads. This 
suggests that the individual pace of maturation is driven by unknown intracellular mechanisms, rather 
than by external, e.g. hormonal, stimuli (9).  
In addition to mere histological criteria, a number of markers for early germ cells have been described 
(10 for review). These could be confirmed and further characterized by our studies (Chapters 2 and 3). 
In particular, the exact timing of the regulation of these markers had previously not been described. In 
our analyses, we could distinguish an immature and a more mature phenotype of human germ cells, 
both in males and females. Immature germ cells are characterized by strong expression of PLAP 
(placental/germ cell alkaline phosphatases), the transcriptional regulator and marker of pluripotency 
POU5F1 (OCT3/4), and the stem cell factor receptor KIT. Furthermore, they show weak expression of 
the germ line specific protein VASA. PLAP is the first factor to be down-regulated during maturation, 
followed by OCT3/4 and then KIT in male germ cells, whereas in female germ cells, expression of 
KIT remains high in oocytes and primordial follicles.  
Female germ cells are characterized by strong expression of E-cadherin and β-catenin during 
maturation, which persists throughout folliculogenesis. It is important to note that the pattern of 
marker expression shows significant differences between human and mouse foetal germ cells, as has 
been described in our study on human foetal germ cells in females (Chapter 2). This should be kept in 
mind when interpreting data from animal studies, and underlines the importance of analyses on human 
tissue.  
Male foetal germ cells lack XPA (11), show weak expression of E-cadherin, but strong expression of 
β-catenin (Chapter 6). They can show expression of TSPY (testis-specific protein, Y-encoded), which 
is detected mainly in prespermatogonia. In both sexes, the pool of immature germ cells expands 
through strong mitotic activity until week 22 to 24. Transition to a more mature germ cell is 
accompanied by stronger expression of VASA and loss of OCT3/4 in both sexes. As this transition 
takes place in males when the gonocyte gets attached to the basal membrane of the seminiferous 
tubule, and in females when the germ cells engage in folliculogenesis, a crucial role of external factors 
like cell-cell contacts is postulated in the course of normal germ cell maturation.  
Recently, the existence of a third population of germ cells showing an intermediate phenotype has 
been described in males (12). Obviously, within a continuous, yet unsynchronized process of 
maturation, different combinations of markers will be found at different time points. However, as there 
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is little necessity to further subdivide maturing germ cells for biological reasons, we and others have 
not made this distinction (13). 
8.2. Disturbed germ cell development and malignant transformation 
More than 30 years after the identification of carcinoma in situ/intratubular germ cell neoplasia 
unclassified (CIS/IGCNU) as an obligatory precursor lesion in the testis (14), we are still far from 
having a clear concept of events mandatory in the process of malignant transformation. Impaired cell 
maturation and retention of pluripotent cells in a phase vulnerable to further hits has been postulated as 
one possible pathogenetic mechanism eventually leading to GCT development (15, 16). Chromosomal 
instability leading to aneuploidy with specific gains and losses has been implicated as relevant factors 
in malignant transformation (17 for review). Moreover, the sex chromosomes X and Y seem to play a 
particular role in germ cell transformation (18 for review).  
Having defined normal germ cell development, we studied cells showing delayed or disturbed 
maturation. Several proteins, like PLAP, KIT, or OCT3/4, have been found both in normal immature 
and malignant germ cells, called CIS/IGCNU in the testis, and gonadoblastoma in dysgenetic gonads. 
We undertook an extensive immunohistochemical analysis in CIS/IGCNU and gonadoblastoma and 
could confirm PLAP, OCT3/4 and TSPY as suitable makers for the diagnosis of preinvasive malignant 
germ cells in postpubertal gonads (Chapter 4). Of these, OCT3/4 shows the clearest and most robust 
staining pattern and is therefore recommended as a marker for the clinical routine. Although de-
differentiation and consecutive re-expression of early markers cannot be ruled out as a mechanism for 
development of CIS/IGCNU, our data are in line with the model of a maturation arrest of immature 
germ cells as one of the first pathogenetic hits in the development of GCTs.  
An interesting, yet little understood factor, TSPY, is worth a more detailed look. Early invasive 
dysgerminoma cells consistently show staining for TSPY, similar to the pattern seen for OCT3/4. In 
contrast, TSPY expression can be lost in invasive dysgerminoma areas at distance from the pre-
invasive lesion, even though the corresponding Y-chromosomal material is still present.  A similar 
pattern is also detected in the testis: TSPY is strongly expressed in CIS/IGCNU. Intratubular 
seminoma is consistently positive, whereas in invasive seminoma, like in dysgerminoma, down-
regulation of TSPY can be observed. Interestingly, TSPY has previously emerged among the top 10 
up-regulated genes in CIS in a microarray analysis (19), supporting the idea that this protein plays a 
role in the pathogenesis of early malignant germ cells. Our results are compatible with the model that, 
following a process of selection and consecutive clonal expansion, immature germ cells in 
gonadoblastoma and CIS/IGCNU expressing OCT3/4 and TSPY progress to the next pathogenetic 
steps, eventually leading to invasive growth. Whether the presence of TSPY is needed to maintain the 
germ line commitment of these cells at an early stage, or confers a growth advantage during the 
critical step to invasiveness, remains to be elucidated.  
In addition to a better definition of the emerging phenotype of CIS/IGCNU and gonadoblastoma, light 
was shed on diagnostic limitations of these markers in high-risk neonates and infants. Two 
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observations from our analyses are particularly noteworthy in that respect. First, the presence of 
markers such as PLAP, KIT, and OCT3/4 is not restricted to early stages of germ cell maturation, but 
can still be found in neonates during the first year of life. In contrast to the situation in the testis of 
adolescents and adults, these markers can be unreliable for the detection of malignant germ cells in 
very young children. Second, gonocytes showing expression of these markers are hardly ever found on 
the basal membrane, but are localized more centrally in the seminiferous tubules. This distinguishes 
them from CIS/IGCNU cells, which are always in contact with the basal membrane and 
phenotypically and ultrastructurally resemble prespermatogonia. This indicates that CIS/IGCNU cells, 
possibly due to a maturation arrest, show expression of markers that are inappropriate regarding their 
localization.  
Recently, two studies from our group have revealed the value of our analyses on normal germ cell 
development as a baseline to which germ cells in different pathological conditions can be compared. 
In a study of diagnostic markers in gonads of young patients with undervirilization syndromes and 
maturation delay of germ cells, abnormal expression of OCT3/4 and TSPY seemed of pathogenetic 
relevance. Position of OCT3/4 positive cells within the seminiferous tubule could be used to 
distinguish maturation delay from CIS/IGCNU in young patients (20). The second study revealed a 
serious delay in germ cell maturation in male foetuses with trisomy 21, a condition associated with a 
higher risk of the development of a GCT. Compared to normal foetal germ cells, prolonged expression 
of OCT3/4 and increased expression of TSPY were observed, adding further evidence that these 
factors are likely to be involved in early malignant transformation (16). 
8.3. Stem cells and germ cells  
The histiogenesis of GCT is a reflection of the normal processes of gametogenesis, fertilization, and 
finally embryonic differentiation. CIS/IGCNU have been deemed a very good example of cancer stem 
cells (21). On the other hand, embryonal carcinoma (EC), which is believed to be the stem cell 
compartment of all non-seminomas, has been seen as a “caricature” of ES cells, pluripotent cells found 
in the inner cell mass of the blastocyst (22 for review). Whereas the relationship of teratomas, ES 
cells, and EC cells has been widely studied in the mouse, the situation in humans is less clear, and for 
obvious ethical and legal issues, there are many experimental limitations. However, when comparing 
human ES and EC cell lines directly, only few differences are seen. For example, it has been 
speculated that the greater repertoire of cell types developing from ES cells in response to 
differentiation could be due to “higher levels of expression/and or a greater repertoire of Wnt genes” 
(23). EC cell lines have been believed to be more developmentally restricted than ES cells. EC cells 
can to contribute to all three germ layers in transplantation experiments. However, in contrast to ES 
cells, they fail to contribute to the germ cell-lineage in chimeric mice, which has been seen as a 
consequence of limitations to differentiate.  
In this light, our finding of germ cell-lineage differentiation is an amazing demonstration of 
developmental potential (Chapter 5). For the first time, human GCT must be regarded as truly 
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totipotent tumours whose developmental potential is seemingly unlimited. Several aspects of that 
study are noteworthy. First, the strict regulation of the markers in the tumour cells at different stages 
of differentiation are in perfect agreement with the pattern seen during normal development (Chapter 
3). Particularly interesting is the re-activation of OCT3/4, possibly as a germ cell survival factor, in 
yolk sac tumour cells. The fact that the maturing germ cells show down-regulation of OCT3/4 and up-
regulation of VASA argues strongly against a role of OCT3/4 as a driving force in the pathogenesis of 
all GCT cells, as has been suggested recently (24). Furthermore, the realization of the fascinating 
inherent potential of these tumour cells in a competitive tumour environment casts doubts on the 
popular thesis that in tumours, the selection pressure of a postulated “micro-evolution” is the main 
defining biological factor. Rather, in GCTs, aggressive tumour growth and differentiation do not seem 
to be mutually exclusive. Which, in consequence, seems an argument against the mechanistic idea of 
interfering with pluripotency as a promising means of controlling tumour growth in human GCTs (24). 
On a more practical note, the finding should stipulate endeavours to cultivate germ cell like cells from 
pluripotent EC cell lines. If successful, such a system could provide us with valuable information on 
growth factor requirements of human germ cells and equip us with a readily accessible experimental 
tool to study differentiation events without the ethical issues and legal restrictions associated with the 
use of human embryos, human ES cells, or human spermatogonial stem cells. 
8.4. Nest or egg: intrinsic and extrinsic factors in germ cell tumour development 
Tumour development is not necessarily and uniquely the consequence of the clonal expansion of a 
disturbed cell in an otherwise normal organism. Alternatively, tumours can result from non-mutated 
pluripotent cells that are localized in an inappropriate environment, possibly lacking important 
growth-inhibiting signals from their neighbouring cells. In others words, in analogy to the puzzling 
question of “chicken or egg”, the question regarding tumour development could be coined as “nest or 
egg”, where obviously the nest is the microenvironment (sometimes referred to as the “niche”) and the 
egg is the premalignant cell. For GCTs, it has been proven experimentally that both intrinsic and 
extrinsic factors have a role to play in tumourigenesis. In mouse experiments, for example, teratomas 
and teratocarcinomas could be obtained by ectopic transplantation of early embryos (25). Maybe more 
surprisingly, injection of pluripotent EC cells into a blastocyst resulted in the development of a 
chimeric mouse with normal tissues, derived from both the blastocyst and the EC cells (26, 27). 
Regarding the role of pluripotency of these tumours, nowadays easily detectable by 
immunohistochemistry for OCT3/4, the phenomenon of total loss of tumourigenicity of human EC 
cells after terminal differentiation in vitro is noteworthy (28, 29). This suggests that epigenetic 
changes, e.g. executed via promoter methylation, regulated by master switches like OCT3/4, can be 
sufficient to ultimately alter the histology and the biological behaviour of GCT.  
In vivo, however, the situation is much less clear. One experimental problem is that CIS/IGCNU, 
which clinically is regarded as the earliest tumour stage, represents a relatively late stage of tumour 
development (30). Finding a proper model for early GCT development with no or only few 
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chromosomal and genetic abnormalities is a difficult task. Both the comparatively young age at 
presentation (31), and their genomic constitution (32) suggest that gonadoblastoma could be the 
earliest accessible stage in the development of a malignant germ cell tumor (Chapter 4). Interestingly, 
when comparing gonadoblastoma and CIS/IGCNU on the one hand and normal gonocytes on the other 
hand (Chapters 3, 4, 6), not one single factor, neither intrinsic, nor extrinsic, could be identified whose 
presence would have been unique for GCT development. Rather, the combination of markers and the 
localization of the suspicious cells is indicative of (pre)malignancy. Quantitatively, a stronger 
expression of TSPY is seen in malignant cells; however, the underlying pathogenetic mechanism 
remains to be elucidated.  
More recently, we detected stronger staining of the KIT ligand stem cell factor (SCF) when comparing 
normal foetal and malignant germ cells at various stages, including gonadoblastoma, CIS/IGCNU, and 
invasive GCTs (Stoop & Honecker, unpublished results). SCF could in fact be one of the first 
significantly altered extrinsic factors in GCT development. Even though preliminary, these results are 
worth further investigation, as activation of the KIT signalling pathway is regarded one of the first 
steps affecting malignant germ cell development (32; 34, 17 for reviews). 
Studying germ cell development in conditions that either affect intrinsic properties of germ cells, like 
chromosomal constitution in trisomy 21, or lead to altered extrinsic factors, like the inappropriate 
environment of ill determined stromal cells in patients with undervirilization syndromes, has 
unequivocally revealed delay in germ cell maturation as a common risk factor for later tumour 
development (20, 16). Recently, the umbrella term “testicular dysgenesis syndrome” (TDS) has been 
introduced, combining different testicular abnormalities like GCTs, genital malformation, 
undescended testis, and infertility (35). However, so far the concept is rather descriptive, and can 
intellectually be criticized for not differentiating between intrinsic and extrinsic factors as the real 
driving forces behind GCT development. Therefore, the question  “nest or egg?” (or both) remains 
open to debate. 
8.5. Differentiation and chemotherapy response 
Seminomas are highly sensitive to both radiation and chemotherapy. Nonseminomas are less 
susceptible to radiation but show an overall high sensitivity to combination chemotherapy. This 
observation might be related to the finding that in general, ES cells show an efficient defense 
mechanisms for DNA damage, resulting in either repair or induction of apoptosis (36, 37). Loss of this 
embryonic feature might in fact be related to the development of treatment resistance, which occurs in 
about 10-30% of patients diagnosed with a metastatic nonseminomatous GCT. A number of reviews 
on this issue have been published recently (38, 39, 40, 41). Here, our findings on involvement of 
OCT3/4, E-cadherin, β-catenin (Chapter 6), and XPA (Chapter 7) in treatment resistance will briefly 
be discussed.  
In our extensive analysis on OCT3/4 in GCTs and other tumours, we also included a series of well-
characterized GCTs with known clinical outcome (42). The results indicate that the staining pattern 
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was strictly determined by histology, irrespective of sensitivity to chemotherapy. Therefore, existence 
of a pool of pluripotent cancer stem cells expressing OCT3/4 can be ruled out as a mechanism of 
treatment resistance in GCTs. Doubts regarding the recently proposed concept of down-regulation of 
OCT3/4 as a promising target in GCT treatment (24) have already been expressed above. In fact, 
intrinsic treatment resistance seems to be a feature of more differentiated GCTs that have lost 
embryonic features. 
The same series has been used to assess possible involvement of E-cadherin and β-catenin in treatment 
resistance and sensitivity. Although expression of both factors was correlated with different 
histological subtypes, and was seen in nonseminomas but not in seminomas, no differences in 
treatment outcome could be detected. Our data suggest that detection of E-cadherin or β-catenin by 
immunohistochemistry has no prognostic or predictive value for patients with newly diagnosed GCTs. 
The overall incidence of nuclear translocation of β-catenin was low in our series. Although the factors 
were not co-localized in around 50 to 60% of all tumours, gross disturbances of β-catenin signalling 
leading to a nuclear translocation of the protein seem to be relatively rare events in GCTs, in contrast 
to other tumours like colorectal cancers.  Two findings from that analysis, even though not relevant in 
the light of treatment resistance, are noteworthy from a developmental point of view. First, β-catenin 
was always found in pre-invasive malignant germ cells, but never in invasive seminomas, suggesting 
that this factor is differentially regulated in these two cell populations that otherwise seem so similar. 
Second, expression of β-catenin is low in undifferentiated carcinoma cells (EC cells) and is 
consistently up-regulated during differentiation. This is in line with findings of others, who have 
described changes in WNT signalling during differentiation (43, 19). Recently, regulation of E-
cadherin during differentiation of CIS/IGCNU and GCTs has been described, and is in accordance 
with our findings (44, 45).  
Finally, our series has also been examined to elucidate the role of XPA in treatment resistance in 
GCTs (Chapter 7). Based on data from cell lines, it has been suggested that due to low levels of XPA, 
GCTs are not able to efficiently repair DNA damage by activating the NER pathway (46). Recently, 
the same group has presented an extended analysis, showing that in addition to XPA, also ERCC1 and 
XPF, other factors involved in DNA repair, are reduced in testis tumour cell lines (47). In our series of 
GCTs of different histologies, XPA could be demonstrated immunohistochemically in the majority of 
tumours. Seminomas and EC components showed the lowest rate of XPA-positivity. Yolk sac tumours 
and choriocarcinomas were found to have positive staining in a higher number of samples, and all 
mature teratomas showed a strong signal for XPA. In other words, less differentiated histologies 
showed less XPA expression than more differentiated tumour components. No differences were 
detected between responding and non-responding cases. Even though GCT-derived cell lines showed a 
slightly weaker XPA signal than other cell lines in our analysis, the differences did not reach the 
extent that has been reported for different GCT cell lines. Our results cast doubt on the model that a 
defect in NER caused by low XPA level is solely responsible for the exquisite chemosensitivity of 
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GCTs. Two findings, however, could indicate a possible relation of XPA to treatment response: all 
mature teratomas were strongly positive for XPA. Furthermore, all seven nonseminomas that were 
resected in relapse after previous treatment, showed a clear XPA signal, possibly due to induction of 
XPA during exposure to cisplatin, or a selection of a XPA-positive subclone of tumour cells. In this 
context, it is noteworthy, that XPA was not induced in GCT-derived cell lines treated repeatedly with 
CDDP. However, given the distribution of histologic subtypes in the group of pretreated tumours, the 
difference between the previously treated refractory samples compared to untreated tumours of the 
same histology is statistically not significant. None of the investigated cases positive for XPA by 
immunohistochemistry harboured an amplification of the gene, which might have been expected based 
on earlier chromosomal analyses (48). Taken together, our data on XPA demonstrate that from a 
clinical point of view, differences in XPA levels detectable by immunohistochemistry have a limited 
impact on treatment outcome at best. Yet, XPA can be regarded as another example of a factor whose 
expression is regulated during differentiation of GCTs. 
8.6. Main findings and future perspectives 
The presented investigations add to the understanding of normal and malignant germ cell 
development. As the investigations presented in this thesis touch on a number of different aspects of 
normal and malignant germ cells, the main findings are summarized before sketching future 
perspectives of human germ cell biology. The results include 
• a presentation of the time frame during which the regulation of selected markers of normal 
human foetal germ cells takes place 
• a comparison of normal and malignant germ cells, highlighting OCT3/4 and TSPY as 
important factors in both normal and disturbed development 
• the finding of germ cell lineage differentiation in nonseminomas, establishing GCTs as truly 
totipotent tumours 
• the description of the involvement of both external and intrinsic factors in the process of 
malignant transformation 
• the analysis of factors putatively involved in responsiveness of GCTs to chemotherapy, and 
which are best interpreted in view of the embryonic properties of their cells of origin 
It lies in the nature of any scientific progress, that any question successfully resolved will be replaced 
by at least one new question, arising from what has been achieved by an investigation. To name just a 
few, the following questions are unanswered so far:  
Does OCT3/4 expression in human germ cells serve as a factor of pluripotency, or as a survival factor? 
Does OCT3/4 merely influence the susceptibility of germ cells to malignant transformation, or is it a 
driving force behind tumour development? What is the role of TSPY in normal and disturbed germ 
cell development? Could forced expression of human TSPY in mouse germ cells help to establish an 
animal model of type II tumours, providing the urgently needed tool for the investigation of GCTs? 
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What is the exact role of extrinsic and intrinsic factors in malignant transformation? Or in other words, 
what is the contribution of the nest, and what of the egg? Could SCF be a factor that allows distinction 
between normal and malignant germ cell development at an early stage? Will it be possible to cultivate 
germ cells from pluripotent EC cells using special cell culture conditions, as has been demonstrated 
for ES cells?  
Regarding investigations of factors involved in treatment resistance, future research should focus on 
whole pathways and interactions of many factors, rather than looking at isolated factors. Determining 
the overall pattern of cell death after exposure to cytotoxic agents will help our understanding of 
pathways involved in chemotherapy response. The identification of factors that play a role in 
chemotherapy response of GCTs should involve the use of global screening instruments, like gene 
microarrays, or whole proteome analyses. These investigations are currently under way, and will 
hopefully contribute to our understanding of these fascinating tumours over the next few years. 
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9 SUMMARY/SAMENVATTING 
 
Defining normal and malignant germ cell development is crucial for understanding the biology and 
behaviour of GCTs. Comparison of tumours and normal counterparts can help to define normal and 
disturbed development of germ cells. Most likely related to their cell of origin, which resembles a 
primordial germ cell (PGC)/gonocyte, GCTs can show significant similarities with immature germ 
cells. Seminomas are uniform tumours, composed of cells sharing characteristics with 
PGCs/gonocytes. Nonseminomas are more heterogenous and can contain one or more histologic 
subtypes representing various differentiation lineages and stages of normal intra-uterine development. 
The embryonal carcinoma cells are the pluripotent stem cell component, which have the potential to 
differentiate towards extra-embryonal tissues and embryonic tissues with mesenchymal, epithelial and 
neuronal appearance. There is sufficient evidence to hypothesize that treatment sensitivity of GCTs 
reflects the intrinsic characteristics of the cell of origin, and their derivatives. The aim of this thesis 
was to identify factors involved in the development of normal and malignant human germ cells. The 
particular marker profile of male and female germ cells during normal foetal development could be 
established, and compared to the profile found in dysgenetic gonads. The intrinsic developmental 
potential of nonseminomatous germ cell tumours as totipotent tumours was established. Furthermore, 
the role of extracellular factors like the microenvironment was addressed. Finally, links between 
pluripotency, cellular differentiation, and treatment response, were investigated. 
By analysing formalin-fixed, paraffine-embedded material, a number of markers for early germ cells 
could be confirmed and further characterized in our studies (Chapters 2 and 3). In particular, we 
describe for the first time the exact timing of the regulation of these markers during normal germ cell 
maturation. We could distinguish an immature and a more mature phenotype of human germ cells, 
both in males and females. Immature germ cells of both sexes are characterized by strong expression 
of PLAP, OCT3/4, and the stem cell factor receptor KIT. Weak expression of the germ line specific 
protein VASA was seen in these cells. PLAP is the first factor to be down-regulated during 
maturation, followed by OCT3/4 and then KIT in male germ cells. In female germ cells, the same 
pattern can be observed for PLAP and OCT3/4, occurring at the same time during foetal development 
as in males (second trimester). However, expression of KIT remains high in oocytes and primordial 
follicles. Furthermore, female germ cells are characterized by strong expression of E-cadherin and β-
catenin during maturation, which persists throughout folliculogenesis. 
Male foetal germ cells show weak expression of E-cadherin, but strong expression of β-catenin 
(Chapter 6). They can show expression of TSPY (testis-specific protein, Y-encoded), mainly in 
prespermatogonia. Double-staining experiments revealed that this factor is not restricted to cells in 
mitosis. In both sexes, the pool of immature germ cells shows strong mitotic activity until week 22 to 
24 gestational age. Human germ cell maturation is characterized by an increase in signal intensity for 
VASA and loss of OCT3/4 expression in both sexes. This transition takes place in males when the 
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gonocytes get attached to the basal lamina of the seminiferous tubule, and in females when the germ 
cells engage in folliculogenesis. This led us to conclude that external factors like cell-cell signalling 
create a niche that is essential to ensure normal germ cell development. 
Using our knowledge from studies defining normal development, we turned to cells showing delayed 
or even disturbed maturation. An extensive immunohistochemical analysis in CIS/IGCNU and 
gonadoblastoma could confirm PLAP, OCT3/4 and TSPY as suitable makers for the diagnosis of 
preinvasive malignant germ cells in postpubertal gonads (Chapter 4). Our data are in line with the 
model of a maturation arrest of immature germ cells as one of the first pathogenetic hits in the 
development of GCTs. Interesting results suggest a pathogenetic role of TSPY, whose role in normal 
and malignant germ cell development is largely elusive at this point. Our results are compatible with 
the model that, following a process of selection and consecutive clonal expansion, immature germ 
cells in gonadoblastoma and CIS/IGCNU expressing OCT3/4 and TSPY progress to the next 
pathogenetic steps, eventually leading to invasive growth. Whether the presence of TSPY is needed to 
maintain the germ line commitment of these cells at an early stage, or confers a growth advantage 
during the critical step to invasiveness, remains to be elucidated.  
In addition to a better definition of the emerging phenotype of CIS/IGCNU and gonadoblastoma, light 
was shed on diagnostic limitations in high-risk neonates and infants. It must be noted that the presence 
of markers such as PLAP, KIT, and OCT3/4 is not restricted to early stages of germ cell maturation, 
but can extend into the first year of life. Therefore, these markers can be unreliable for the detection of 
malignant germ cells in very young children. Of diagnostic importance could be the observation that 
gonocytes showing expression of early markers are hardly ever found on the basal lamina, but are 
localized more centrally in the seminiferous tubules. This distinguishes them from CIS/IGCNU cells, 
which are always in contact with the basal lamina.  
An amazing finding was the detection of germ cell-lineage differentiation in nonseminomatous GCTs 
in a limited number of cases (Chapter 5). Human GCT must therefore be regarded as truly totipotent 
tumours with unrestricted developmental potential. Interestingly, the strict regulation of the germ cell 
markers observed in the tumour cells at different stages of differentiation was perfectly mimicking 
normal development. The fact that the maturing germ cells show down-regulation of OCT3/4 and up-
regulation of VASA can be seen as an argument against a role of OCT3/4 as a driving force in the 
pathogenesis of all GCT cells. Rather, in GCTs, aggressive tumour growth and differentiation do not 
seem to be mutually exclusive. From a technical point of view, the finding of germ cell development 
in GCTs should encourage efforts to cultivate germ cell like cells from pluripotent EC cell lines. Such 
a system could help to characterize human germ cell development in a readily accessible cell system 
without the ethical issues and legal restrictions associated with the use of normal primordial germ cells 
derived from healthy human sources. 
Finally, our investigations present findings of different factors supposedly involved in chemotherapy 
resistance in a series of well-characterized GCTs with known clinical outcome. Neither E-cadherin or 
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β-catenin (Chapter 6), nor XPA (Chapter 7) were found to be clearly associated with treatment 
resistance. Interesting, however, is the finding that expression of E-cadherin, β-catenin and XPA 
correlated with different histologies, irrespective of sensitivity of the tumours to chemotherapy. 
Therefore, all these proteins can be regarded as examples of factors that are differentially regulated 
during GCT development. This illustrates nicely that in GCTs, it is particularly important to be able to 
interpret results in view of the underlying aspects of developmental biology, in order to avoid 
misinterpretation of experimental findings. 
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Samenvatting 
 
Het definiëren van normale en kwaadaardige kiemcelontwikkeling is essentieel voor het kunnen 
begrijpen van de biologie het gedrag van kiemceltumoren (KCT). Hierbij kan de vergelijking van 
tumoren en de normale tegenhangers waardevol zijn voor het beschrijven van normale en afwijkende 
kiemcel ontwikkeling. Vermoedelijk op grond van een gemeenschappelijke oorsprong, namelijk een 
primordiale kiemcel/gonocyte, kunnen KCT gelijkenis vertonen met ongedifferentieerde kiemcellen. 
Seminomen zijn uniforme tumoren, opgebouwd uit cellen die overéénkomsten vertonen met 
primordiale kiemcellen/gonocyten. Nonseminomen zijn meer heterogeen en kunnen meer dan één 
histologische variant bevatten. Deze vertegenwoordigen de verschillende lijnen van differentiatie in de 
embryonale en  foetale ontwikkeling. De embryonaal carcinoomcellen worden beschouwd als het 
stamcelcompartiment van de nonseminomen en hebben het vermogen om zowel extra-embryonaal en 
embryonaal weefsel te vormen. Er zijn duidelijke aanwijzingen dat chemotherapie-gevoeligheid en – 
resistentie van KCT een afspiegeling zijn van de eigenschappen van de cel van oorsprong en haar 
afstammelingen. Het doel van dit proefschrift was het identificeren van factoren die een rol spelen in 
de ontwikkeling van normale en kwaadaardige kiemcellen. De karakteristieke opéénvolgende 
aanwezigheid van eiwit merkers voor mannelijke en vrouwelijke kiemcellen tijdens de normale 
ontwikkeling wordt beschreven, en dit patroon wordt vergeleken met het profiel in abnormaal 
aangelegde gonaden. Tevens wordt het ontwikkelingsvermogen van nonseminomen bestudeerd, en 
hun totipotentie wordt voor het eerst beschreven.  De rol van omgevingsfactoren, zoals het 
micromilieu, wordt geanalyseerd. Tenslotte worden connecties tussen pluripotentie, cellulaire 
differentiatie en behandelingsrespons gelegd. 
Met gebruik van paraffine-ingebed weefsel wordt een aantal merkers voor vroege ontwikkelingsstadia 
van kiemcellen bevestigd en verder gekarakteriseerd (Hoofdstukken 2 en 3). Hierbij wordt vooral de 
volgorde van de aanwezigheid van eiwit-merkers voor normale kiemcellen binnen de zich 
ontwikkelende gonaden beschreven. Deze studies maken het mogelijk om onrijpe en meer uitgerijpte 
kiemcellen in zowel de  mannelijke en vrouwelijke gonaden te onderscheiden. In beide situeaties 
brengen onrijpe kiemcellen de eiwitten PLAP, OCT3/4, en de stamcel factor receptor KIT tot 
expressie. De desbetreffende cellen vertonen een zwakke expressie van VASA, een specifieke merker 
voor kiemcellen. In mannelijke kiemcellen is PLAP de eerste factor die afname in expressie laat zien, 
gevolgd door OCT3/4 en tenslotte KIT. Vrouwelijke kiemcellen vertonen hetzelfde patroon voor 
PLAP en OCT3/4, en veranderingen vinden plaats op hetzelfde tijdstip als in mannelijke gonaden 
tijdens de foetale ontwikkeling (tweede trimester). Anderzijds blijft de expressie van KIT hoog in 
oocyten en primordiale follikels. Voorts zijn vrouwelijke kiemcellen gekarakterisieerd door E-
cadherin en β-catenine, die tijdens de gehele ontwikkeling tot de folliculogenese een sterke expressie 
tonen.  
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Mannelijke fetale kiemcellen laten een zwakke expressie van E-cadherin en een sterke expressie van 
β-catenine zien (Hoofdstuk 6). Daaréntegen vertonen ze een wisselende expressie van TSPY (testis-
specific protein, Y-encoded), meestal in prespermatogonia. Dubbelkleuringen bewijzen dat deze factor 
niet alleen beperkt is tot cellen die in deling (mitose) zijn. In beide geslachten tonen onrijpe 
kiemcellen een sterke mitotische activiteit tot en met week 22 tot 24 van de zwangerschap. Rijping 
van kiemcellen gaan gepaard met een versterking van het signaal van VASA en het verlies van 
OCT3/4. Deze overgang vindt bij de mannelijke ontwikkeling plaats op de tijdstip wanneer de 
gonocyten terechtkomen op de basaallamina van de zaadbuisjes, en bij de vrouwelijke ontwikkeling in 
het begin van de folliculogenese. Dit leidt tot de veronderstelling dat uitwendige factoren zoals cel-cel 
contacten essentieel zijn om de juiste mico-omgeving voor een normale ontwikkeling van kiemcellen 
te vormen. 
Met de verkregen kennis omtrent de regulatie van de normale ontwikkeling worden gonaden met een 
vertraagde of gestoorde rijping bestudeerd. Een uitgebreide studie van immuunhistochemische 
merkers op carcinoma in situ/intratubular germ cell neoplasia unclassified (CIS/IGCNU) toont de 
waarde van PLAP, OCT3/4 en TSPY aan als diagnostische merkers voor het aantonen van de 
preinvasieve in situ letsels in postpubertaire gonaden (Hoofdstuk 4).  De resultaten zijn in 
overeenstemming met het model dat rijpingsremming één van de eerste stappen is in de ontsporing 
van kiemcellen op weg naar een KCT. De resultaten betreffende TSPY zijn met name interessant en 
suggereren een belangrijke rol in de pathogenese van KCT, hoewel tot nu toe weinig bekend is over de 
mogelijke mechanisme. Een model is dat als gevolg van selectie en klonale expansie onrijpe 
kiemcellen in gonadoblastoom en CIS/ITGCNU, die OCT3/4 en TSPY tot expressie brengen, 
uiteindelijk progressie tot een invasief groeipatroon plaats vindt. Of de aanwezigheid van TSPY in 
deze cellen noodzakelijk is om een kiemcel-differentiatie te bepalen, ofwel een groeivoordeel tijdens 
de evolutie van de (nog) niet invasieve cellen oplevert moet worden onderzocht.  
Op grond van een betere definitie van het fenotype van CIS/IGCNU en gonadoblastoom,  wordt een 
diagnostische dilemma bij neonaten een jonge patiёnten aangetoond. Hierbij moet benadrukt worden 
dat expressie van merkers zoals PLAP, KIT en OCT3/4 niet beperkt is tot vroege ontwikkelingsstadia 
van kiemcellen, maar tevens in het eerste jaar na de geboorte aanwezig kunnen zijn.  Om die reden 
kunnen de merkers onbetrouwbaar zijn in het diagnostiseren van kwaadaardige kiemcellen in jonge 
patiёnten. In dit verband is het feit dat normale gonocyten die nog expressie van de vroege merkers 
vertonen bijna nooit op de basaallamina gelocaliseerd zijn, maar in een meer centrale positie in de buis 
aangetroffen worden, van diagnostische waarde. Dit onderscheidt deze cellen van CIS/IGCNU, die per 
definitie in contact zijn met de basaallamina. 
Een verbazingwekkende observatie was de detectie van kiemceldifferentiatie in enkele gevallen van 
nonseminomen (hoofdstuk 5). Op grond van deze bevinding moeten humane KCT van nu af aan als 
echte pluripotente tumoren (dus met een onbeperkt ontwikkelingspotentiaal) worden beschouwd. 
Opmerkelijk was de strikte opéénvolgende expressie van kiemcelmerkers in de tumorcellen die een 
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perfecte afspiegeling vormden van het normale proces. Het gegeven dat tijdens uitrijping van deze 
kiemcellen verlies van OCT3/4 plaats vindt en een toename van VASA,  kan gezien worden als 
argument tegen de gedachte dat OCT3/4 een drijvende rol speelt in de pathogenese van deze tumoren. 
Een agressieve tumorgroei en differentiatie in KCT is niet wederzijds uit te sluiten. Vanuit een 
biotechnologisch perspectief zou deze observatie inspanningen aanmoedigen om kiemcellen uitgaande 
van pluripotente KCT cellijnen te kweken. Dit zal kunnen leiden tot een model systeem voor het 
bestuderen van de humane kiemcel ontwikkeling, zonder de ethische en legale beperkingen in verband 
met het gebruik van primordiale kiemcellen, afkomstg van humane embryo’s of humane ES cellen. 
Ten slotte presenteren Hoofdstukken 6 en 7 de resultaten van studies op factoren die een mogelijke rol 
spelen in het mechanisme van chemotherapie-resistentie. De analyses zijn uitgevoerd op tumoren van 
goed gedefinieerde patiёntenpopulaties. Het expressiepatroon van zowel E-cadherin als β-catenine 
(Hoofdstuk 6) als ook XPA (Hoofdstuk 7) geeft geen duidelijke relatie met resistentie. Het is 
interessant dat E-cadherin, β-catenine en XPA wel verschillende expressiepatronen vertonen in de 
verschillende histologische subgroepen van KCT, onafhankelijk van chemotherapie-gevoeligheid. 
Deze eiwitten zijn in feite voorbeelden van factoren die differentieel gereguleerd worden tijdens KCT 
ontwikkeling. Dit is een informatief voorbeeld dat bij het interpreteren van resultaten van studies aan 
KCT altijd de ontwikkelingsbiologie betrokken moet worden om misinterpretaties te vermijden. 
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10 ABBREVIATIONS 
 
BCRP breast cancer resistance protein 
BMP4 bone morphogenetic protein 4 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21) 
CDKN1B cyclin-dependent kinase inhibitor 1B (p27) 
CDKN2A cyclin-dependent kinase inhibitor 2A (p16) 
CDKN2B cyclin-dependent kinase inhibitor 2B (p15) 
CDKN2C cyclin-dependent kinase inhibitor 2C (p18) 
CDKN2D cyclin-dependent kinase inhibitor 2D (p19) 
CIS/IGCNU carcinoma in situ/intratubular germ cell neoplasia unclassified
DNA deoxyribonucleic acid 
EC cell embryonal carcinoma cell 
ES cell embryonic stem cell 
GCT germ cell tumor 
GST glutathione S-transferase 
KCT kiemceltumor 
LRP lung resistance protein 
MDR multidrug resistance 
MMR DNA mismatch repair 
MRP1/2 multidrug resistance related protein 
PGC primordial germ cell 
PLAP placental/germ cell alkaline phosphatases 
POU5F1 POU domain, class 5, transcription factor 1 (OCT3/4) 
RB retinoblastoma gene protein 
RNA ribonucleic acid 
TDS testicular dysgenesis syndrome 
TP53 tumor protein p53 
TSPY testis-specific protein, Y-encoded 
SCF stem cell factor 
XPA xeroderma pigmentosum complementation group A protein 
109 
Danksagung   
 
11 DANKSAGUNG 
 
Dank zu sagen am Ende eines so langen Projekts gehört zu den vornehmsten Aufgaben dieses 
Büchleins und bietet die Chance, einen Bruchteil dessen, was ich in dieser Zeit erfahren durfte, 
zurückzugeben.  
 
Gerne möchte ich der Dr. Mildred Scheel Stiftung für Krebshilfe danken, die meinen 
Forschungsaufenthalt finanziell unterstützt und damit dieses Projekt ermöglicht hat. 
 
Leendert danke ich dafür, dass er mir immer dann Unterstützung gegeben hat, wenn ich sie benötigte, 
mir andererseits aber völlige Freiheit gewährte, wenn es um den weiteren Fortgang meiner 
Untersuchungen ging. Dieses Vertrauen hat mir in Rotterdam viel ermöglicht und mich ermutigt, auf 
diesem Weg auch nach Rotterdam weiter zu gehen. Unsere Besprechungen waren das Beste an 
wissenschaftlichem Austausch, was ich bisher erfahren durfte – kurz, ich hätte mir keinen besseren 
Begleiter wünschen können! 
 
Wolter gilt mein Dank für viele gemeinsame Stunden hinter dem Mikroskop und eine Begeisterung für 
das Forschungsgebiet, die sich fast mit Händen greifen lässt. Welche Motivation könnte besser sein?! 
 
Herr Bokemeyer, Ihnen verdanke ich so manche Bewegung in meinem Leben, und wer mich kennt, 
weiss, dass ich das durchaus positiv meine. Wäre ich ohne unsere Zusammenarbeit nach Rotterdam 
und später nach Hamburg gegangen? Wohl kaum. Für Ihre inzwischen schon lange Jahre währende 
zuverlässige Unterstützung danke ich Ihnen sehr. 
 
Den Herren Professoren A. Grootegoed, P. Sillevis Smitt und J. Trapman danke ich für Ihre 
konstruktiven Beiträge, die geholfen haben, dieser Arbeit ihre endgültige Form zu geben. 
 
Frank, durch Dich bin ich überhaupt erst auf die Idee gekommen, mich mit einem 
Forschungsaufenthalt im Ausland zu beschäftigen. Vom ersten Besuch in Rotterdam im Frühjahr 
2001, noch zu Zeiten Deines Aufenthalts dort, bis zu meiner promotie im Herbst 2006 spannt sich ein 
weiter Bogen. Danke für viel Unterstützung auf dem Weg. 
 
Hans, Du warst im Labor immer mein erster Ansprechpartner. Dafür, und noch viel mehr für die 
Tatsache, dass uns inzwischen eine Freundschaft verbindet, die von Forschungsideen zu Jazz bei 
Kneipenbesuchen und wieder zurück reicht, möchte ich Dir danken. Möge es noch viele Besuche 
zwischen Bergen und Hamburg hin und her geben! 
110 
  Danksagung 
 
Michel, von allen Rotterdamern hast Du am meisten an meiner Zeit dort Anteil genommen. Danke, 
dass Du mit dabei warst – an guten wie an schlechten Tagen. 
 
Ad, Annemarie, Anne-Marie, Claudia, Fons, Gaetano, Lucienne, Marjan, Martine, Monique, Pascal, 
Paul, Remco und Ruud, Euch allen ein dickes DANKE für die gemeinsame Zeit inner- und außerhalb 
des Labors und vielfältige Unterstützung. Ein Extra-Dank geht an Ad und Gaetano: ich weiß, dass ich 
Eure Zeit und Geduld manchmal arg strapaziert habe. Ihr habt einen besonderen Anteil daran, dass 
meine Zeit in Rotterdam erfolgreich war.  
 
Allen JNIlern, die zwischen 2002 und 2004 meinen Weg gekreuzt haben, mein Dank für so manche 
Hilfe und gemeinsam verbrachte Stunden. Stellvertretend für das Haus seien hier neben den Kollegen 
des 4. Stocks insbesondere Ingrid aus Wolters Sekretariat und Frank aus der Photoabteilung genannt, 
sowie die Mitglieder des feest commissie 2003.  
 
Frieder Kerler danke ich herzlich für die Umschlagsgestaltung des Büchleins und so manchen guten 
CD-Tip! 
 
Valerie, Simone, Lisette, Birgitta und Sjoerd, was wäre die Architektur-Stadt Rotterdam ohne Euch 
gewesen? Sicher so manchen Spaß ärmer, und dafür vielen Dank! 
 
Liebe Musici, allen voran Annabelle und Clara, liebe Cellotruppe von Krashna (hier sollen Anna, 
Franca und Christian besonders erwähnt werden), meine 26 Monate Holland, das wart neben dem 
Labor zu einem Großteil Ihr! Freundschaften und Verbindungen, die aus der Musik heraus entstehen, 
sind auf wundervolle Weise anders als das alltägliche Geschehen. Etwas von Euch habe ich mit mir 
zurück nach Deutschland genommen! 
 
Meine lieben Rotterdam-Besucher, Ade, Anke, Claudia und Jens, Heidi, Jan-Philip, Ina, Marcus, Oda 
und Arvid, Susanne, Suse, sowie Zsi, es ist sicher kein Zufall, dass gerade Ihr den Weg nach Holland 
gefunden habt. Ihr gehört mit Sicherheit zu einem „best of“ an Freunden. Bei all meinen Ortswechseln 
ist es wichtig zu wissen, dass Ihr ein Zuhause seid, dass ich immer dabei habe. 
 
Last but not least, liebe Familie – liebe Eltern, Geschwister und „Anhang“; dieses Büchlein ist Euch 
allen gewidmet. Ihr steht hinter mir, nehmt mich so, wie ich bin, und gebt mir die Freiheit, meinen 
eigenen Weg zu gehen. Euer Mitleben und Eure Anteilnahme versichern mir, wo der Platz ist, an dem 
ich immer dazugehören werde. In dieser Arbeit geht es ja wiederholt um das Verhältnis von Ei und 
Nest – also, wenn ich das Ei bin, dann seid Ihr das Nest, soviel ist klar! Danke für Alles. 
111 
Curriculum vitae   
12 CURRICULUM VITAE 
Name:  Friedemann Honecker 
Date of birth: 15 September 1969 
Place of birth: 
  
Cali, Colombia 
Undergraduate education  
1980 - 1989 
1976 - 1980 
Hohenstaufengymnasium Göppingen 
Elementary School in Wäschenbeuren and Göppingen 
 
Medical school  
1995 - 1999 
1998 
 
Berlin Free University Medical School, Germany 
Auckland University Medical School, New Zealand  
McGill University Medical School, Canada 
1994 - 1995 University of Newcastle Medical School, Great Britain 
1991 - 1994 University of Lübeck Medical School, Germany 
 
Internship/Residency:  
01/2005 - present Internal Medicine 
Department of Oncology, Hematology, Bone Marrow 
Transplantation and Pneumology, University of Hamburg Medical 
Center, Germany 
04/2004 - 12/2004 Internal Medicine 
Department of Oncology, Hematology, Imunology and 
Rheumatology, University of Tübingen Medical Center, Germany 
02/2002 - 03/2004 Research Fellow, Department of Pathology 
Laboratory for Experimental Patho-Oncology,  
Josephine Nefkens Institute, Erasmus MC,  
University Medical Center Rotterdam, Daniel den Hoed 
Cancer Center, The Netherlands 
supervisor: Prof. Dr. L Looijenga 
07/1999 - 01/2002 Internal Medicine 
Department of Oncology, Hematology, Imunology and 
Rheumatology, University of Tübingen Medical Center, Germany 
  
Grants:  
02/2002 - 04/2004 Postdoctoral fellowship program Dr. Mildred Scheel Cancer 
Foundation, Germany 
1991 - 1998 Student educational grant: Studienstiftung des deutschen Volkes, 
Germany 
112 
  List of publications 
13 LIST OF PUBLICATIONS 
 
Articles in peer reviewed journals: 
Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S, Hartmann JT, 
Bokemeyer C, Mayer F: Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. 
Int J Oncol 2006;29(2):471-479 
 
Cools M, Honecker F, Stoop H, Veltman J, de Krijger RR, Steyerberg E, Wolffenbuttel KP, 
Bokemeyer C, Lau Y-FC, Drop SLS, Looijenga LHJ: Maturation delay of germ cells in fetuses with 
trisomy 21 results in increased risk for the development of testicular germ cell tumors. Hum Pathol 
2006;37:101-111 
 
Honecker F, Stoop H, Mayer F, Bokemeyer C, Castrillon DH, Lau Y-FC, Looijenga LHJ, Oosterhuis 
JW: Germ cell lineage differentiation in nonseminomatous germ cell tumours. J Pathol 2006;208:395-
400 
 
Kersemaekers AMF, Honecker F, Cools M, Stoop H, Molier M, Wolffenbuttel KP, Bokemeyer C, Li 
Y, Lau Y-FC, Oosterhuis JW, Looijenga LHJ: Identification of germ cells at risk for neoplastic 
transformation in gondadoblastomas An immunohistochemical study for OCT 3/4 and TSPY. Hum 
Pathol 2005;36:512-521 
 
Stoop H, Honecker F, Cools M, de Krijger RR, Bokemeyer C, Looijenga LHJ: Differentiation and 
development of human female germ cells during prenatal gonadogenesis: an immunohistochemical 
study. Hum Reprod 2005;20(6):1466-1476 
 
Honecker F, Stoop H, de Krijger RR, Chris Lau YF, Bokemeyer C, Looijenga LH: Pathobiological 
implications of the expression of markers of testicular carcinoma in situ by fetal germ cells. J Pathol 
2004;203(3):849-857 
 
Honecker F, Wedding U, Bokemeyer C: Chemotherapy in elderly patients with advanced lung cancer. 
Part I: General aspects and treatment of small cell lung cancer (SCLC). Onkologie 2004;27(5):500-505 
 
Honecker F, Wedding U, Bokemeyer C: Chemotherapy in elderly patients with advanced lung cancer. 
Part II: Treatment of non-small cell lung cancer (NSCLC). Onkologie 2004;27(6):583-588 
 
113 
List of publications   
 
Honecker F, Kersemaekers AMF, Molier M, van Weeren PC, Stoop H, de Krijger RR, Wolffenbuttel 
KP, Oosterhuis JW, Bokemeyer C, Looijenga LHJ: Involvement of E-cadherin and beta-catenin in 
germ cell tumours and in normal male fetal germ cell development. J Pathol 2004;204:167-174 
 
Honecker F, Oosterhuis JW, Mayer F, Hartmann JT, Bokemeyer C, Looijenga LH: New insights into 
the pathology and molecular biology of human germ cell tumors. World J Urol 2004;22(1):15-24 
 
Koch S, Mayer F, Honecker F, Schittenhelm M, Bokemeyer C: Efficacy of cytotoxic agents used in 
the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J 
Cancer 2003;89(11):2133-2139 
 
Hartmann JT, Oechsle K, Quietzsch D, Wein A, Hofheinz RD, Honecker F, Nehls O, Kohne CH, 
Kafer G, Kanz L, Bokemeyer C: Protracted infusional 5-fluorouracil plus high dose folinic acid 
combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation 
study. Br J Cancer 2003;89(11):2051-2056 
 
Honecker F, Mayer F, Stoop H, Oosterhuis JW, Koch S, Bokemeyer C, Looijenga LHJ: Xeroderma 
pigmentosum group A protein and chemotherapy resistance in human germ cell tumors. Lab Invest 
2003;83(10):1489-1495 
 
Looijenga LHJ, Stoop H, de Leeuw HPJC, de Gouveia Brazao CA, Gillis AJM, van Roozendaal KEP, 
van Zoelen EJJ, Weber RFA, Wolffenbuttel KP, van Dekken H, Honecker F, Bokemeyer C, Perlman 
EJ, Schneider DT, Kononen J, Sauter G, Oosterhuis JW: POU5F1 (OCT3/4) identifies cell with 
pluripotent potential in human germ cell tumors. Cancer Res, 2003;63(9):2244-2250 
Honecker F, Köhne CH, Bokemeyer C: Colorectal cancer in the elderly: Is palliative chemotherapy of 
value? Drugs Aging 2003;20(1):1-11 
 
Mayer F, Honecker F, Looijenga LHJ, Bokemeyer C: Towards understanding of the biological basis 
of the response to cisplatin-based chemotherapy in germ cell tumors. Ann Oncol, 2003;14(6):825-832 
 
Bokemeyer C, Honecker F, Wedding U, Späth-Schwalbe E, Lipp HP, Kolb G; DGHO/DGG study 
group „Geriatrische Onkologie“ (Geriatric Oncology): Use of hematopoietic growth factors in elderly 
patients receiving cytotoxic chemotherapy. Onkologie 2002;25(1):32-39 
 
Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, 
Baronius W, Hempel V, Kanz L, Bokemeyer C: Phase II study of weekly paclitaxel plus 24-h 
 114
  List of publications 
continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients 
with advanced gastric cancer. Anticancer Drugs 2002;13(5):497-503 
 
Honecker F, Wedding U, Kolb G, Bokemeyer C: Chemotherapy of Colorectal Cancer – Which 
therapy is justified? Onkologie 2001;24:87-94 
 
 
Book chapters: 
 
J. Wolter Oosterhuis, Friedemann Honecker, Frank Mayer, Carsten Bokemeyer, L.H.J. Looijenga: 
Pathobiological basis of treatment strategies in Germ Cell Tumors, in Urological Cancers: Science and 
Treatment, edited by Jonathan Waxman, Springer-Verlag UK 2005 
 
Hartmann JT, Kuczyk M, Mayer F, Honecker F, Bokemeyer C: Chemotherapie metastasierter 
Keimzelltumoren des Hodens, in Pharmakotherapie urologischer Tumoren, Springer Verlag 
Heidelberg 2001 
 
Bokemeyer C, Kollmannsberger C, Hartmann JT, Honecker F, Mayer F, Kanz L: Chemotherapie des 
Urothelkarzinoms der Harnblase – update 2001, in Aktuelle Onkologie, Zuckschwerdt-Verlag, 
München 2001 
 
Friedemann U. Honecker: Molekulare Mechanismen der Wachstumsregulation von Tumorzellen 
durch das Integrin α5β1, Verlag Buch und Mensch, Berlin 1999 
115 
  
  Appendix – colour figures  
Chapter 2: Figure 2
117 
Chapter 2: Figure 3
 118
Appendix – colour figures   
  Appendix – colour figures  
Chapter 3: Figure 1
119 
 Chapter 4: Figure 1
 120
Appendix – colour figures  
  Appendix – colour figures  
Chapter 4: Figure 2
121 
 Chapter 5: Figure 2
 122
Appendix – colour figures  
  Appendix – colour figures  
Chapter 6: Figure 1
123 
 Chapter 6: Figure 2
 124
Appendix – colour figures  
  Appendix – colour figures  
Chapter 7: Figure 1 
125 
